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ABSTRACT 
Osteoporosis affects bone mass and bone micro-architecture, reducing 
mechanical strength. SDF-1 and its ligand CXCR4 play significant roles in the 
migration and engraftment of mesenchymal stem cells (MSCs). The aim of this 
study was to investigate the effects of CXCR4 transfected MSCs on bone 
formation in osteopenic rats. The hypothesis was that MSCs genetically 
modified to over-express CXCR4, would enhance migration of stem cells from 
osteopenic rats and when injected intravenously in ovariectomised (OVX) rats, 
would improve bone formation.  
MSCs were harvested from femora of young, OVX and adult control rats. The 
differentiation, CXCR4 expression, in vitro migration and phenotypic 
characteristics of the cells were compared. Although the phenotypic 
characteristics of cells from all groups of rats were the same, their 
differentiation capability, CXCR4 expression and migration was significantly 
different. MSCs were genetically modified to over-express CXCR4 and in vitro 
migration investigated. It was found that although young MSCs had the highest 
migration capability (2x more than their uninfected counterparts, p=0.006), the 
OVX MSCs when transfected with CXCR4 had the most significant migration 
from their un-transfected counterpart cells(5x more, p=0.025). Additionally, 
differentiating MSCs to osteoblasts reduced their CXCR4 expression as well 
as their migration towards SDF1.  
The CXCR4 transfected MSCs were administered intravenously in OVX rats. 
Fluorescent labelled cells were tracked after 1 week and were located in the 
blood vessels of the femur. 11-weeks post-injection, OVX rats injected with 
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young-CXCR4 MSCs had significantly higher BMD(694.0±80.1mg/cm3) 
(p<0.05) in comparison to rats injected with saline. Rats injected with OVX-
CXCR4 MSCs(645.4±79.3mg/ccm) had a higher BMD in comparison to those 
injected with OVX MSCs(631.4±69.5mg/ccm) and saline(563.4±82.9mg/ccm). 
The L4 vertebral stiffness was also higher in rats treated with young-CXCR4 
MSCs in comparison to those treated with saline.  
CXCR4 genetically modified MSCs from young and OVX patients may help in 
boosting bone formation in osteoporosis.  
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1.1 Introduction to the Thesis 
Osteoporosis is a debilitating condition of the bone that results in fragility fractures, 
which are then difficult to treat. Fragility fractures also cause a socio-economic burden 
to the patient and the society. There have been problems with current treatment 
therapies as they are anti-catabolic, and the focus is therefore moving towards using 
anabolic treatments such as the use of stem cells. The aim of this work is to use 
genetically modified stem cells that over-express CXCR4, to help improve bone 
formation in osteopenic rats. 
The main purpose of this work is look at the role of CXCR4 in osteoporosis. Therefore, 
the main introduction of the thesis is a general overview of osteoporosis and bone 
and current treatments of osteoporosis will be described. There is also a detailed 
description of the role of stem cells in bone formation, the signalling pathways in bone 
formation and how ageing and osteoporosis affects stem cells. The mobilization 
mechanism of stem cells will also be explained and how it influences formation of 
bone and a significant focus will be on the SDF1-CXCR4 pathway and how this 
pathway influences the homing of stem cells. Finally, the last section of the 
introduction will explain the current animal models used to emulate osteoporosis in 
humans. 
1.2 Osteoporosis 
Osteoporosis is a disease that causes a decrease in bone mass (osteopenia) and 
deterioration in bone micro-architecture which leads to an enhanced fragility of the 
skeleton and therefore a greater risk of fracture, otherwise known as fragility fractures. 
It results in a significant psychological and financial burden on the affected individual, 
their family and the society (Jee and Yao, 2001). A reduction in bone density causes 
increased chances of vertebral fractures, Colles’ fracture of the distal forearm, and 
hip fractures, as well as fractures at other sites in the body (Kanis et al., 1994). 
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Worldwide, approximately 200 million women are affected by osteoporosis and in 
developed countries 1 in 3 women and 1 in 5 men over the age of 50 years will suffer 
from an osteoporotic-related fracture. Annually, there are approximately 1.6 million 
reported cases of osteoporotic hip fractures worldwide, with a projected rise of 4.5 to 
6.3 million cases by 2050 (Johnell and Kanis, 2006, Gullberg et al., 1997). With the 
world’s ageing population increasing, the future economic burden of osteoporotic 
fractures is also expected to dramatically increase. The International Osteoporosis 
Foundation (IOF) has estimated the direct medical costs of treating 2.3 million 
fractures in Europe and United States as $27 billion (Burge et al., 2007).  
Bone mineral density (BMD) can be assessed using dual x-ray (DXA), and 
osteoporosis is defined by a T score of less than 2.5 standard deviations below the 
average of a young adult. More recent advancements to predict an individual’s 10 
year risk of sustaining an osteoporotic hip fracture, include using a decision-making 
method of fracture-risk assessment tool (FRAX), integrated clinical risk factors with 
DXA-based BMD as well as a 10 year probability of incurring a major osteoporotic 
fracture (Rachner et al., 2011). However, problems with DXA include its inability to 
distinguish between cortical bone, trabecular bone, the outer shell and the spongy 
inner part of bone, which play significant roles in determining the bone strength and 
loss at different rates and it does not give a true volumetric density of bone. DXA is 
also incapable of determining the morphology of the trabecular organisation or the 
actual porosity of cortical bone that is the bone microarchitecture which plays a 
significant role in bone strength (Rachner et al., 2011, Kanis, 1994).  
Reports suggest that between the ages of 12 and 18 years, there is a maximum rate 
of bone mass acquisition, due to a combination of hormonal and environmental 
factors interacting with the genetic makeup of an individual, to stimulate bone 
formation. Conditions such as anorexia nervosa, growth-hormone insufficiency, 
delayed puberty and amenorrhea change the normal hormonal balance which results 
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in lower peak bone mass. In women bone mass reduces after menopause and the 
level of peak bone mass which is a consequence of bone formation at puberty, is 
important. Reduced or impaired bone formation during puberty, results in a greater 
risk of fracture later in life. By the age of 50, on average, both in men and women, 
bone resorption outpaces bone formation, setting into pace a process of inevitable 
bone loss. This condition is further escalated by the decline of osteoblast function late 
in life, further exaggerating the imbalance between bone resorption and formation 
(Rosen and Bouxsein, 2006)  
Ageing is one of the risk factors for the development of osteoporosis. Age-related 
bone loss is characterised by the uncoupling of the bone remodelling network 
whereby there is a reduction in bone formation and an increase in bone resorption 
(Kawai et al., 2012). Bone remodelling in a healthy skeleton entails removal of the 
older bone and replacing it with newer bone, and in osteoporosis this balance is 
interrupted, resulting in greater bone removal than replacement. This imbalance 
occurs during menopause and advancing age. During menopause the rate of bone 
remodelling increases which amplifies the impact of the remodelling imbalance. The 
loss of bone tissue leads to a disordered skeletal architecture and an increase risk of 
fracture (Cosman et al., 2014). 
There are two types of osteoporosis; primary osteoporosis and secondary 
osteoporosis. Primary osteoporosis is the deterioration of bone mass caused by either 
a decrease in sex hormone, ageing or both. In women, menopause or premenopausal 
oestrogen deficiencies can increase the development of osteoporosis. Secondary 
osteoporosis results due to chronic conditions such as excess endogenous and 
exogenous thyroxin, malignancies, gastrointestinal diseases, hyperparathyroidism, 
connective tissue diseases, renal failure and medications such as glucocorticoids. 
Additionally prolonged periods of inactivity or immobilization, inadequate calcium 
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intake, alcohol and tobacco abuse can also contribute to osteoporosis (Downey and 
Siegel, 2006).  
Osteoporosis does not only affect women. Men are also affected by osteoporosis due 
to secondary causes mentioned above. Some of the secondary causes include 
corticosteroid use, excessive alcohol use, hypogonadism, and vitamin D deficiency, 
as well as testosterone deficiency which act in synergy with oestrogen in men. Studies 
have suggested that in men bone loss accelerates after the age of 70 years. However 
unlike women who lose trabeculae connectivity due to bone resorption with age, in 
men the bone loss due to trabeculae thinning is as a result of reduced bone formation 
(Ebeling, 2008, Gennari and Bilezikian, 2007).  
1.3 Bone 
1.3.1 Function of bone and the skeleton 
Bone is a dynamic and a highly vascularised tissue. It has a unique capacity to heal 
and remodel itself without leaving a scar, therefore making it an important structural 
support for the body. Additionally, the skeleton also serves as a mineral reservoir, 
supports muscular contraction resulting in motion, withstands load bearing and 
protects internal organs (Rodan, 1992, Sommerfeldt and Rubin, 2001, Knight and 
Hankenson, 2013). Structurally, bone functions as a load bearing tissue to support 
and protect the human body for daily physical activities. Bone is composed of organic 
and mineralised components mainly made up of a matrix of cross-linked type I 
collagen mineralised with nano-crystalline, carbonated apatite (Olszta et al., 2007, 
Ruppel et al., 2008).  
The skeleton is composed of two parts: the axial skeleton consists of the bones of the 
head and trunk and the appendicular skeleton which is made up of bones of the limbs 
and pelvic girdle. A long bone is usually used as a standard example to discuss the 
macroscale structure of whole bones in the appendicular skeleton. Long bones such 
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as the tibia, femur, and humerus are divided into three parts: the epiphysis, 
metaphysis and diaphysis. The physis is a layer of growth cartilage that separates 
the epiphysis from the metaphysis. The epiphysis is found at either end of the bones 
while the metaphysis is a region between the physis and central portion or shaft of a 
long bone, the diaphysis (Morgan E F, 2008).  
1.3.2 Gross structure of bone 
1.3.2.1 Cortical and cancellous bone structure 
Cortical bone is a dense tissue and has a relatively low surface area. 80% of the mass 
of the skeleton is made up of cortical bone. It is found in the shaft of long bones, the 
outer shell at the end of joints, the vertebrae and ribs. Mineralised collagen fibres are 
arranged to form lamellae. The lamellae surround a central canal containing blood 
vessels and this forms the Haversian canal (Ralston, 2005, Rho et al., 1998b).  
Trabecular or cancellous bone has a lower density and a much higher surface area 
as it is a porous structure. The medullary cavities at the end of long bones and the 
interior of short bones such as ribs and vertebrae are normally composed of 
trabeculae bone. It is made up of an interconnecting meshwork of bony trabeculae 
separated by spaces filled with bone marrow and it therefore fills the middle of long 
bones, flat bones and the vertebrae (Ralston, 2005).  
The hierarchical structure of human cortical bone is approximately 95% solid and 5% 
porous. A cross section of human long bone is composed of osteons and interstitial 
tissue between periosteal and endosteal lamellae. Lamellae are layered sheet-like 
structures and are the basic building blocks of the human cortical bone. Osteons (also 
called Haversian systems) are tube-like structures of multiple concentric lamellae with 
a canal in the centre for blood vessels to transport. Trabecular bone is also composed 
of lamellae but these are usually organised in flattened sheets (Figure 1.1) (Reznikov 
et al., 2014). 
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Figure 1.1:The trabecular and cortical structure of bone (A). The rods and plates 
in the trabecular bone (B). Martius Scarlet Blue stain demonstrating collagen 
stained in red and bone stained in blue, separated by the osteoid. A scanning 
electron microscopy image of osteoblasts and osteocytes embedded in bone. 
The cortical structure of bone consists of the Haversian system that is made 
up of a central canal of blood vessels surrounded by the concentric collagen 
lamellae (E) (Adapted from (Tortora and Derrickson, 2013). 
 
1.3.3 Bone cells 
Three distinctly different cell types can be found within bone; osteoblasts, osteocytes 
and osteoclasts (Rodan, 1992, Sommerfeldt and Rubin, 2001, Knight and 
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Hankenson, 2013). The human skeleton is composed of approximately 20% 
trabecular bone and 80% cortical bone. Trabecular bone has a higher remodelling 
level compared to cortical bone as its 3D microarchitecture is directly controlled by 
mechanical strains exerted on it (Chappard et al., 2008). Bone is divided into 
hierarchical structural levels; the macrostructure which is composed of the cancellous 
and cortical bone; the microstructure composed of the Haversian systems, osteons 
and single trabeculae and the sub-microstructure (Rho et al., 1998a). 
 
Mesenchymal stem cells or osteoprogenitor cells migrate from the marrow, 
endosteum, periosteum and bone canals, and they differentiate to osteoblasts and 
osteocytes. Osteoblasts are cuboidal cells and they are responsible for depositing the 
bone matrix and they regulate the differentiation and activity of the osteoclasts, 
therefore making them important role players in calcium homeostasis. Osteoblasts 
contain characteristic rough endoplasmic reticulum, golgi apparatus and various 
secretory vesicles therefore making them protein synthesising cells. As polarised 
cells, the osteoblasts secrete osteoid toward the bone surface. The commitment of 
MSCs towards osteoblasts is influenced by certain genes and pathways such as Bone 
Morphogenetic proteins (BMPs) and Wingless (WNT) pathway (Mackie, 2003, 
Downey and Siegel, 2006, Florencio-Silva et al., 2015).  
 
Some of the osteoblasts producing bone eventually become trapped in the bone 
matrix and differentiate into osteocytes and form the mechano-sensor cells of the 
bone tissue. Osteocytes are encapsulated in the bone matrix and form long processes 
that extend through the lacunocanalicular system of the bone. They create an 
interconnected network in bone that allows intercellular communications between 
both neighbouring osteocytes and the surface-lining osteoblasts and which allows the 
transmission of mechanical and chemical signals across a network created by 
mechanical forces (Morgan E F, 2008).  
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 Osteoclasts are multinucleated cells that are involved in the resorption of fully 
mineralised bone at sites called Howship’s Lacunae. They originate from the 
hematopoietic stem cell lineage (Sommerfeldt and Rubin, 2001, Teitelbaum, 2000, 
Ralston, 2005). Osteoclasts dissolve the inorganic fraction of bone matrix by 
acidification and lysosomal enzymes. The mineralised bone surface in contact with 
the osteoclast is broken down by acidification while lysosomal enzymes digest the 
organic components. The acid and the enzyme capable of operating under acidic 
conditions (cathespin K) is formed in intracellular vesicles and released by fusion of 
the vesicles with the plasma membrane. This causes the plasma membrane in 
contact with the bone surface to form a ruffled border. The osteoclasts are adherent 
to the bone surface around their periphery producing a sealing zone rich in alpha 5-
beta 3-integrins which are vitronectin receptors. In this way a resorption pit is formed 
under the central portion of the osteoclast and this is called a Howship Lacunae 
(Stenbeck, 2002, Florencio-Silva et al., 2015).  
 
Aging bone is steadily replaced by new bone through a process called bone 
remodelling or turnover and this process occurs through the co-ordinated action of 
osteoblasts and osteoclasts, in a defined anatomical space called a basic multicellular 
unit (BMU). A remodelling cycle begins when bone-lining cells disappear and 
osteoclasts invade the region. The osteoclasts generate a Howships resorption 
lacunae over a 2-week interval. After this osteoclasts are inactivated, and osteoblasts 
are recruited to the site, to fill the resorption cavity with new bone (Weitzmann and 
Pacifici, 2006, Riggs et al., 2002). 
1.3.4 Stem cells and bone 
Stem cells have the capability to self-renew and to differentiate into at least one or 
more mature cell types (Krause, 2002). If provided with certain environmental stimuli, 
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they are capable of generating cells belonging to other tissues, and this process is 
known as stem cell plasticity. An adult stem cell can cross lineages and transform into 
another cell that is similar to the alternative tissue-specific stem cell (Sozer et al., 
2008). Many adult tissues contain populations of stem cells that have the capability 
to self-renew after injury, disease or aging and these cells can be found within the 
tissues or in other tissues that serve as stem cell reservoirs.  
 
The bone marrow is a source of adult hematopoietic stem cells (HSCs) and 
mesenchymal stem cells (MSCs)(Pittenger et al., 1999). MSCs give rise to those cells 
that form the mesenchymal tissues, including bone, cartilage, tendon, muscle, 
ligament and marrow stroma (Burder et al., 1994). They express a fibroblastic 
morphology and are obtained as a heterogeneous population from bone marrow after 
the removal of the non-adherent contaminating haematopoietic cells (Fox et al., 
2007). MSCs are characterised as plastic-adherent when maintained in standard 
culture conditions. MSCs must also express CD105, CD29, CD73 and CD90 and lack 
expression of CD45, CD34, CD14 or CD11b, CD79 or CD19 on their surface. They 
must also be able to differentiate to osteoblasts, adipocytes and chondroblasts in vitro 
(Dominici et al., 2006). There is a belief that mesenchymal-like stem cells can be 
isolated from a number of vascular tissues and that these are pericytes which 
surround blood vessels and which express CD146, a characteristic stem cell marker 
(Shi and Gronthos, 2003). For characterising MSCs, a combination of few positive 
and negative markers are selected (Table 1.1).  
Stem cells are widely being used to investigate the treatment of bone disorders and 
injuries. Stem cells from the bone marrow as well as adipose tissue have been used 
to heal defects using collagen scaffolds (Niemeyer et al., 2010). Interestingly most of 
these studies have utilised a cocktail of Platelet Rich Plasma (PRP) and stem cells to 
enhance bone regeneration as well as use genetically modified stem cells (Niemeyer 
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et al., 2010, Yamada et al., 2004, Gao et al., 2014), highlighting their potential clinical 
use in patients. 
 
Table 1.1: Main group of CD markers used to characterise MSCs. A combination 
of positive and negative markers is used to specifically identify a stem cell 
population (Ode et al., 2011, Dominici et al., 2006, Chamberlain et al., 2007).  
  
1.3.5 Bone formation 
There are two separate methods for bone formation; Endochondral ossification and 
Intra-membranous ossification. In intramembranous ossification, bone is formed in a 
matrix of haphazardly arranged collagenous fibrils. Just before ossification occurs, 
the mesenchymal stem cells proliferate and start to differentiate into osteoblasts, and 
the intracellular matrix becomes denser and homogenous. The osteoblasts then 
produce more matrix, which is then calcified. Some of the cells then become trapped 
in the matrix and transform into osteocytes (Sumner-Smith, 2002).  
Endochondral ossification occurs predominantly when bone elongates at the growth 
plate and it entails the replacement of cartilage with bone. Endochondral ossification 
can occur during fracture repair.  During endochondral ossification, chondrocytes 
proliferate, undergo hypertrophy and die. The cartilage extracellular matrix is then 
Positive MSC markers  Biological role 
CD29 Involved in MSC migration in vivo 
CD90 Wound repair, cell-cell and cell-matrix 
interactions. 
CD105 Vascular homeostasis and modulates TGF-beta 
functions. 
CD73 Catalyses production of extracellular adenosine 
from AMP. 
  
Negative MSC markers Used to exclude  
CD34 Primitive hematopoietic cells and endothelial 
cells 
CD45 Leukocytes 
CD14 and CD11b Monocytes and macrophages 
CD79 and CD19 B cells 
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invaded by blood vessels, osteoclasts, bone marrow cells and osteoblasts. The 
osteoblasts deposit bone on the calcified cartilage matrix (Mackie et al., 2008, 
Sumner-Smith, 2002). The chondrocytes deposit an extracellular matrix (ECM) which 
is made up of Type II collagen and aggrecan and then the chondrocytes differentiate 
into hypertrophic chondrocytes that deposit an ECM that contains type X collagen. 
This matrix is then partially mineralized, resorbed by osteoclast like cells often termed 
chondroclasts and replaced with a matrix consisting of Type I collagen by osteoblasts 
(Behonick et al., 2007). Endochondral ossification in the growth plate is controlled by 
various transcription factors and locally secreted systemic factors such as IGFs, 
Wnts, BMPs and this in turn influences the signalling pathways that control the 
proliferation and hypertrophy of chondrocytes (Mackie et al., 2008). In the growth 
plate but not necessarily during endochondral ossification during fracture repair, other 
locally secreted factors that control proliferation and maturation of the chondrocytes 
in a time dependent manner include parathyroid related peptide, Indian hedgehog 
and a number of fibroblast growth factors. These factors act to control proliferation 
and maturation of the chondrocytes so that the orientation of the growth plate is 
maintained (Kozhemyakina et al., 2015).  
 
The important role of chondrocytes in the initial stages on bone formation has been 
highlighted in many studies. Harada and co-workers implanted MSCs pre-
differentiated to chondrocytes in vitro before implanting them in Poly(lactic-co-
glycolic) acid (PLGA) scaffolds in a 5mm and 15 mm rat defect site. The strategy of 
the study was to mimic endochondral ossification. After 8 weeks, in the 15mm gap, 
they observed a 75% biomechanical strength in comparison to the normal bone and 
union occurring in a both gap sizes (Harada et al., 2014). Van der Stok et al, 2014 
also looked at differences in non-union fracture healing when undifferentiated and 
chondrogenic differentiated MSCs were implanted into a 6mm defect site in mice. The 
chondrogenic differentiated implants had improved bone formation compared to the 
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groups that received undifferentiated MSCs (van der Stok et al., 2014). These studies 
show that cells differentiated to chondrocytes encourage bone formation as it initiates 
the stages of endochondral ossification.  
It is well known from humans that osteoporosis affects fracture healing. Animal 
models, which do not recapitulate human osteoporosis but rather develop a more 
osteopenic bone structure have been used to investigate the effects of osteoporosis 
on fracture healing. Animal studies conducted on ovariectomised rodents as well as 
sheep have shown a delay in ossification in tibia or femur osteotomy, a decrease of 
20-40% in callus area and a reduction in BMD by around 20%. They also observed a 
decrease in mechanical strength of the callus, decrease peak failure load and 
decreased bending stiffness. Most importantly the architecture of the callus in the 
osteotomy in the osteopenic animals was different to the control animals, with 
disrupted and thinner trabeculae and reduced connectivity (Lill et al., 2003, Cao et 
al., 2002, McCann et al., 2008a).  
 
Studies have also investigated the release of growth factors that influence bone 
formation at a fracture site in an ovariectomised model. Xu and co-workers,observed 
a lower BMD at the fracture site in osteopenic Wistar rats. However, most importantly, 
3-4 weeks after the fracture, they observed a reduction in TGFβ expression in the 
vicinity of the bone trabeculae in these rats, showing that osteoporosis affects release 
of bone growth factors, therefore affecting bone remodelling (Xu et al., 2004).  
1.3.6 Signals regulating MSCs during bone regeneration 
Bone regeneration is a complex process involving cells and factors from many 
different compartments of bone. Both local and distant progenitor cells contribute to 
repair and various soluble factors are important components of bone repair. In 
addition, physiologic stimuli such as hypoxia and mechanical loading influence the 
signalling for the migration, proliferation and differentiation of the MSCs to the site of 
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injury. These factors include; fibroblast growth factor, sclerostin, Bone Morphogeneic 
Protein (BMP), Wnt/β-catenin, and Notch signalling pathways (Knight and 
Hankenson, 2013).  
Under the control of transcription factors RUNX2 and osterix, Vitamin D, BMPs and 
Wnt signalling, MSCs differentiate to osteoblasts. Mature osteoblasts then proceed 
to produce an extracellular matrix rich in type I collagen that is mineralised and serves 
as a scaffold. Osteocytes are embedded in the mineral matrix where they act as 
mechanosensors and regulate mineral homeostasis.  
RANKL is a key osteoclast regulator and is expressed on MSCs, osteoblasts and 
osteocytes. Osteoclasts differentiate from haemopoietic stem and progenitor cells in 
the presence of macrophage colony-stimulating factor and receptor activator of NF-
kB ligand (RANKL). In oestrogen deficiency and vitamin D insufficiency, RANKL is 
up-regulated and this therefore stimulates RANK on osteoclasts, encouraging their 
proliferation and activation, increasing the number of active osteoclasts. Both RANK 
and RANKL are bound to the cell surface but a soluble factor osteoprotegerin (OPG) 
that is secreted by stromal cells including osteoblasts, bind with RANKL preventing 
osteoclastogeneis (Hofbauer et al., 2014). 
Oestrogen is important for epiphyseal closure during puberty in males and females, 
as well as regulation of bone turnover. Oestrogen acts through 2 receptors; oestrogen 
receptor α (ERα) and oestrogen receptor β (ERβ). ERα has been shown to be the 
primary mediator of oestrogen’s actions on the skeleton. As well as acting on the 
BMU, its direct role on stem cells has also been identified. Oestrogen affects bone 
production by altering the T cell cytokine production and the production of RANKL or 
OPG from stromal or osteoblastic cells, by inhibiting the differentiation of osteoclasts 
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and also by stimulating bone formation by enhancing the response to mechanical 
forces of osteoblasts and osteocytes ( 
 
Figure 1.2) (Raisz, 2005). 
 
Figure 1.2: The main pathways for bone formation that control the function of 
osteoblasts, osteoclast and osteocytes. The RANK/RANKL pathway is 
important for osteoclast proliferation and activation. The WNT signalling 
pathway encourages the formation of osteoblasts from MSCs. 
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1.3.7 Biomechanics of Bone 
Resisting fractures while optimising the weight of the skeleton is an important function 
of the bone. Stiffness (resistance to deformation) and strength (maximum stress to 
failure) are necessary to accommodate large loads while toughness or ductility allows 
the bone to absorb the energy from impact loads. Higher tissue mineral content as 
well as a change in cross-linking structure of collagen would produce a stiffer but 
more brittle bone (Boskey and Coleman, 2010). Bone strength depends on age, 
gender, and species of animal and location of bone such as the humerus versus 
femur. Moreover, bone strength also depends on properties of bone such as inherent 
composition, microscopic morphology of bone components, bonds between fibres 
and matrix and bonds at points of contact of fibres. The structural properties of bone 
also determine bone strength such as geometry of whole bone, bone length, and bone 
curvature. Therefore, impaired bone strength might result from a reduction of bone 
mass, changes in bone micro-architecture or geometry (Fonseca et al., 2014, Smith, 
1985). However, these bone properties may also have a U-shaped relationship with 
bone strength; for example, too low or too high mineralisation may both cause bone 
to become fragile. 
Bisphosphonates cause osteoclast death, decrease bone turnover but this decreases 
fracture risk. Teriparatide increases bone turnover, but instead leads to an average 
decrease in bone tissue mineralisation, yet it has been shown to decrease fracture 
risk. The use of these drugs therefore proves that there are other determinants of 
bone strength apart from mineralisation (Arlot et al., 2005, Finkelstein et al., 2006, 
Maruotti et al., 2012).  
The micro-architecture of bone also affects the biomechanical strength of bone. Plate-
type trabecular bone has been shown to be much more mechanical efficient 
compared to rod-type trabecular bone. Thinning and loss of trabeculae is therefore 
associated with trabecular failure and a decrease in strength. The trabecular bone 
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properties are also affected by the degree of mineralisation (Hernandez and Keaveny, 
2006). Reducing the number of trabeculae has a greater deteriorating effect on the 
strength of bone compared to reducing the thickness of the trabeculae, hence the 
importance of maintaining the trabecular number (Silva and Gibson, 1997).  
1.4 Osteoporosis and Fractures 
Fragility fractures are a major problem in osteoporosis and probably its most 
distinguishable factor. These fractures can be a socioeconomic and health burden to 
the patient as well as the health care system as they would most likely result into non- 
and delayed union. Oestrogen deficiency during growth and ageing is a cause of bone 
fragility fractures in women. The biological and mechanical environment is really 
important for fracture repair and influence the processes of cell and tissue proliferation 
and differentiation (Augat et al., 2005). However, fracture healing in an osteoporotic 
bone is more complex than in normal bone as the differentiation potential of the stem 
cells and structural capability of bone is compromised (Almeida and O'Brien, 2013, 
Féron and Mauprivez, 2016). This therefore presents as a problem in osteoporotic 
patients.  
1.4.1 Fracture healing 
The process of fracture healing involves the action and interaction of many cells, 
regulated by biochemical and mechanical signals (Geris et al., 2008). Fracture 
healing is divided into three main phases; inflammatory, repair and the remodelling 
stage. When injury occurs to the bone, bleeding occurs due to numerous blood 
vessels rupturing. A haematoma develops in the fracture site during the first few hours 
and days after injury. The fracture site becomes hypoxic and osteocytes and 
damaged tissues become deprived of their nutrients. This then triggers an 
inflammatory response, whereby inflammatory cells such as leukocytes and 
macrophages are brought to the site. These inflammatory cells secrete fibroblast 
growth factor (FGF), tumour necrosis factor-α (TNF-α), PDGF and TGF-β and also 
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release a variety of cytokines such as interleukin-1 (IL-1) and interleukin-6 (IL-
6)(Komatsu and Warden, 2011, Geris et al., 2008). 
In addition, granulation tissue is formed, vascular tissue develops and mesenchymal 
cells migrate into the fracture site from blood, periosteum, bone marrow and other 
tissue niches. The mesenchymal stem cells then proliferate and differentiate into 
osteoblasts and chondrocytes (Dimitrou et al., 2011). Osteoblasts from the cortex and 
osteoprogenitor cells from the periosteum proliferate and differentiate to form 
immature woven born. This type of bone is characterised by the haphazard 
organisation of the collagen fibres, which have a woven appearance and by large 
rounded osteoblasts which typically secrete extracellular matrix in a non-directed 
manner. Fibroblasts begin to lay down a stroma that helps support vascular ingrowth. 
As vascular ingrowth progresses, a collagen matrix is laid down while osteoid is 
secreted and subsequently mineralized, which leads to the formation of a soft callus 
around the repair site. The callus is then ossified by the osteoblast, forming a bridge 
of mineralised woven bone between the fracture fragments (Kalfas, 2001, Geris et 
al., 2008, Planell et al., 2009, Einhorn and Gerstenfeld, 2015).  
In the remodelling phase, the original shape and mechanical strength of the healing 
bone is restored and the blood supply reverts to a normal state(Geris et al., 2008, 
Planell et al., 2009). Initially the trabecular bone is first resorbed by osteoclasts 
creating a resorption pit. Osteoblasts enter the resorption pit and manufacture new 
bone matrix of either the woven or lamellar type, starting from the outer surface and 
moving inwards, hence balancing the external removal with the addition on new bone 
to the internal surfaces(Kraus and Kirker- Head, 2006, Geris et al., 2008).  
1.4.2 Influence of mechanical environment on fracture healing 
There are many mechanical factors that influence fracture healing. The fracture 
geometry, which is portrayed by fracture type and gap size, is an important 
Chapter 1. Literature Review 
43 
 
mechanical factor that affects fracture healing. The mechanical environment 
influences the progress and outcome of the healing as it manipulates the 
differentiation and proliferation of cells in the defect region.  The size of the fracture 
gap is another important factor. With increasing distance between the fracture 
surfaces, the ability for a fracture to repair decreases. Smaller gaps demonstrate a 
faster and more successful healing process than larger gaps (Claes et al., 1997, 
Harrison et al., 2003). Differentiation of tissue in the gap is also determined by the 
inter-fragmentary strain. According to Perren, strains below 2% result into direct 
healing, strains below 10% stimulate healing through endochondral ossification and 
strains between 10-100% lead to granulation tissue and non-union (Gitajn and 
Rodriguez, 2011, Perren, 1979).  
There are two types of fracture healing: Primary or direct fracture healing and 
secondary or indirect fracture healing. Indirect (secondary) fracture healing is the 
most common form of fracture healing and consists of both endochondral ossification 
and intramembraneous bone healing and does not require rigidly stable conditions. 
Primary fracture healing, however, involves direct contact and requires stabilisation 
for healing (Féron and Mauprivez, 2016). 
Most importantly, in this context, the mechanical quality of the entire bone affects the 
fracture geometry and the inter-fragmentary movement. Hence the poor strength of 
osteoporotic bone influences the initial stability and fracture stabilization is reduced. 
In ageing postmenopausal women, periosteal bone formation increases the cross 
sectional area of the bone, hence decreasing the load per unit area of bone. The bone 
size and volumetric BMD is reduced to below a critical level and the tolerance of 
bone’s structural ability to sustain these loads decreases (Seeman, 2002, Augat et 
al., 2005). Lill et al, 2003 demonstrated no difference in bone healing at the beginning 
of the healing process between osteopenic and normal sheep. However, in normal 
sheep at 4 weeks, stiffness of the healing bone was higher compared to the 
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osteoporotic group, with callus formation affected in the early bone healing period and 
callus mineralisation in the later healing period. This illustrates the role of osteoblast 
function in bone formation and how osteoporosis prolongs the remodelling periods 
and affects fracture healing (Lill et al., 2003).  
With increasing age and particularly with osteoporosis, bone mass diminishes. 
Osteopenia in rats has been shown not to significantly delay fracture healing 
compared to non-ovariectomised rats and an early healing process was found to be 
similar in ovariectomised and non-ovariectomised rats. However interestingly, there 
was reduced mechanical strength of bone after completion of healing in the 
osteopenic rats (Waters et al., 2000, Wheeler et al., 2000, Cao et al., 2002). In 
secondary osteoporosis, steroid treatment delays fracture repair with respect to callus 
mineralisation and biomechanical properties. Meyer and co-workers also measured 
the biomechanics of fractured femora over a time period. They observed no difference 
in rigidity and breaking load between OVX rats and their control counterparts. 
However, importantly they noticed a significant variability between different age 
groups of the rats. The femora from the younger rats healed much better and much 
faster in comparison to those from older rats (Meyer et al., 2001).  
Therefore, there is no clear indication whether fracture healing in osteoporotic 
patients is slower due to their condition or their age. The lack of oestrogen as well as 
steroids in secondary osteoporosis could impair the function of osteoblasts hence 
affecting bone formation. Whether this affects the biomechanics during healing is still 
to be answered.  
1.4.3 Fracture, ageing and osteoporosis 
Ageing and osteoporosis are two inter-related yet separate degenerating conditions. 
Not all elderly patients are osteoporotic and an osteoporotic individual may not be 
elderly. Therefore, it is not clear whether poor healing capability of bone is due to 
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ageing or osteoporosis. Juvenile bone has a better healing response compared to 
adult bone due to a thicker and a more cellular periosteum as well as a better vascular 
supply. Since biological factors such as cells play an important role in fracture healing, 
the repair of bone is questionable in osteoporotic patients as their cells have a lower 
differentiation potential(Féron and Mauprivez, 2016, Almeida and O'Brien, 2013). 
However, it would be controversial to fully blame osteoporosis for the poor healing 
capacity of bone. This is because these patients suffer from other conditions such as 
age, rheumatism, thyroid and parathyroid disorders, and malignancy. The nutritional 
status of elderly patients is also compromised, which would further impair bone 
healing (Meyer et al., 2001, Paiva et al., 2016). A study by Meyer et al, 2000 showed 
that in older rats, neither sham operated or ovariectomised rats regained their 
mechanical strength in their fractured femora, 24 weeks after fracture. This was not 
the case with younger ovariectomised rats. This shows that age could also be a 
contributing factor in fracture healing (Meyer et al., 2001).  Ovariectomy has been 
shown to delay fracture healing in rats. McCann and co-workers showed that OVX 
animals had a lower BMD, slower fracture repair, reduced stiffness in the fractured 
femur and strength after 8 weeks post-fracture (McCann et al., 2008a).  
Age, rheumatism, thyroid and parathyroid disorders, and malignancy may influence 
the function of bone cells and impede healing through poor vascularisation. Tissue 
vascularisation is important for successful bone healing. Ageing affects the surface 
density of blood vessels but also signalling factors such as VEGF, HIF-1 and MMP-9 
that regulate the process of angiogenesis. VEGF and HIF-1 also play important roles 
in endochondral ossification (Lu et al., 2008).  
Summary: Mesenchymal stem cells play an important role in bone healing as they 
differentiate to osteoblasts and they can also form bone through the   endochondral 
ossification. Even though the commitment of MSCs to osteoblasts is influenced by 
Chapter 1. Literature Review 
46 
 
various genes and pathways, the question remains whether their differentiation ability 
is affected by ageing and osteoporosis.  
1.5 Osteoporosis and Ageing  
1.5.1 Ageing of bone 
In healthy individuals, the osteoblast progenitors, namely mesenchymal stem cells 
(MSCs), occur in low number (0.01 %–0.001 % of the nucleated portion) in the bone 
marrow (Wexler et al., 2003). In the aging population, the number of MSCs further 
decreases, thus leading to a significant reduction in bone formation (Garvin et al., 
2007). Bone remodelling is the key method in bone structural reorganisation and 
changes in bone remodelling can disrupt the mechanical strength of bone. Osteons 
reflect different bone remodelling patterns. Young individuals have high osteon 
diameter, osteon area, and osteon wall thickness than osteoporotic and old 
individuals. Osteoporotic patients have thin walled osteons in their bone structure. 
Young individuals also display higher numbers of osteocyte lacunae per osteon than 
the aged individuals (Bernhard et al., 2013). 
1.5.2 Stem Cells and Ageing 
Impaired migration of MSCs has been shown in various studies and there is need to 
upregulate the expression of important homing molecules (Devine et al., 2001, 
Lapidot and Kollet, 2002, Petit et al., 2002b). However, what many of these studies 
have failed to answer is if this is due to the poor expression of homing molecules such 
as CXCR4 and whether this is associated with age or osteoporosis. Previous reports 
have suggested that with age, the proliferation, differentiation and the in vivo bone 
formation ability of stem cells reduce and their senescence increases. However, it is 
unclear how many passages, population doublings, or senescent-associated 
molecular changes are associated with ageing (Wagner et al., 2010, Sethe et al., 
2006). Additionally, it is important to determine how age affects the proliferation rate 
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of MSCs, so as to enable MSCs from these older patients to be used in autologous 
transplantation, in age related diseases (Fossett et al., 2016). There are mixed results 
on the effect of ageing on the proliferation of MSCs. Stolzing et al, 2008 investigated 
the proliferation of MSCs from three different groups of patients; young (7-18 years 
old), adult (19-40 years) and aged (over 40 years). They observed a similar initial 
phase of growth up to 5 weeks in culture. However after 5 weeks the proliferation in 
the ‘aged’ MSCs began to decline while the MSCs from the ‘adult’ donors continued 
to proliferate throughout (Stolzing et al., 2008).  
MSC deficiency in cellular function may be one reason that the repair and 
regeneration of musculoskeletal injury and disease is more impaired in older patients. 
It is not just the structure of the bone and the osteoprogenitor cells that are affected 
with age, but the bone marrow as well. Histological examination of the bone marrow 
in the proximal tibia of 26 month old mice showed significantly more fat cells 
compared to the marrow of 8 month old mice. The stem cells from the bone marrow 
of the old mice are more likely to form fat and chondrogenic matrix in vitro due to the 
increase in sensitivity of the PPAR-γ (Moerman et al., 2004b, Zheng et al., 2007). Shi 
and co-workers observed greater attachment and proliferation as well as adipogenic 
differentiation of juvenile adipogenic derived stem cells (ADSCs) isolated from 6 day 
old juvenile mice in comparison to adult ADSCs from 60 day old adult mice. However, 
both types of cells had similar osteogenic differentiation ability (Shi et al., 2005).  
The link between osteoporosis, ageing and stem cells is debatable. There has been 
speculation that osteoporosis could partly be caused by a deficiency in BMSC 
osteogenesis. It has been reported that MSCs from osteoporotic postmenopausal 
women have poor osteogenic differentiation ability in comparison to MSCs from 
‘healthy’ control individuals (Rodriguez et al., 1999). However, Stenderup and co-
workers reported no difference in number, proliferation and osteogenic differentiation 
between osteoprogenitor cells from young, postmenopausal and osteoporotic 
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humans and concluded that there may be other mechanisms responsible for the 
defective osteoblast function in osteoporosis (Stenderup et al., 2001). The differences 
in the results from these studies could be because of differences in age and sex of 
patients. Stenderup’s study used female as well as male subjects. The results may 
therefore be subjective as men have a different bone structure compared to women, 
at different time points in their life. This would therefore imply that the osteoprogenitor 
cells from male subjects may not be directly comparable to female subjects of the 
same age.  
Another important factor to consider is whether age affects the pathway for bone 
formation. Meorman and co-workers showed increased sensitivity to PPAR-γ as well 
as a significant decrease in mRNA expression of the cytokines TGF-β2 and TGF-β3 
with aging (Moerman et al., 2004b). Osteoporosis not only results in the decrease in 
the number and activity of stem cells but also a decrease in signalling molecules such 
as oestrogen, IGH, TGF-B, and calcitropic hormones. Notch signalling increase bone 
formation over bone resorption and therefore raising the question of whether its loss 
may contribute to age-related osteoporosis(Engin et al., 2008).  
1.6 The role of Oestrogen in bone formation 
Oestrogen has a significant influence on bone formation in vivo, and reduced levels 
result in considerable bone loss due to increased bone resorption. Oestrogen 
deficiency has been shown to cause the development of osteoporosis in elderly men 
and in postmenopausal women. This deficiency causes an increase in bone 
resorption associated with increased osteoclast number, activity and reduced 
osteoclast apoptosis (Riggs, 2000, Almeida et al., 2013). Conversely an increase in 
oestrogen also causes an increase in osteoblast number, therefore implying its critical 
role in maintaining a balance between bone formation and resorption. The full role of 
oestrogen in osteoporosis therefore remains unknown because it either exerts its 
influence on bone through anti-resorptive actions or additional bone-forming effects 
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(Almeida et al., 2013).  Lack of oestrogen causes T-cells to produce tumour necrosis 
factor (TNF) which increases the effect of RANKL mediated osteoclastogenesis 
(Roggia et al., 2001).  
The deletion of the oestrogen receptor-α (ERα) from cells of the osteoclast lineage 
has been shown to accelerate bone resorption and loss of cancellous bone. It has 
been shown the inactivation of the ER-α gene in female mice, results in a significant 
decrease in the trabecular and cortical bone volumes compared to control mice. 
However, in male mice it was shown that the osteoblastic ER-α is not required for the 
regulation of bone formation during skeletal growth but it is necessary for the 
maintenance of the trabecular bone volume (Maata, 2013 & Melville, 2014).  
In vivo, bone goes through an adaptive change to loading conditions and this 
response is less effective in the absence of the α-form of the oestrogen receptor (ER-
α).  Osteoblast-like cells require ER-α to proliferate in response to mechanical strain 
in vitro. Oestrogen concentration determines the ER-α expression in osteoblasts and 
osteocytes. This therefore causes the ER-α activity in bone cells to reduce after 
menopause, limiting their anabolic response to mechanical loading. Lee et al, 2003 
showed an increased proliferation of a monolayer culture of osteoblast-like cells when 
applied with a single period of dynamic strain and there was improved response when 
the osteoblasts were transfected with ER-α. This response was inhibited by ER-α 
blockers (Lee et al., 2003).  
Oestrogen withdrawal causes an increased production of cytokines such as IL-7 and 
TNF, which limit the activity of mature osteoblasts. RANKL and M-CSF are important 
cytokines required for osteoclast formation and they are produced by stem cells, 
osteoblasts and activated T-cells. They induce the differentiation and proliferation of 
early osteoclasts. RANK-L binds to a receptor RANK, expressed on the surface of 
osteoclasts and osteoclast precursors. RANK-L also binds to OPG. During oestrogen 
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deficiency, additional cytokines produced or regulated by T-cells are responsible for 
the up regulation of osteoclast formation. TNF increases the osteoclastogenic activity 
of RANKL and together they up regulate RANK expression in osteoclast precursors 
(Figure 1.3)  (Weitzmann and Pacifici, 2006).  
 
Figure 1.3: The role of oestrogen in bone formation. Proliferation of osteoclast 
is influenced by WNT signalling pathway and RANK/RANKL pathway. PTH 
which is applied in a continuous or an intermittent manner, stimulates 
modelling and remodelling of bone by acting on osteoblasts.  
 
1.7 Current treatments of Osteoporosis 
Bone mass can be changed in two ways; the anti-catabolic route prevents the loss of 
bone caused due to ageing and reduction in sex hormones. The second route is the 
anabolic route, which increases bone mass through net bone formation. The current 
treatment of osteoporosis is mainly anti-catabolic agents such as bisphosphonates, 
which increase bone mineral density by inhibiting osteoclast activity. The four most 
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commonly used bisphosphonates clinically include: alendronate, ibandronate, 
risedronate, and zoledronate (Favus, 2010). The action of bisphosphonates is 
explained by their binding to bone mineral. Osteoclasts then uptake bisphosphonates 
by endocytosis, resulting into osteoclast apoptosis (Russell et al., 2008). This 
consequently leads to a reduction in bone remodelling, which slows bone loss and 
also leads to alteration in the bone material properties reducing fracture risk. 
However, the prolonged use of this treatment can cause "bisphosphonate fractures", 
which is a cortical expansion in the subtrochanteric region leading to femoral neck 
fractures (Dosier et al., 2015). Importantly bisphosphonate treatment seeks to only 
reduce bone resorption and does not encourage bone formation. A number of agents 
act in an anabolic manner and increase bone formation such as anti-sclerostin 
antibody or cathespin K. Teriparatide and Abaloparatide have a dual anti-catabolic 
and anabolic effect   (Bhargava et al., 2007, Zhang et al., 2014).  
Parathyroid Hormone (PTH) 
Parathyroid hormone and its N-terminal analogues (PTH1-34 and PTH 1-84) are used 
in the treatment of osteoporosis in postmenopausal women and both have shown to 
reduce the risk of new vertebral fractures (Nakajima et al., 2002). PTH is an anabolic 
agent that stimulates both remodelling and modelling that result in the formation of 
new bone, leading to an increase in bone mass (David B. Burr, 2013). PTH can be 
applied in a continuous or an intermittent (iPTH) manner and both types of 
administration lead to increased bone turnover at trabecular and cortical sites. 
However, unlike continuous dosing that results in increased osteoclast activation and 
lifespan, and thus enhanced endosteal resorption, iPTH results in increased 
trabecular bone volume, facilitated by the osteoblast. The primary receptor for PTH 
and PTHrP is the G-protein coupled receptor PTH1R, known to be expressed on the 
surface of osteoblasts, osteocytes, stromal cells, T-cells and macrophages. At low 
concentrations PTH binds preferentially to PTHR1 on cells of the osteoblastic lineage, 
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thus driving osteoblastic bone formation (Jilka et al., 2007, Bellido et al., 2003). 
Additionally, the rapid degradation of the hormone ensures that osteoclastic bone 
resorption is not activated via this mechanism. Intermittent PTH also induces the 
activation of RUNX2. This transcription factor not only drives the differentiation of 
stem cells down the osteoblastic lineage, it also maintains osteoblast maturity and 
thus has a role in increasing bone formation in both osteoporotic and increased bone 
turnover states (Powell et al., 2011, Mason et al.,2010). 
Anti-Sclerostin therapy 
Anti-Sclerostin therapy has been shown to be effective at increasing bone density 
and strength in animal models with osteopenia and patients with osteoporosis. 
Sclerostin is produced by osteocytes embedded in the bone matrix. Sclerostin inhibits 
BMP modulated bone formation by antagonising Wnt signalling. It acts by binding to 
intracellular LRP5 and/or LRP6, thereby impairing further signalling through B-
catenin. This decreases osteoblastic activities, reducing the production of new bone 
and mineralization. It also acts by blocking the maturation of osteocytes and controls 
the expression of genes involved in bone matrix mineralization (Shah et al., 2015, 
Poole et al., 2005, van Bezooijen et al., 2007). A number of studies have investigated 
the effect of anti-sclerostin on fracture repair and healing. Systemic administration of 
sclerostin antibody has been shown to enhance bone repair in a critical-sized femoral 
defect in a rat model at 12 weeks (Virk et al., 2013). Liu and co-workers also 
investigated the effect on MSCs of rats injected with anti-sclerostin. They found MSCs 
isolated from rats injected with anti-sclerostin proliferated faster and expressed 
greater levels of ALP than cells isolated from non-treated rats. Additionally, the same 
authors demonstrated that anti-sclerostin increases bone mass, bone strength and 
bone formation in an osteopenic closed fracture model in Sprague Dawley rats, at a 
fracture site at 8 weeks compared to rats treated with saline (Liu et al., 2016).   
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Denosunab 
Denosumab (Prolia*) is a human monoclonal RANKL antibody that causes the 
inactivation of osteoclasts, apoptosis, and reduction in osteoclasts’ differentiation by 
preventing RANKL from binding to RANK. This drug mimics osteoprotegerin that 
binds to RANKL, preventing RANKL from binding to RANK on the osteoclast surface, 
therefore preventing osteoclast differentiation.  The reduced RANK-RANKL binding, 
inhibits bone resorption and therefore bone mass is increased (Lipton and Goessl, 
2011, Bone et al., 2011). However, the use of Denosumab has been associated with 
immunity and infection problems. There have been reports of serious infection and 
skin reaction with long term use of Denosumab which may be associated with 
disruption of the receptor sites of RANK on cells of the immune system (T cells). 
There have also been concerns of fractures when patients discontinue the use the 
denosumab due to the rapid reversibility of the anti-resorptive effect (Leder et al., 
2017, Zaheer et al., 2015).  
Hormone Replacement Therapy (HRT) 
Another treatment option available for osteoporotic patients is Hormone Replacement 
Therapy (HRT). In this treatment therapy Oestrogen or Oestrogen in combination with 
progesterone is given to relieve symptoms of menopause. In HRT regimens, the 
oestrogen is taken daily and with the sequential or daily addition of progesterone. 
Indeed, it has been shown to improve bone density in post-menopausal women. 
However, it has been linked to breast cancer, stroke, thrombo-embolic events and 
cardiovascular disease (Nelson et al., 2002, Hickey et al., 2012, Prince et al., 1991).  
Strontium Ranelate 
This drug has been developed to reduce the risk of vertebral and non-vertebral 
fractures in postmenopausal women with osteoporosis (Meunier et al., 2004). It 
stimulates a dual action on bone formation by encouraging the differentiation of 
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osteoblasts and inhibits osteoclast differentiation, hence causing a negative effect on 
osteoclast resorption activity. (Reginster et al., 2005, Bonnelye et al., 2008). It 
therefore increases bone mineralisation and has also been shown to increase the 
trabeculae thickness and reduction in trabeculae separation in patients treated for 3 
years (Jiang et al., 2006). Strontium ranelate acts on bone metabolism by interfering 
with the bone formation pathway by acting on RANKL/OPG ratio. It has been shown 
to reduce RANKL levels and increase OPG concentration, hence preventing the 
interaction of RANKL to RANK and reducing bone resorption by osteoclastic 
mechanisms (Marie et al., 2001, Brennan et al., 2009).  
1.7.1 Stem cell therapy 
Bone remodelling occurs through two mechanisms; one in the trabecular bone next 
to the red marrow, where the osteoprogenitor cells migrate from the marrow directly 
to the bone surfaces and a second mechanism within the cortical bone, where the 
osteoprogenitor cells arrive at the bone via an alternate route. As well as stem cells 
from the bone marrow, remodelling occurs in vascularised bone-remodelling 
compartments. Cells destined to become osteoblasts enter these compartments via 
the capillaries rather than the bone marrow. Circulating osteoblastic cells and 
haematopoietic stem cells enter the defect sites via these capillaries. Also it has been 
stated precursor cells within the capillary walls differentiate into osteoblastic 
progenitors. Some of these osteoprogenitor cells also originate from the perivascular 
compartments (pericytes) into the vascular system, and also contribute to bone 
formation (Fayaz et al., 2011, Mödder and Khosla, 2008).  
There are various sources of stem cells that could contribute to bone formation and 
stem cells derived from these tissues have been used from bone regeneration.  
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Bone marrow Derived Mesenchymal stem cells (BMSCs) 
Mesenchymal stem cells (MSCs) are multipotent adult stem cells that can be obtained 
from various sources such as bone marrow, adipose, muscle and umbilical cord blood 
tissue. They are pluripotent progenitor cells that divide many times and give rise to 
skeletal tissue: cartilage, bone, tendon, ligament, marrow stroma and connective 
tissue (Caplan, 2007). MSCs can be differentiated into several different cell types in 
vitro and their relative ease of expansion in culture, as well as immunologic 
characteristic makes them a good source for tissue repair and gene therapy. 
Recruitment of inflammatory cells, endothelial cells and MSCs from the tissues, 
circulation and the bone marrow is essential for bone healing. Stem cells can be used 
to restore tissue function either by integrating into the target tissue or acting as a 
medium to deliver complex signals to a target tissue without integrating into the tissue 
itself (Daley and Scadden, 2008). Unique to bone regeneration, MSCs differentiate to 
become either chondrocytes or osteoblasts and they are therefore a critical 
component for bone healing (Knight and Hankenson, 2013).  
Perinatal derived stem cells 
Perinatal derived stem cells can be derived from the umbilical cord, the placenta, as 
well as Wharton’s jelly. Wharton’s jelly is the mucoid connective tissue surrounding 
the umbilical cord vein and its main function is to protect the vasculature from 
pressure. Umbilical cord blood-derived stem cells (UCB) have also recently 
generated tremendous interest in the orthopaedic field. UCB can be harvested non-
invasively without any risk to the donor, while possessing a low immunogenic 
potential, giving them a diverse application in cell therapy. An et al, demonstrated a 
30% increase in bone mineral density (BMD) in mice when human UBC-MSCs were 
injected in OVX mice after 4 and 8 weeks, with increases in trabecular volume, 
number and thickness compared to mice treated with sham injections (An et al., 
2013).  
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Placenta derived MSCs have been shown to tri-differentiate and express stem cell-
like CD markers. They have also been capable of differentiating to osteoblasts and 
lay a mineralised matrix (Zhong et al., 2012). Interestingly when implanted with 
hydroxyapatite/tricalcium phosphate particles, the cells were capable of forming 
ectopic bone 8 weeks after transplantation in mice, with high expression of bone 
markers such as osteocalcin and osteopontin (Kusuma et al., 2015). 
Adipose derived Mesenchymal stem cells (ADMSCs) 
The vast majority of pre-clinical studies have investigated the use of implanted bone 
marrow derived stem cells, though a growing body of work is exploring the use of 
adipose derived stem cells (Brennan et al., 2013, Hicok et al., 2004). Studies have 
suggested superior cell yield (6-fold), differentiation capacity and immune-modulation 
of adipose derived cells versus those from bone marrow, hence increasing interest in 
their in vivo osteogenic capacities (Fraser et al., 2006). Subsequently, canine and 
murine studies have demonstrated the efficacy of allogenic adipose derived cells in 
the healing of long bone and calvarial defects, though little work has demonstrated 
the use of autologous minimally manipulated adipose derived cells to improve bone 
formation in human studies  (Cui et al., 2007, Levi et al., 2010, Mesimaki et al., 2009, 
Lendeckel et al., 2004, Thesleff et al., 2011). 
 
Similarly, ADMSCs are also easy to isolate and they produce a large cell yield. Ye et 
al, transplanted autologous ADMSCs in alginate in the femoral condyles of rabbits, 
and found that it enhanced bone mass, increased cancellous bone formation and 
trabecular bone structure and decreased bone loss at 8 weeks in comparison to the 
groups with only alginate transplanted in the condyles. Additionally, at 12 weeks, the 
BMD reached 88% of the normal rabbit’s value, much higher than the alginate-
injected group. Additionally, they also demonstrated that ADMSCs in alginate 
composites positively induced a BMP signalling pathway that could favour 
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osteogenesis and inhibit adipogenesis of stem cells from osteoporotic rabbits (Ye et 
al., 2014). Jeong et al. injected ADMSCs into OVX rats through the lateral tail vein. 
An increase in the BMD and trabecular thickness was seen in the stem cell group 
when compared with the control; denoting the significance of stem cells in the 
pathophysiology and treatment of osteoporosis (Jeong et al., 2015).  
Embryonic stem cells (ES cells) 
Embryonic stem cells are derived from the inner cell mass of blastocyst, and are self-
renewing and pluripotent. Their ability to differentiate to any tissue makes them ideal 
for regenerative purposes (Wu, 2015). The osteogenic differentiation of ES cells on 
scaffolds has been examined in vivo. Jukes and co-workers, 2008, differentiated ES 
cells into a cartilage matrix and transplanted these into critical-cranial defects in rats. 
They observed calcification of the cartilage and bone formation in the defect sites. 
They reported that pre-differentiation of ES cells to chondrocytes, to mimic 
endochondral ossification, encouraged bone formation in vivo. This was not observed 
with ES pre-differentiated to osteoblasts, even though these cells easily differentiated 
to bone in a tissue culture dish (Jukes et al., 2008) 
ES cells have also been stimulated mechanically by cyclic loading and culturing them 
on BioFlex plates to encourage successful differentiation of ES cells to osteoblasts in 
vitro (Ehnes et al., 2015, Li et al., 2013). However, results from in vitro studies need 
to be considered with caution as they do not predict in vivo bone formation. 
Additionally, derivation of human ES cells have several ethical limitations as it 
involves the destruction of human embryos and it is not possible to generate patient-
specific lines (Wu, 2015, Yamanaka, 2009).   
Induced Pluripotent stem cells (iPS) 
iPS cells are pluripotent stem cells derived from fibroblasts. In 2006, Shinya 
Yamanaka showed that mouse embryonic and adult fibroblasts acquire properties 
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similar to ES cells after retrovirally introducing genes encoding Oct3/4, Sox2, Klf4, 
and c-Myc (Takahashi and Yamanaka, 2006). This has increased the potential to 
derive pluripotent stem cells from easily accessible somatic cells. In vivo osteogenic 
differentiated iPS cells have been transplanted in a critical calvarial bone defect in 
SCID mice and were shown to form new bone in the defect site. However, if the iPS 
cells were not treated with irradiation before transplantation, they caused teratoma 
formation (Hayashi et al., 2012). In vitro their ability to differentiate to bone has been 
proven by many studies, however in vivo and clinically, their effectiveness to 
differentiate to bone still needs to be established (Grigoriadis et al., 2010, Li et al., 
2010, Tashiro et al., 2009). 
1.7.2 Gene therapy for bone regeneration 
To improve the function by enhancing growth-factor delivery, recent work has 
involved genetically modifying stem cells. Gene therapy offers an alternative means 
to achieve controlled delivery of specific proteins for bone regeneration through the 
transfer of nucleic acids to somatic cells for a continuous therapeutic expression of 
osteoinductive factors. This regulates cell activity at a specific site by the release of 
appropriate concentrations of functional growth factors. Gene therapy has many 
possible applications in orthopaedic practice, including the enhancement of bone 
healing (Evans et al., 2005, Betz et al., 2005, Vo et al., 2012).  The controlled delivery 
of growth factors and cells, at sites of bone injuries, can enhance and accelerate 
functional bone formation. Gene transfer can be performed using a viral (transfection) 
or a non-viral (transduction) vector, and by either an in vivo or ex-vivo gene transfer 
strategy (Dimitriou et al., 2005). In vivo transfer strategies to enhance bone formation 
include delivery of growth factors such as BMP-2, 4 and 7 directly to the site of repair 
either by injection or by incorporation on a scaffold. This approach has many 
disadvantages such as short half-life, instability which results in the repeated 
administration of the growth factors and safety issues. Gene therapy where cells are 
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transfected in vitro with a virus carrying a gene which has perceived beneficial effects, 
before being transplanted in vivo, could be advantageous for delivery of growth 
factors (Hao et al., 2009).  
Since cells do not take up genes spontaneously, vectors have to be used for gene 
transfer into the cell. Viruses are effective vectors for delivering cDNA as they are 
designed to efficiently infect cells and transmit genetic material (Pensak and 
Lieberman, 2013). Commonly used viral vectors include; Oncoretrovirus and 
Lentivirus which are retrovirus, adeno-associated virus (AAV), adenovirus and 
Herpes simplex virus (Betz et al., 2005). Clinically adenoviruses have been used to 
treat cystic fibrosis in patients (Knowles et al., 1995, Zabner et al., 1996). Retroviruses 
integrate their genetic material into the chromosomal DNA of the cells they infect. This 
is advantageous when long-term transgene expression is required. However there is 
a low chance that the insertion site is random which may result in insertional 
mutagenesis, raising huge concerns about the safety of these vectors (Betz et al., 
2005).  
Bone healing does not require long-term transgene expression and therefore the 
application of non-integrating vectors such as adenovirus and adeno-associated virus 
(AAV), can be used. The advantages of using an adenoviral vector system for this 
type of gene therapy include; extremely high transduction efficiencies compared to 
liposome-mediated gene transfer methods and the ability to accommodate large (up 
to 7.5kb) cDNAs. The virus can also be grown to high titers, which can readily be 
prepared and used to efficiently infect a number of cell types.  Unlike retrovirus 
transfection, adenovirus has a low pathogenicity in humans and does not integrate 
into the host genome which avoids potential problems associated with insertional 
mutagenesis. This is important because the viral genome will not be replicated into 
the host cells and would eventually be lost by dilution, due to cell division and 
apoptosis (Luo et al., 2007, Franceschi et al., 2000, Evans et al., 2007). Adenoviral 
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transfection has been used in bone regeneration studies such as adenoviral gene 
transfers of bone morphogenetic protein-2 (BMP-2) to enhance fracture healing. 
Egermann and co-workers, created osteotomies in osteoporotic sheep and 
transplanted osteoblasts and MSCs transduced with a recombinant adenovirus 
carrying BMP-2 cDNA (Ad.BMP-2). Ad-BMP-2 treatment caused increased 
mineralisation and stiffer callus formation (Egermann et al., 2006). Lieberman and co-
workers transplanted adenoviral transfected murine MSCs with BMP2 and 
demineralised bone (DBM) into femoral defects and showed successful healing of the 
large bone defects in comparison to empty defects (Lieberman et al., 1998). Ho and 
co-workers, 2014 adenovirally transfected SDF-1 into MSCs and transplanted these 
modified cells into fracture sites and showed improved bone formation when 
genetically modified cells were used compared to an empty gap (Ho et al., 2014a). 
Tang et al, 2008 also transplanted hBMP-2 transfected bone marrow MSCs into 
scaffolds and implanted them into a defect site in the ramus of the mandible of 
osteoporotic rats and they showed improved bone formation (Tang et al., 2008).   
Genetic engineering can also be achieved using non-viral methods (transduction). 
They have an advantage over the viral methods since they produce low immunogenic 
reactions; they have a nearly unlimited size of transgene and a well-established, 
straightforward transduction procedure. Such therapies include the use of 
photoporation, magnetoporation, hydroporation and chemical carriers. Lipids have 
also been developed for use in gene therapy. Lipid carriers developed to deliver 
genes directly into cells, have a positively charged hydrophilic head and a 
hydrophobic tail. The positively charged head binds with the negatively charged 
phosphate group in nucleic acids. However, the problem is that the positively charged 
liposomes interact non-specifically with negatively charged serum proteins and 
enzymes, resulting in low transfection rates. Additionally, the use of the other currently 
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available non-viral vectors does not fulfil the ideal vector properties and they have 
been proven to be very expensive (Ramamoorth and Narvekar, 2015).  
Summary: In conclusion, the current treatment such as bisphosphonates, are 
catabolic and other treatments like HRT and Denosunab have been associated with 
problems. There has been research on using stem cells as well as gene therapy for 
bone regeneration. However, it still remains to be seen whether stem cell therapy is 
effective in osteoporosis. There is evidence showing that stem cells have the potential 
to regenerate in fractures but as osteoporosis affects bones throughout the body, and 
as such is not site specific, intravenous administration or endogenous mobilisation 
may be an effective way of treating it.   
1.8 Osteoporotic animal model 
To select an adequate animal model to study a disease, it is important to reproduce 
the disorder as closely as possible. In orthopaedic research, the choice of species is 
varied. After analysing 21,500 mammals, Martini et al showed that from 1970 – 2001 
rats are most commonly used (36%), followed by mice (26%), rabbits (13%), dogs 
(9%), primates (3%), sheep, pigs and cats (2% each) (Martini et al., 2001). There are 
several factors to be considered when choosing an appropriate animal model for 
osteoporosis research: 
• Cost and availability 
• Ethical and societal implications 
• Transferability of information 
• Genetic uniformity of organisms where applicable 
• Reproducibility  
The main types of osteoporosis in humans are postmenopausal osteoporosis, disuse 
osteoporosis, and glucocorticoid-induced osteoporosis. Animal models for 
postmenopausal osteoporosis are achieved by ovariectomy to emulate the loss of 
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hormonal balance that interrupts the bone formation cycle. In the adult human 
skeleton, bone formation is coupled to bone resorption. Therefore, a ‘perfect’ animal 
model for an osteoporosis study would be a living animal in which spontaneous or 
induced bone loss is caused due to a deficiency of oestrogen, and in which the 
characteristics of the bone loss and its progression resemble those found in 
postmenopausal women in one or more respects (Kalu, 1991, Jee and Yao, 2001). 
The ovariectomised rat is considered an appropriate model for investigating human 
postmenopausal osteoporosis because of many similarities in their 
pathophysiological mechanisms. The rat skeleton demonstrates a gradual transition 
from modelling to remodelling that relates to age progression in both cancellous and 
cortical bone  (Comelekoglu et al., 2007, Han et al., 1998, Zhang et al., 2007, 
Francisco et al., 2011, Lelovas et al., 2008).  
Rats reach skeletal maturity at the age of 2.5 months but their skeleton is considered 
mature after the age of 10 months. However, this does work to the advantage of using 
the rat as an osteoporotic model, because skeletally immature rats have a low peak 
bone mass which is a high risk factor for human osteoporotic fractures. The skeletally 
mature rat, on the other hand, is considered an appropriate model for the research of 
postmenopausal and immobilization osteoporosis (Turner et al., 2001). However, the 
biggest drawback of the rat skeleton is that some bones maintain a lifelong growth 
and their epiphyses do not fuse. Trabecular bone and Haversian bone do not remodel 
in a rat skeleton and they also have a slow developing cortical bone loss compared 
to humans. In a rat’s cortical bone, bone gain occurs in the periosteum and cortical 
bone is lost at the endosteum (Jee and Yao, 2001, Lelovas et al., 2008, Erben, 1996). 
The rat OVX model has been used in several studies to test treatment regimens for 
osteoporosis. Khajuria and co-workers tested the combination effect of Zoledronic 
acid and Propranolol on trabecular microarchitecture. The female Wistar rats were 
ovariectomised at 3 months and treatment regimens were applied 12 weeks post 
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ovariectomy. The bones from the rats were analysed 12 weeks after drug 
administration (Khajuria et al., 2014). Several other studies have also used the 
ovariectomised rat model to study the therapeutic effects of other drugs for 
osteoporosis such as anti-Sclerostin, teraparatide, and the bisphosphonate 
risedronate (Sugie-Oya et al., 2016, Li et al., 2014, Chen et al., 2015). 
Mice, another commonly used animal model in orthopaedics are attractive due to their 
low cost, ease of handling, and the availability of genetic knockout varieties. However, 
they lack a Haversian canal system and there is concern about their size and how 
results from a small animal can be translated into humans (Viateau et al., 2008).  
Large animals such as rabbits, dogs and primates have a similar Haversian 
remodelling to humans. However, these animal models are not used that much in 
studies because of high cost of maintenance, ethical dilemmas and also because they 
are inappropriate models for postmenopausal osteoporosis. Dogs have similar bone 
composition, remodelling and architecture as humans, but have lamellar and 
plexiform bone. Additionally their bones have different biomechanical properties as 
well as a variable remodelling rate from humans (Pearce et al., 2007, Kuhn et al., 
1989).  
 A sheep OVX model has been used to model bone loss in osteoporosis (Newton et 
al., 2004). Ewes ovulate spontaneously and have a similar sex hormone profile to 
women. Sheep also present fewer ethical controls than domestic pets such as cats, 
dogs and non-human primates. Older sheep also display Haversian bone remodelling 
and they are genetically more identical to humans compared to rodents (Wilke et al., 
1997, Newman et al., 1995).  
Although the trabecular and cortical bone of older sheep (> 1 year) is composed of a 
well-developed Haversian system as well as bone remodelling by bone multicellular 
units (BMUs), the cortical bone of young sheep (<1 year) which is plexiform is 
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significantly different from the human cortical lamellar bone. Plexiform bone is 
characterised by a combination of woven and lamellar bone, which allows the animals 
to grow rapidly under optimal mechanical properties (Turner et al., 2001, Oheim et 
al., 2012). Additionally, the main problem with using sheep as an OVX model is that 
sheep attain bone loss in 3-8 years within their adult life while humans have a 10-fold 
longer period of development. Sheep also develop osteopenia at various sites and to 
different extents (Newton et al., 2004, Zarrinkalam et al., 2009). Additionally in 
comparison to a small animal such as a rat, which takes around 12 weeks to attain 
osteopenia, in sheep osteopenia takes around 12 months to develop (Zarrinkalam et 
al., 2009).  
Therefore, for this study, I would be using a rat model for osteoporosis. The stem cells 
harvested from OVX rats would be genetically modified and injected intravenously 
into an OVX rat to investigate whether it would improve bone formation.  
1.9 Migration of MSCs - The role of SDF1 and CXCR4 in cell 
homing and bone regeneration. 
Cellular movement and re-localization are crucial for many important physiologic 
properties such as, embryonic development, neovascularisation and angiogenesis, 
immunologic responses, wound healing, and organ repair. Both local MSCs from the 
injured tissue and circulating MSCs collaborate in the healing of organs during organ 
regeneration. Cell movement is regulated by chemotaxis, which causes directional 
migration via signalling molecules called chemokines (Dar et al., 2006, Ito, 2011). 
During organ regeneration, it has been suggested that local MSCs derived from the 
injured tissue and circulating MSCs work together in healing of the damaged organs. 
Stem cells sense the tissue injury, migrate to the site of damage and undergo 
differentiation (Shyu et al., 2006, Ito, 2011) and this may explain the profound 
increment of stem cells found in damaged tissues compared to normal healthy tissues 
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such as impaired sites in the brain after Hypoglossal Nerve injury (Ji et al., 2004) and 
cerebral injury (Imitola et al., 2004). As a result of injury, the surviving cells may 
produce chemoattractants such as SDF-1 that may direct the migration of MSCs to 
the injury site through the interaction with CXCR4 (Imitola et al., 2004).  
Cytokines and chemokines play important roles in maintaining the mobilization, 
trafficking and homing of stem cells. Stromal cell-derived factor SDF-1 and its 
receptor, CXCR4, are important in the mobilization of MSCs (Liu et al., 2009) (Figure 
1.4). SDF-1 is produced in many organs, including the bone marrow and it therefore 
has a role in leukocyte trafficking and retention of hematopoietic stem and progenitor 
cells within the bone marrow (Petit et al., 2002a, Zou et al., 1998). CXCR4 has been 
shown to mediate the migration of MSCs to the bone marrow. Wynn and co-workers, 
(2004) showed that neutralizing anti-CXCR4 antibody inhibited MSC migration by 
approximately 46%. This showed that MSCs express functionally active CXCR4 
receptor, which causes the migration of MSCs to the bone marrow. Additionally, the 
migration of MSCs in a transwell assay was also studied to investigate the response 
of CXCR4 receptor to the SDF1. It was found that dose dependent migration of MSCs 
occurred with maximum migration occurring at a SDF-1 concentration of 30ng/ml. 
However it was found that CXCR4 receptor is present at low levels on the cell 
surfaces of MSCs and to improve the engraftment of MSCs to bone marrow and bone, 
an increase in its functional expression may be required (Wynn et al., 2004b).  
A study by Kitaori and co-workers (2009), investigated the role of SDF-1 and its 
receptor, CXCR4, in bone healing. It was found that SDF-1 promoted endochondral 
bone repair by recruiting mesenchymal stem cells in the periosteum of the injured 
bone and administration of anti-SDF-1 antibody resulted into cell migration being 
inhibited with decreased callus formation(Kitaori et al., 2009). In addition, Granero-
Molto et al (2009) showed that implanted MSCs migrated to a fracture site and this 
was driven by CXCR4. The MSC transplant improved fracture healing by increasing 
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the material toughness of the callus and causing it to be less brittle. Interestingly they 
separated CXCR4(+) and CXCR4(-) from a stem cell population isolated from the 
bone marrow. They then injected these cells separately into rats with stabilized tibial 
fractures. They showed that CXCR4(-) MSCs were not capable of migrating to the 
fracture site, up to 14 days post-injection (Granero-Molto et al., 2009). This therefore 
proves that systematically transplanted MSC are able to home to fracture sites, but 
this migration is reliant on CXCR4.  
The role of SDF-1/CXCR4 in recruiting stem cells has been studied for various injured 
tissues such as myocardial injury. It has been observed that SDF-1 expression is 
rapidly increased within minutes to an hour after myocardial infarction, providing a 
signal for stem cell recruitment and engraftment into the injured tissue. When treated 
with SDF-1 expressing cardiac fibroblasts, an increase in left ventricular mass and a 
significant increase in the anterior-wall thickness was observed (Askari et al., 2003). 
CXCR4 also serves as a guidance molecule for neural stem cells in injured sites in 
the central nervous system. The expression of CXCR4 on human neural stem cells 
and the exposure of these cells to the ligand SDF-1 led to the increased migration 
and homing of the neural stem cells, in vitro and in vivo in injured cerebral parts of 
the brain. Additionally hMSCs homed to areas of increased SDF-1 expression in the 
injured cortex (Imitola et al., 2004).  
In a study by Yamaguchi and co-workers, 2003 the effect of SDF-1 on endothelial 
progenitor cells (EPCs) was investigated. Three days after the administration of local 
SDF-1, there was accumulation of EPCs and neovascularisation was significantly 
greater in the SDF-1 treatment group compared to the control group. Moreover it was 
observed that, EPCs widely expressed CXCR4 and local administration of SDF-1 
improved vasculogenesis, neovascularisation and recruitment of transplanted EPCs 
in ischemic tissues in vivo (Yamaguchi et al., 2003).  
Chapter 1. Literature Review 
67 
 
Chemokine mediated MSC migration has also been demonstrated in Myocardial 
Infarction, whereby the levels of CXCL12 (SDF-1) have been shown to increase 
significantly in the left ventricle of mice, after MI (Abbott et al., 2004). Abbott et al 
(2004) induced MI of the left anterior descending coronary artery and then 
intravenously introduced BM-derived MSCs into the mice 48 hours later. They 
observed MSC migration within 72 hours to the infarcted tissue and the administration 
of AMD3100, a CXCR4 receptor antagonist, inhibited the MSC migration to the 
infarcted site. Additionally the introduction of CXCL12 into the myocardium led to a 
significant increase of MSCs in the heart (Abbott et al., 2004). 
 
 
Figure 1.4: Diagram showing the localisation of SDF-1 in the bone marrow, and 
how this aids in attracting CXCR4 expressing MSCs. The SDF-1 is released by 
stromal cells and endothelial cells in the bone marrow. 
 
The problem is only a small proportion of systemically administered MSCs actually 
reach and remain in the target tissue. This could be because the CXCR4 expression 
on the membrane of MSCs is very low, with some groups claiming there is no CXCR4 
expression at all (Wynn et al., 2004a, Von Luttichau et al., 2005). Many groups have 
therefore designed transfection or transduction techniques, whereby CXCR4 
plasmids are non-virally or virally introduced into the cells. CXCR4 over-expression 
improved the homing of adipose-derived MSCs to the bone marrow after intra-cardiac 
 
SDF-1 
CXCR4 
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injection in a NOD/SCID transplant mice. Not only was CXCR4 shown to improve 
migration to the bone marrow, but 90% of the transfected MSCs were retained in the 
bone marrow and maintained their ability to differentiate to osteocytes (Bobis-
Wozowicz et al., 2011). 
Lien and co-workers over-expressed MSCs with CXCR4 or Rank-Fc and injected 
these cells in glucocorticoid-treated mice to evaluate bone formation in an osteopenic 
mice model. The CXCR4-expressing MSCs were found to home and retain in the 
bone marrow (Lien et al., 2009b). A similar study by Cho et al, 2009 demonstrated 
enhanced cell trafficking to bone in ovariectomised mice, by over-expression of MSCs 
with CXCR4. Further bone production was enhanced by co-overexpressing the MSCs 
with RANK-Fc (Cho et al., 2009b). In both these studies, MSCs were intravenously 
introduced into the mice through the tail vein, and MSCs over-expressing CXCR4 
promoted in vivo cell trafficking to bone in OVX mice. The interesting and ingenious 
aspect about these studies included; the therapeutic effect of CXCR4 protecting 
against bone loss, and bone formation was further boosted by the effect of Rank-Fc 
and Cbfa1 (Cho et al., 2009b, Lien et al., 2009b).  
A problem with intravenous delivery of stem cells is that a large number become 
trapped in the spleen and in the lungs. In order to combat this effect, sodium 
nitroprusside, which dilates blood vessels, has been used. Cell size is an important 
factor and determines how many cells get trapped in organs such as lungs and 
therefore expanded MSCs tend to be larger than normal cells. This emphasises the 
importance of using sodium nitroprusside when expanded cells are administered 
intravenously (Gao et al., 2001, Fischer et al., 2009, Schrepfer et al., 2007).  
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1.9.1 The SDF-1/CXCR4 pathway. 
It has been reported that stromal cells and endothelial cells residing in the bone 
marrow, produce the chemoattractant, SDF1, which acts as a chemoattractant for 
haemapoeitic stem cells to their niche.  
SDF-1 is expressed in several organs including lung, liver, skin and Bone marrow. 
CXCR4, a receptor of SDF-1 is expressed in numerous tissues, including mature and 
immature hematopoietic and endothelial cells, EPCs, and smooth muscle cell (SMC) 
progenitors, which all have direct or indirect pro-angiogenic properties. Indeed, the 
SDF-1/CXCR4 pathway plays an important role in stimulating the trafficking and 
engraftment of hematopoietic stem cell and reconstitution of haematopoiesis. This 
implies that the expression of SDF-1 in a large number of tumors and injured tissues 
activates CXCR4 therefore promoting neo-angiogenesis (Ratajczak et al., 2006).  
SDF-1 is released from the stromal cells into the intravascular compartment and it is 
transported from the plasma to the Bone marrow compartment. This process is known 
as transcytosis and it is accomplished through a complex vesicular transport system 
(Dar et al., 2005). When SDF-1 enters the BM microenvironment, it induces the 
activation of matrix metalloproteinase-9 (MMP-9) and the release of soluble kit-ligand 
(sKitL). Subsequently, sKitL induces the release of more SDF-1, enhancing 
mobilization of the CXCR4+ and c-Kit+ cells to the circulation (Heissig et al., 2002). 
Additionally, the SDF-1 response is activated through the nitric oxide (NO) pathway. 
SDF-1 causes the endothelial cells to release NO which causes an upregulation of 
MMP-9. NO induces vasodilatation of BM endothelium which induces the release of 
cells (Aicher et al., 2003). In bone repair, SDF-1 is induced in the periosteum of injured 
bone and promotes endochondral bone repair by recruiting mesenchymal stem cells 
to the site of injury. Moreover, activation of osteoclasts and cathepsins also causes 
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the mobilization of the hematopoietic and endothelial progenitor cells (Urbich et al., 
2005, Kollet et al., 2006).  
1.9.2 Mobilization of stem cells 
The importance of Mesenchymal stem cells, haematopoeitic stem cells as well as 
Haematopoeitic progenitor cells, in bone formation has been highlighted earlier in this 
chapter. SDF-1 secretion by stromal cells in the marrow enhances retention of these 
stem cells in the bone marrow. Haematopoetic stem cells reside in the bone marrow 
but can be forced into the blood using cytokines such as granulocyte colony 
stimulating factor (GCSF) and are then harvested in large number of cells for 
transplantation (Suarez-Alvarez et al., 2012). Mobilization of progenitor cells is a 
multistage process, which involves their release from the bone marrow niche and then 
the active migration across the bone marrow sinusoidal endothelium. The chemokine 
axis SDF1/CXCR4 has an important role in the retention of the hematopoietic stem 
cells within the bone marrow (Levesque et al., 2003, Pitchford et al., 2009). It is 
therefore important to emphasize how these cells can be mobilised from the blood. 
AMD3100 is an antagonist of CXCR4 that binds to its receptor, SDF1. A dose 
dependant increase in Haematopoeitic stem and progenitor cell (HSPCs) mobilization 
was also observed in healthy human volunteers, when AMD3100 was administered. 
There was an increase in CD34+ cells, identified using flow cytometry, as well as an 
increase in colony forming units (CFUs) (Liles et al., 2003). AMD3100 is currently 
being used in patients as Plerixafor (Mozobil, AMD3100). It has been approved to be 
used with G-CSF for stem cell mobilization in patients with myeloma and lymphoma 
(Hopman and DiPersio, 2014, Devine et al., 2004).  
AMD3100 has been shown to induce rapid mobilization and engraftment of human 
and murine HPCs and this was further enhanced with G-CSF induced HPCs 
(Broxmeyer et al., 2005). GCSF disrupts the SDF1/CXCR4 axis by reducing the 
CXCR4 expression on HPCs and SDF1 levels in the bone marrow. It also encourages 
Chapter 1. Literature Review 
71 
 
the release of proteolytic enzymes, neutrophil elastase (NE) and cathespin G (CG), 
which cleave various molecules such as VCAM-1 that are responsible for HSC 
retention in the bone marrow (Levesque et al., 2003). Indeed Petit and co-workers, 
2002 demonstrated that GCSF caused an up-regulation of CXCR4 expression and 
reduced the amount of SDF1 in the bone marrow (Petit et al., 2002b). Administering 
IGF1, PDGF, SCF or VEGF followed by AMD3100 all resulted in a larger number of 
colony forming MSCs, with the greatest response observed with IGF1. A follow on in 
vivo study demonstrated that AMD3100 with IGF1 treatment significantly improved 
bone formation in a mouse segmental defect model compared to each of the growth 
factors administered separately. Interestingly AMD3100 + IGF1 also increased 
proliferation, in vitro migration of MSC isolated from the blood and CXCR4 expression 
of MSCs isolated from tibial fracture demonstrating its critical role in improving the 
homing capability of MSCs to the required sites (Kumar and Ponnazhagan, 2012). 
Apart from GCSF and IGF1, VEGF has also been used as a mobilization agent 
(Figure 1.5). Pitchford and co-workers, 2009 noticed a significant increase in 
circulating stromal progenitor cells when mice were given VEGF treatment in 
combination with AMD3100. Pitchford investigated three subsets of cells mobilised 
from the bone marrow; Haemapoetic progenitor cells (HPCs), Endothelial progenitor 
cells (EPCs) and stromal progenitor cells (SPCs). Interestingly his study found that a 
different regime was required for optimal mobilisation for each set of progenitor cells. 
GCSF treatment with AMD3100 stimulated a significant mobilization of HPCs and 
EPCs, while VEGF treatment with AMD3100 induced the release of EPCs and SPCs 
and not HPCs(Pitchford et al., 2009).  
The SDF-1-CXCR4 pathway and mobilising agents seem to be influential in tissue 
regeneration. However, it would be interesting to investigate whether the SDF-
1/CXCR4 pathway can be manipulated to mobilise stem cells and cause them to 
migrate to the bone marrow to improve bone formation in osteoporosis.  
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Figure 1.5: The mobilisation mechanism of cells from their niche. There are 
different modes of mobilisation of stem cells. circulating stem cells can be 
mobilised using GCSF/VEGF/FGF or AMD3100 (an antagonist of stem cells). 
 
1.10 Research gap 
The current treatment for osteoporosis such as bisphosphonates inhibits the catabolic 
activity of osteoclasts and subsequent bone resorption, but does not increase bone 
formation. There is therefore interest in using anabolic factors such as stem cells to 
augment fracture repair. Mesenchymal stem cells (MSCs) from postmenopausal 
women have a slower growth rate and osteogenic differentiation ability and this may 
possibly explain delayed unions in osteoporotic patients. Another factor associated 
with healing is the retention and migration of stem cells to the site of injury. Local 
mesenchymal stem cells (MSCs) from injured tissues and circulating MSCs aid in 
healing of injured tissues. Cytokines and chemokines such as SDF1 and its receptor 
CXCR4 play important roles in maintaining mobilization, trafficking and homing of 
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stem cells from bone marrow to the site of injury. Literature fails to clearly demonstrate 
the differences in proliferation, differentiation and migration as well as CXCR4 
expression in MSCs from young, aged and OVX rats. Additionally, studies by Lien 
and Cho have shown a significant improvement in bone formation when OVX mice 
have been injected with CXCR4 transfected MSCs (Lien et al., 2009a, Cho et al., 
2009b). However, these studies failed to show whether injecting MSCs from OVX rats 
is beneficial in bone formation and strength.  
1.11 Aims and Hypothesis 
The aim of this study was therefore: 
• To establish an osteopenic rat model and to isolate stem cells from osteopenic 
rats, control rats and young rats and investigate the differences in proliferation, 
differentiation and migration of these cells in vitro. 
• To transfect these MSCs with CXCR4 using an adenovirus and investigate 
whether viral transfection affects their differentiation, proliferation and CD 
marker expression.  
• To investigate whether CXCR4 transfection improves in vitro migration of 
MSCs and whether differentiating MSCs to osteoblasts affects their migration 
towards SDF1 in a Transwell chamber.  
• To inject transfected stem cells intravenously in OVX rats and investigate 
whether they improve bone formation and strength.  
The hypothesis of this study is that the migration of MSCs from young, adult and 
ovariectomised (OVX) rats will have different migratory abilities but this will increase 
when they are genetically modified to over-express CXCR4. 
Additionally, when CXCR4 transfected MSCs are injected intravenously into OVX 
rats, they would enhance bone formation and strength. 
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2.1 Introduction 
A ‘perfect’ osteoporosis animal model would be a living animal in which spontaneous 
or induced bone loss is caused due to a deficiency of ovarian hormone, and in which 
the characteristics of bone loss and its progression resemble those found in 
postmenopausal women in one or more respects (Kalu, 1991, Jee and Yao, 2001). 
However, in nature animals do not suffer from osteoporosis in the same way as 
humans. The reason for this remains unclear. However, in an attempt to replicate the 
human condition so that interventions can be studied, a number of animal models 
have been used. The ovariectomised rat is considered the most appropriate model 
for investigating human postmenopausal osteoporosis because of many similarities 
in pathophysiological mechanisms. The rat skeleton demonstrates a gradual 
transition from modelling to remodelling that relates to age progression in both 
cancellous and cortical bone  (Comelekoglu et al., 2007, Han et al., 1998, Zhang et 
al., 2007, Francisco et al., 2011, Lelovas et al., 2008).  
Bone mineral density (BMD) is widely used for detecting osteoporosis and dual X-ray 
absorptiometry (DEXA) is a non-invasive method for measuring BMD. Bone mineral 
density measurements are used to assess osteoporosis, fracture risk and as a 
diagnosis for prescribing osteoporosis treatment.  Together with bone strength, BMD 
is an important parameter for assessing bone quality. Bone strength can be measured 
using mechanical testing techniques where bone strength, stiffness, energy 
absorption capacity, and elastic modulus (young modulus) are quantified 
(Comelekoglu et al., 2007). Clinically BMD measurements are used to categorize the 
onset and extent of osteoporosis; however trabecular bone microarchitecture is also 
a key component of bone quality and is an important determinant of bone strength 
(Kanis, 1994, Dempster, 2000). Therefore, BMD as well as bone histomorphometry 
are important factors to evaluate the extent of osteoporosis. 
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The aim of this chapter was to describe the changes that occur in bone architecture 
and bone density in osteopenic Wistar rats 4 months post-ovariectomy.  
The hypothesis was that ovariectomy induced osteopenia results in a reduction in 
BMD as well as a decrease in the mechanical strength of bone. This is important 
because one of the goals of my thesis is to investigate the effect of stem cell therapy 
on osteopenic bone. The results presented in this chapter allows me to investigate 
changes in bone density and architecture in animals before stem cell therapeutic 
intervention. In addition, this model would allow me to get stem cells (rat MSCs) from 
these rats to be used for further experiments in this thesis.  
2.2 Methodology 
2.2.1 Validation of Rat Ovariectomy 
6 to 9 month old female Wistar rats were weighed, anaesthetised and shaved over 
the dorsal spine lumbar spine area (n=5). Using aseptic techniques, a longitudinal 
skin incision was made over the centre of the spine.  The incision was reflected 
laterally on the right hand side to expose the peritoneal cavity, which was perforated 
by an incision and adipose tissue surrounding the ovary was exposed and retracted. 
The area around the distal uterine horn was tied using non-resorbable suture and the 
ovary removed. The procedure was then repeated and the left ovary removed through 
the same skin incision. Two experimental groups were investigated: (i) 
ovariectomised (OVX) rats were compared to (ii) non-OVX control rats of the same 
age (n=5).  At 4 months post-ovariectomy and following euthanasia, femoral bone 
mineral density was measured using peripheral quantitative computed tomography 
pQCT (Stratec XCT1000), compression testing was carried out on L4 and L5 
vertebrae and the medial gastrocnemius muscle was carefully excised from the left 
and right leg, weighed and results compared between groups. Bone specimens were 
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processed for decalcified histology and trabecular length, thickness, connectivity, 
distance between trabeculae and percentage soft tissue were quantified.   
The skin and soft tissue around the right and left femur were removed and BMD 
measured within each femoral condyle in vitro using pQCT (XCT 2000, Stratec, 
Pforzheim, Germany). The samples were fixed in formalin before been scanned and 
were placed in a sealed tube during the scan. As a standard procedure a scout view 
was obtained to locate the desired scan position. A reference line was then positioned 
through the adjacent joint region at the femoral condyle.  The total length of the bone 
was obtained prior to scanning and the femoral condyle of each sample was scanned 
symmetrically at slice intervals of 0.5mm. 3 slices were acquired at 10% and 1 slice 
was acquired at 20% (of the femoral length) from the proximal femur end. The 
samples were analysed using XCT software.  
2.2.2 Compression Testing and Muscle Weight 
L4 and L5 vertebrae were obtained from six adult and eight OVX rats. Tests were 
carried out on fresh samples on the day of retrieval and stored in saline before testing. 
Each vertebra was carefully separated from the rest of the vertebral column by halving 
the discs and dissecting away adjacent tissue and ligaments. The thickness of the 
vertebrae was then measured before being loaded onto the machine. The vertebrae 
were positioned between the parallel base plate and circular metal plate and a pre-
load of 2N was applied (Figure 2.1). Each vertebrae was loaded in compression at a 
velocity of 5mm/min until failure (Zwick Roell 5T, UK). Load to failure and structural 
stiffness of the vertebrae was obtained from the load-deformation graph obtained 
from TestXpert testing software (Zwick, Roell, UK) (Figure 2.2).  
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Figure 2.1: A photograph showing the compression test setup of a L4 vertebrae. 
L4 and L5 vertebrae was compressed until failure to obtain a force/deformation 
curve using a zwick machine.  
 
Figure 2.2: A graph showing how the maximum load to failure of a vertebrae 
sample was obtained from a compressive testThe first peak highlights the 
point where the first cortical bone of the vertebrae fails.  
 
The medial gastrocnemius muscle was carefully excised bilaterally and each 
weighed. The weight of the muscle from the two groups of rats was compared. Muscle 
weight is important because the maintenance of adequate bone strength, density and 
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balance is associated with adequate muscle strength and mass (Szulc et al., 2005, 
Blain et al., 2010). 
2.2.3 Histological Analysis  
Both left and right tibiae were retrieved and specimens fixed in 10% buffered 
formaldehyde before decalcification in ethylenediaminetetraacetic acid (EDTA) 
(Sigma Aldrich, UK). An EDTA solution was made by first dissolving 250g EDTA in 
1,750ml distilled water followed by 25g of sodium hydroxide (Sigma Aldrich, UK). 
Decalcification was confirmed by radiography, after which the specimens were 
dehydrated, treated with chloroform to de-fat the tissue and then embedded in wax. 
Longitudinal sections measuring 5µm thick were made using a microtome (Life 
Technologies, UK).  
Following sectioning, samples were de-waxed twice in xylene, placed in two changes 
of 100% alcohol and then hydrated in serial dilutions of alcohol. After hydration, 
samples were stained in haematoxylin (Solmedia labs, UK), a nuclear stain, for 5-10 
minutes. Excess stain was removed by immersing slides in running water for 5 
minutes. Samples were then differentiated in 0.5% HCL acid (made up in 70% 
alcohol) and washed using water. Samples were then counterstained with 1% eosin 
(Sigma Aldrich, UK) for 3-4 minutes, washed in water and dehydrated in serial 
dilutions of alcohol. Finally, samples were cleared with xylene and mounted under 
coverslips using Pertex Mounting Medium (CellPath plc, UK). Samples were 
observed under light microscopy (KS-300 Zeiss, UK). All samples were analysed 
blind of experimental group. The following parameters were quantified: 
• Length of the trabeculae 
• Percentage area of soft tissue compared to calcified tissue 
• Connectivity of the trabeculae 
• Distance between neighbouring trabeculae.  
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• Thickness of the trabeculae 
To measure the connectivity of the trabeculae and percentage area of soft tissue, a 
line intercept method using a 1cm by 1cm grid on a x2.5 magnification image, 
whereby tissue under each interception point was counted and converted to a 
percentage. A region of interest (ROI) was selected close to the growth plate. Since 
the region selected was site specific, close to the growth plate and with x2.5 
magnifications, it was possible to view the whole region to carry out the 
histomorphometric analysis. Only one region of interest was analysed per rat. Length, 
thickness and distance between trabeculae were measured using ImageJ software 
(ImageJ 1.47v, USA).  
2.2.4 Statistical Analysis 
The normality was checked using Kolmogorov- Smirnov and Shapiro Wilkinson test 
and where the data was normal, comparison was made using independent student 
T-test. Where the data was non-parametric comparison was made using Mann-
Whitney U test with a Bonferroni correction. All data was analysed using SPSS 
version 24 (Chicago, USA).  
2.3 Results 
No surgical complications and no macroscopic signs of infection were observed in 
any of the rats investigated. At 4-months post-surgery, the OVX rats weighed 430.0 
± 33.8 g and adult control rats weighed 400.8 ± 55.3g.  
2.3.1 Bone Mineral Density (BMD) 
The mean femoral BMD measured in the OVX rat group was significantly lower (538.2 
± 23.3g/cm3) when compared with control rats (666.9 ± 46 g/cm3) (p=0.0002).  BMD 
was seen to reduce by 19.3 ± 9% (Figure 2.3 & Figure 2.4).  
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Figure 2.3: pQCT images showing the differences in BMD between OVX  (A) 
(n=5) and adult control (B) (n=5) rats of the femurs. The XCT software was used 
to analyse the BMD in the femoral condyles of rats from each group of rats. 
BMD is scaled from a range of red to blue, with red representing the lowest 
BMD and blue representing the highest BMD.  
 
Figure 2.4: A graph showing mean BMD of the femurs measured using pQCT in 
the two experimental groups of rats (n=5)  ( * shows significance of p < 0.001). 
The OVX rats had significantly lower BMD compared to adult control rats.   
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2.3.2 Compression Testing and Muscle Weight. 
The maximum load to failure for the L4 and L5 vertebrae was significantly increased 
in the adult non-OVX control rats compared to the OVX rats (p=0.0009 and p=0.001 
respectively). The maximum load to failure for the L4 and L5 vertebrae in OVX rats 
was 126.7±34 N and 115±41.4N respectively, while in the control group, load to failure 
was 231.7±78.8N and 248.5±74.5N respectively. However, the stiffness was only 
significantly (p=0.02) higher for the L4 vertebrae in the non-OVX rats (130.7±30.9 
N/mm) compared to the OVX rats (82.1±24.4 N/mm). Although the stiffness of the L5 
vertebrae from the OVX rats (75.1±20.7 N/mm) was lower than those from non-OVX  
adult rats (101.6±21.8 N/mm), this was insignificant (p=0.08) (Figure 2.5 & Figure 
2.6). There was no significant difference in muscle mass (Figure 2.7) between the two 
groups of rats. 
 
Figure 2.5: Maximum load to failure of L4 and L5 vertebrae from OVX and adult 
control rats. Vertebrae from the OVX rats had significantly lower load to failure 
compared to vertebrae from adult control rats. * shows significance of p < 0.001. 
(n=5). 
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Figure 2.6: The stiffness of the L4 and L5 vertebrae from OVX and adult control 
rats. The L4 vertebrae from the OVX rats had significantly lower stiffness 
compared the adult control rats. However, this significant difference was not 
observed in the L5 stiffness. * shows significance of p < 0.05 (n=5). 
  
Figure 2.7: The mass of the left and right gastroscenemius muscle from the 
OVX and adult control rats. There was no significance between OVX and adult 
rats and also between the left and right muscles. (n = 5). 
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2.3.3 Histological Analysis. 
Loss of trabeculae is a characteristic feature in osteoporosis. Results demonstrated 
significantly higher trabecular thickness (p=0.0008) in OVX bone when compared to 
the adult control rat group.  Mean percentage soft tissue increased in the OVX group, 
however no significant difference was seen when the two groups were compared. 
Trabeculae length and distance between trabeculae was significantly less in OVX rats 
compared to the adult control rats (p=0.004 and p=0.0008 respectively). No significant 
difference in trabecular connectivity was observed when the two groups were 
compared (p=0.13) (Table 2.1, Figure 2.8). 
 
Figure 2.8: Histological sections of trabecular bone from the femoral condyles 
obtained from the OVX (left) and adult control rat (right). The trabeculae from 
the OVX bone was shorter with no connectivity. The trabeculae from the adult 
control bone was longer and displayed more connectivity The bone from the 
OVX rats also displayed a higher soft tissue area compared to that from the 
adult control rats. 
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Table 2.1: Histology results from femur of OVX and control rats (n=5).  
Parameter Adult Control 
(n=5) 
OVX (n=5) P Value 
Trabeculae length (um)  1136.4 ± 463.4 408.0 ± 
101.3 
0.004 
Percentage soft tissue area (%) 38.8 ± 10.2 43.5 ± 11.9 0.26 
Trabecular connectivity (%) 7.2 ± 4.03 4.7 ± 2.2 0.13 
Distance between trabeculae 
(um) 
448.6  ± 122.2 185.1  ± 82.7 0.002 
Trabeculae thickness (um) 54.02  ± 12.1 93.6  ± 14.3 0.0008 
 
2.4 Discussion 
In this chapter, results showed that BMD, vertebral compression, trabecular length, 
thickness and distance between trabeculae were all significantly reduced in the OVX 
rat group. Bone density and quality are terms used to describe a composite of 
properties that together evaluate the property of bone. BMD is often used clinically to 
assess bone quality and accounts for approximately 70% of bone strength. 
Additionally, histomorphometric analysis of trabecular bone reflects the quality of the 
bone (Liu et al., 2015).   
In this study, osteopenia was confirmed in this model as a significant reduction (20%) 
in BMD was seen in OVX rats when compared with the control group. The load to 
failure of L4 and L5 vertebrae was also significantly lower in the OVX group when 
compared with control. This was possibly due to rapid loss in trabecular bone mass, 
as shown histologically. Studies have reported that the cortical shell determines the 
flexibility and energy absorption of bone while trabecular bone affects the load bearing 
capacity. Due to the rapid loss of trabecular bone mass seen during menopause, the 
cortex is thought to play an important mechanical role during weight-bearing activities.  
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Roux et al. showed that despite a significant age related decrease in lumbar vertebral 
cortical thickness, there is evidence showing that the contribution of the shell to 
vertebral strength increases with age (Roux et al., 2010). A study by Comelekoglu 
and co-workers also found a 14% decrease in rat femoral BMD and a thinner cortex 
compared to the control rats. They also observed a reduced elastic modulus and 
ultimate stress and strain in the femora of OVX rats, implying that the biomechanical 
properties of bone are related to its material and geometric properties (Comelekoglu 
et al., 2007). Yang and co-workers also found similar results in trabecular and soft 
tissue structure in the mandible and tibia of OVX and control rats when investigated 
using micro-CT analysis (Yang et al., 2014).  
Vertebral bodies consist of two main structural components: trabecular and cortical 
bone and an age-related loss in trabecular bone structure have been shown in several 
studies (Comelekoglu et al., 2007, Liu et al., 2015). The histomorphological analysis 
of OVX femora in this chapter showed a reduced trabecular bone mass, trabecular 
connectivity, trabecular length and as a result the trabecular shape was more rod-like 
rather than plate-like. The connectivity of the trabecular system is important as it 
forms a supportive interconnected system that is able to resist loads. During the early 
stages of osteoporosis, contraction and loss of trabeculae results in the thickening of 
neighbouring trabeculae so as to fulfil mechanical strain placed on the bone. In the 
later stages of osteoporosis, the bone trabeculae are thinned and reduced to a 
thickness of only a few bone lamellae (Marcu et al., 2011). Euler’s principle states 
that the resistance of a bar during a vertical load is inversely proportional with the 
square of its whole length. Additionally, the strength of the trabecular structure is 
proportional to its radius squared. This concept can be applied to the trabeculae if 
they are considered as bars. Bone resorption due to osteoporosis results in loss of 
horizontal trabeculae causing an increase in the formation of vertical trabeculae, 
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which decreases resistance to bending (Marcu et al., 2011, Mosekilde, 2000) and 
results in bone with poor mechanical strength.  
Due to the functional interdependence of the bone marrow and the trabecular bone, 
a decrease in bone density would result in an increase in adipogenic tissue as 
essentially there is more space available. In addition the increase in adiposity is a 
result of reduced osteoblastic differentiation of the stromal cells and an increase in 
adipogenic differentiation (Marcu et al., 2011, Gödri and Neica, 2010). This was 
evident in my study as the bones from the OVX rats had a higher soft tissue area in 
comparison to the adult control group.  
Age and osteoporosis are a major determinant of vertebral bone strength, mass and 
microarchitecture and therefore vertebral fractures are very common in osteoporotic 
patients. The vertebral body is the load bearing part of the vertebra. With age, there 
is alteration in the internal trabecular bone mass and changes in bone architecture 
causing a reduced resistance to loading. Additionally, due to resorption of the 
endosteal bone, there is also age-related thinning of the end plates and of the cortical 
shell, which would therefore compromise the strength of the vertebrae (Mosekilde, 
2000). It would have been interesting to look at the vertebrae histologically in this 
chapter, but this was not investigated because the vertebrae were used for the 
compression test and therefore there was a limited number of samples.  
Natural menopause drives a loss of muscle tissue as well as skeletal mass. Loss of 
activity with age also causes muscle atrophy. In this chapter I found no significant 
difference in muscle mass of the left and right gastrocnemius muscle in the OVX and 
control rats. Osteoporosis is a metabolic bone disease and theoretically it should not 
affect muscle strength. However, the reduction in muscle strength may be attributed 
to the pain and skeletal deformity related to osteoporosis. It has been shown that the 
reduction in muscle strength could further increase the postural abnormalities caused 
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by the disease and possibly bone density. Additionally, the loss of muscle mass may 
also cause a loss of skeletal mass as it decreases the mechanical stress on the 
skeleton and hence causes a decline in strength (Sinaki et al., 1993, Trombetti et al., 
2016).  
The results in this chapter have demonstrated that ovariectomy reduced BMD and 
changed trabecular structure in a rat model. Similar changes are seen in humans with 
osteoporosis and therefore this model is often used to study various therapeutic 
regimens investigated to treat osteoporosis. However, a disadvantage in using a rat 
osteopenic model is that rats grow continuously throughout their life and therefore 
their growth plates do not completely close which causes poor remodelling of their 
cortical bone. This therefore suggests that caution should be used when comparing 
results obtained in the rat model with that seen clinically and emphasizes the 
importance in using larger animal models (in addition to smaller animal models) to 
investigate new therapies to treat osteoporosis in patients (Hartke, 1999). It is also 
important to understand that although the rat model is an osteopenic model rather 
than an osteoporotic model exhibited in humans, it is the cheapest and most 
reproducible.  
The aim of this chapter was to establish an osteopenic rat model so that MSCs could 
be harvested from these rats to investigate and compare the in vitro differences in 
MSCs with adult control and young rats. Osteopenic rats similar to the ones used in 
this chapter would also be used to determine whether injecting CXCR4 transfected 
MSCs would help with improving their bone formation. This chapter is therefore 
important as it measures the baseline osteopenia, as a result of OVX, before 
intervention with stem cells.
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 3.1. Introduction  
Osteoporosis causes over 8.9 million fractures annually worldwide, characterised by 
loss of trabecular architecture and bone mass, the disease has a 40% lifetime risk for 
sustaining a fragility fracture (hip, distal radius and vertebral (Raisz, 2005, Randell et 
al., 1995, Sambrook and Cooper, 2006)). Type I osteoporosis, also known as 
postmenopausal osteoporosis, is characterised by increased bone turnover and 
accelerated cancellous bone loss, resulting in an increased risk of vertebral fractures. 
Type II osteoporosis affects both men and women and leads to an increased 
incidence of fractures; mortality and morbidity are thus increased accounting for 
nearly 3 million disability adjusted life years. Regardless of type, the underlying 
pathology of osteoporosis is aberrant bone turnover, secondary to imbalanced bone 
resorption and formation (Bonyadi et al., 2003). Osteoporosis can impact on a number 
of conditions where bone formation is required. These conditions are often 
challenging and therefore new techniques involving gene therapy, cell therapy and 
tissue engineering are being explored to improve bone regeneration (Chen et al., 
2012). 
Bone loss in osteoporosis is a consequence of the imbalance between bone formation 
by the osteoblast and bone resorption carried out by the osteoclast, resulting in net 
bone loss (Sandhu and Hampson, 2011). In osteoporotic patients, regeneration of 
damage bone is impaired as a consequence of this imbalance.  There may be a 
number of reasons for this associated with:  a) The number of MSCs within bone 
marrow, which decrease with age and this may be associated with a reduction in bone 
formation (Lane, 2006, Lippuner, 2012, Chen et al., 2007, Katsara et al., 2011) b) The 
ability of MSCs  in osteoporotic  patients  to differentiate into osteoprogenitor cells 
and mature osteoblasts (Sethe et al., 2006, Brack and Rando, 2007, Muschler et al., 
2001, Wang et al., 2006).  c) The ability of MSCs to mobilise from their niche, home 
across the tissue endothelium and mature into active cell types that modulate the 
Chapter 3. The Influence of Age and Osteoporosis on Rat Bone Marrow Stem Cells 
91 
 
fracture environment. The stromal derived factor-1/CXCR4 (SDF-1/CXCR4) axis has 
been found to be an important regulator of stem cell migration. SDF-1 is produced by 
a multitude of tissue types including stromal cells in the endosteum. In its active form 
SDF-1 is bound to the CXCR4 receptor found on MSCs. Amongst others Granero-
Molto et al demonstrated that stem cell migration to the fracture site in a stabilised 
tibial osteotomy model was CXCR4 dependent. The over-expression of CXCR4 on 
mesenchymal stem cells led to significant increases in bone mineral density in an 
osteopenic mouse model indicating the clinical significance of the SDF-1/CXCR4 axis 
in the treatment of osteoporosis.  One of the reasons for this may be that MSCs 
derived from osteoporotic patients may have reduced levels of CXCR4, however the 
role of aging and osteoporosis on CXCR4 cell expression and thus migration to SDF-
1 has not been investigated (Granero-Molto et al., 2009). 
Osteoporosis and ageing may be interlinked, and differences between stem cells from 
young and old patients have been reported.  It is therefore important to compare the 
biological differences in stem cells from young, adult as well as osteoporotic patients. 
As yet studies have not compared the functional differences between MSCs from 
these three groups.  
The aim of this chapter was establish an OVX model and examine the influence of 
age and osteopenia on the morphology, proliferation, differentiation, CXCR4 
expression and migration of bone marrow derived MSCs. Results from OVX and non-
OVX rats were compared with MSCs obtained from young rats.  
The hypothesis was that MSCs from OVX rats have a lower proliferative and 
osteogenic potential, a lower CXCR4 expression and migratory capacity and will be 
more likely to differentiate into adipocytes compared to MSCs obtained from young 
rats. 
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3.2. Materials and Methods 
3.2.1 Culture of Bone Marrow stem cells (Young Rats) 
Rat bone marrow mesenchymal stem cells (rBMCs) were harvested from 2-4 week 
old young Wistar rat femora (n=6). Bone marrow cells were harvested by flushing the 
femora with Dulbecco's modified Eagle medium (DMEM), 20% fetal calf serum, 1% 
Penicillin Streptomycin (P/S) in a 25 cm2 flask. The aspirate obtained from the flushing 
was directly plated and cultured. Cells were cultured at 37C at 5% CO2. Media was 
changed after 4 days to remove non-adherent cells and then continuously refreshed 
twice a week thereafter. After 10-14 days of primary culture and when the cells were 
70-80% confluent, they were passaged using Trypsin-EDTA (Sigma-Aldrich, MO). 
rBMCs were passaged every 7-8 days. MSCs were characterised by differentiating 
them into osteoblasts, adipocytes and chondrocytes and were stained using Alizarin 
Red (Sigma Aldrich, UK), Oil Red O (Sigma Aldrich, UK) and Alcian Blue (Sigma 
Aldrich, UK) respectively. They were also phenotypically identified by 
immunocytochemistry using Anti-CD106, Anti-CD105, Anti-CD45 and Anti-CD34 
markers, purchased from Abcam (Cambridge, UK).  
 3.2.2 Flow Cytometry Analysis (CD Marker Expression) 
10,000 rBMCs from young, adult control and OVX rats (n = 3) were analysed for their 
surface expression of CD29, CD90, CD45 and CD34. The cells were labelled with 
Anti-mouse/Rat CD29-FITC (eBioscience), anti-mouse/Rat CD90-APC 
(eBioscience), Anti-Rat CD45-APC (eBioscience) and CD34-PE (Abcam). The CD 
expression was compared to the isotype control. 10,000 cells were fixed in 4% 
formalin for 15 minutes at room temperature, washed with 0.5% Bovine serum 
albumin (BSA), stained with the conjugated primary antibody for 1 hour at room 
temperature in the dark. After 1 hour the cells were washed with 0.5% BSA and 
analysed on flow cytometer (Cytoflex, Beckman Coulter) (Cell Signalling 
Technology).  
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As explained in the introduction, from a vast selection of CD markers used to 
characterise MSCs, CD29, CD90, CD45 and CD34 were chosen because they are 
expressed on MSCs irrespective of the cell passage and are commonly used to 
identify rat MSCs (Harting et al., 2008, Dominici et al., 2006, Karaoz et al., 2009). 
3.2.3 Cell Morphology  
Passage 2 and 3 rBMCs were cultured and their morphology assessed by measuring 
their ‘Aspect Ratio’, whereby the ratio of the length of a cell to its width was calculated 
using Image J software (n=3). This was calculated for cells from young, adult and 
OVX rats.  
3.2.4 Cell Proliferation     
An Alamar Blue assay (AbD Serotec, UK) was used to measure rBMC proliferation 
from young, adult and OVX rats (n = 3). 10000 MSCs were seeded in a 6 well plate 
and metabolic activity was measured using an Alamar Blue assay (AbD Serotec, UK) 
at day 3, 7, 10 and 14.  10% Alamar blue was added to the culture medium for 4 hours 
and excitation at 560 nm and emission at 590 nm were measured using a Tecan plate 
reader (Tecan, Infinite Pro 200 series, Switzerland). The mean absorbance was 
determined from triplicate samples. The absorbance was then normalised to the DNA 
assays and a comparison was made between the cell groups (Czekanska, 2011).  
3.2.5 Osteogenic Differentiation  
30,000 MSCs (n = 3) from each of the three experimental groups were cultured in a 
48 well plate in osteogenic media that consisted of DMEM supplemented with 100nM 
dexamethasone, 50ug/ml L-ascorbic acid 2-phosphate and 10mM beta-glycerol 
phosphate (Pittenger et al., 1999, Jaiswal et al., 1997). The cells were grown at 37°C 
at 5% CO2 and their Alkaline Phosphatase (ALP) activity was measured at 3, 7, 14 
and 21 days. ALP was measured by freezing and thawing the cells three times, 
centrifuging and incubating the cell lysate in equal volumes of the ALP substrate 
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solution (p-Nitrophenyl Phosphate Liquid Substrate System, Sigma Aldrich, UK) for 
15 minutes at 37 degrees on a shaker. This was then normalised against the DNA 
Hoescht assay (Sigma Aldrich, UK). The amount of DNA in samples was quantified 
using a fluorimetric dye. 2ng/ml Hoechst 33258 (Sigma 14530) was added to the cell 
lysates and fluorescence was measured at a wavelength of 460 nm (Moe et al., 1994). 
Additionally, calcium phosphate deposition was measured by quantification of Alizarin 
Red staining using cetylpyridium chloride (CPC). The cells were washed in phosphate 
buffered saline (PBS), fixed in 10% formalin for 15 minutes and then stained with 
Alizarin Red solution (pH 4.2) for 10 minutes at room temperature. The cultures were 
then rinsed five times with PBS (Stanford et al., 1995). The stained samples were 
photographed and then quantitatively de-stained using 10% CPC made in 10mM 
sodium phosphate, pH 7.0 for 15 minutes at room temperature. The samples were 
de-stained while being shaken. The Alizarin Red concentration was then read on a 
plate reader at a wavelength of 570 nm (Tecan, Infinite Pro 200 Series, Switzerland). 
The concentration of Alizarin Red was determined using a standard curve obtained 
from 10-fold serial dilution of Alizarin Red. The Alizarin Red analysis was repeated 
for cells seeded in normal media with FCS and P/S, to validate the calcium phosphate 
production of cells seeded in osteogenic media (Stiehler et al., 2008, Cotter et al., 
2011).  
3.2.6 Adipogenic Differentiation 
30,000 cells from young, adult and OVX rats were cultured in a 48 well plate in 
adipogenic media that consisted of DMEM supplemented with 0.1mM 
dexamethasone, 50mM Indomethacin, 0.45mM IBMX and 10mg/ml Insulin. The cells 
were grown at 37°C at 5% CO2 and the presence of lipid droplets within the cells 
confirmed by staining with Oil Red O at 7, 14 and 21 days (Jaiswal et al., 1997, 
Pittenger et al., 1999). Additionally, Oil Red O staining was quantified using 100% 
isopropanol. The cells were washed in PBS, fixed in paraformaldehyde for 5 minutes, 
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washed with 60% isopropanol for 10 minutes and then stained with Oil Red O solution 
for 15 minutes at room temperature. The cultures were then rinsed five times with 
PBS. The stained samples were photographed and then quantitatively de-stained 
using 100% isopropanol for 15 minutes at room temperature. The Oil Red O 
concentration was read on a plate reader at a wavelength of 510 nm (Tecan, Infinite 
Pro 200 Series, Switzerland). The concentration of Oil Red O was determined by 
using a standard curve obtained from a 10-fold serial dilution of Oil Red O stain.  In 
order to compare the adipogenic differentiation of these cells this was repeated for 
cells seeded in normal media with FCS and P/S (Cotter et al., 2011).  
3.2.7 Chondrogenic Differentiation 
To promote chondrogenic differentiation, mesenchymal cells were centrifuged to form 
a pelleted mass and the cells were cultured without 2% serum. Chondrogenic 
differentiation was induced in the expanded mesenchymal cell cultures by treatment 
with 1x Insulin-Transferrin-Selenium (ITS) (ThermoFisher Scientific, UK), 40ug/ml 
Proline (Sigma Aldrich, UK), 100nM Dexamethasone (Sigma Aldrich, UK), 100um 
Ascorbate-2-phosphate (Sigma Aldrich, UK) and 10ng/ml TGF-β1 (Peprotech, UK). 
Positive chondrogenic differentiation was established using Alcian Blue staining. The 
pellets were washed with PBS (Sigma Aldrich, UK), fixed for 1 hour in cold methanol 
(Sigma Aldrich, UK), and stained overnight in 1% Alcian Blue solution (Sigma Aldrich, 
UK). The pellets were then washed extensively with PBS and pictures of the stained 
pellets were obtained (Jaiswal et al., 1997, Pittenger et al., 1999).  
3.2.8 Flow Cytometry Analysis (CXCR4 Expression)  
Young rBMCs (n = 5) from the third passage were trypsinised and centrifuged at 2000 
rpm for 10 minutes before being re-suspended at 100,000 cells in PBS. Cell aliquots 
were incubated with primary CXCR4 antibody (Abcam, UK) for 30 minutes at room 
temperature. The cells were washed in PBS and then incubated in secondary goat 
anti-rabbit antibody (Abcam, Cambridge UK) for 30 minutes at room temperature. The 
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negative control consisted of cells incubated in the secondary antibody only. 10,000 
cells were then analysed using flow cytometry (Cytoflex, Beckman Coulter, UK). This 
was repeated with MSCs from OVX and adult rats (n = 5) (Cell Signalling 
Technology). 
3.2.9 Cell Migration  
A chemoinvasion assay was used to evaluate the ability of rBMCs from young, adult 
and OVX rats, to migrate towards SDF-1. rBMCs from the three groups were loaded 
separately in serum free medium in the upper compartment of the Boyden chamber, 
which had a membrane with a 5µm pore size that separated it from the lower 
compartment (Corning, UK). The lower compartment was filled with 100ng/ml SDF-1 
(Peprotech, UK) in DMEM, FCS and P/S. The chambers were incubated at 37°C, 5% 
CO2 for 16 hours to allow for cell migration through the chamber. After 16 hours, the 
cells that migrated to the opposite side of the membrane were fixed in 10% 
formaldehyde (Sigma Aldrich, UK) and stained with Crystal violet (Sigma Aldrich, UK). 
The migrated cells were counted by selecting six random fields at x20 magnification 
and calculating the percentage average number of cells. For each cell type (young, 
adult and OVX), the experiment was repeated three times. For the control, both the 
top and bottom of the chamber were filled with normal media with no SDF-1 and the 
cells were loaded in the upper chamber as before (Chen, 2005, Shaw, 2005).  
3.2.10 Statistical Analysis 
The normality was checked using Kolmogorov- Smirnov and Shapiro Wilkinson test 
and where the data was normal, comparison was made using independent student 
T-test. Where the data was non-parametric comparison was made using Mann-
Whitney U test with a Bonferroni correction. All data was analysed using SPSS 
version 24 (Chicago, USA).  
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3.3 Results 
3.3.1 Flow Cytometry Analysis (CD Marker Expression) 
There was no significant difference in the percentage of cells expressing the different 
CD markers when young, adult control and OVX rBMCs were compared. Flow 
cytometry showed high expression of CD29, CD90 and low expression of CD34 and 
CD45 in all three groups. CD marker expression was similar in all three groups  (Table 
3.1, Figure 3.1).  
Table 3.1: Percentage CD marker expression of cells from the 3 different type 
of rats. Data is represented as mean ± Standard deviation. 
Type of cells     
    CD29    CD90      CD34       CD45 
Young MSCs 98 ±1.9 96.8±5.0 1.4±1.2 7.03±4.8 
Adult MSCs 95.6±3.6 98.6±0.7 3.2±4.1   21.9±20.8 
OVX MSCs   91.7±8.9 94.4±4.3 3.3±4.4 3.9±5.8 
 
3.3.2 Cell morphology  
MSCs from young rats at passage 2 and 3 were smaller and had more spindle-like 
features (longer) compared to MSCs from adult control and OVX rats. Although the 
MSCs from the older rats still had spindle like features, they were more spread out 
and this became more evident with increasing passaging (Figure 3.2). The mean 
aspect ratio measured in the young MSC group was 18.66±13.45, which was larger  
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Figure 3.1: CD29, CD90, CD45 and CD34 expression of young (top), adult 
control (centre) and OVX (bottom) MSCs. MSCs from all three groups of rats 
had high expression of CD90 and CD29 and all low levels of CD45 and CD34 
(n=3).  
Figure 3.2: rBMCs from young (A), adult control (B) and OVX rats (C) x10 
magnification. The young MSCs were longer and more spindle like shaped, the 
adult MSCs and OVX MSCs were wider (as demonstrated by the arrows). The 
young MSCs had the largest aspect ratio (length: width ratio) compared to cells 
from adult control and OVX rats. 
 
when compared to cells obtained from adult (4.99±4.67, p=0.06) and this was 
significant when compared to MSC obtained from OVX rats (2.25±0.94, p=0.03). 
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3.3.3 Tri-differentiation 
The isolated young rat MSCs positively differentiated to osteoblasts, adipocytes and 
chondrocytes. Osteogenic differentiation was evident by calcium deposits which 
stained red with Alizarin Red. Under adipogenic conditions for 3 weeks, the formation 
of intracellular micro-droplets stained positive for Oil Red O. After 21 days in 
chondrogenic media, the cells were positively differentiated to chondrocytes, which 
was confirmed by Alcian Blue staining for cartilage (Figure 3.3). 
 
Figure 3.3: Characterisation of bone marrow MSCs from young rats using tri-
differentiation after 21 days. Red positive stain for Alizarin red for calcium 
phosphate deposition after osteogenic differentiation (A), Red Oil Red O stain 
for fat droplets after adipogenic differentiation (B) and bright blue Alcian Blue 
stain to show chondrogenic differentiation of the pellet (C). Their control 
counterparts are shown by negative staining (B, D and F respectively).  
 
3.3.4 Cell Proliferation  
Histograms of mean absorbance were plotted to examine cell proliferation. After 3 
days in culture, the rBMCs showed time dependent growth in all samples until day 7. 
Overall there was no significant difference in proliferation between rBMCs from 
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young, adult control and OVX rats. An increase in cell proliferation was seen in all 
groups between days 3 and 7 (Figure 3.4). 
 
Figure 3.4: Proliferation of MSCs from young, adult control and OVX rats at Day 
3, 7, 10 and 14 (n = 3) as measured by the reduction of Alamar Blue and 
corresponding absorbance (A) and mean absorbance readings normalised 
against DNA to reflect their metabolic activity (B).  
3.3.5 Osteogenic Differentiation  
The amount of Alizarin Red staining (measured in mM) indicated the production of 
calcium phosphate mineral.  Mineralisation of the extracellular matrix in young, adult 
and OVX rBMCs increased significantly from day 7 to day 21 in all the three 
experimental groups. These results were compared to mineralisation in the control 
group, which received normal media and where no calcium phosphate was seen 
(Figure 3.5, Table 3.2). At day 7, the amount of calcium phosphate produced was 
relatively low and was similar between the three groups of cells. At day 14 and day 
21 there was a significant increase in the amount of calcium phosphate produced by 
all groups.   At day 14 MSCs from young rats produced nearly three times the amount 
of mineral compared to cells isolated from ovariectomised animals (p=0.004). This 
significant difference in mineralisation was also apparent at 21 days (p = 0.0018) but 
the difference was less.  
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Table 3.2: Quantification of Alizarin Red staining measured in nM indicating 
osteogenic differentiation of young, adult and OVX MSCs at day 7, 14 and 21 
for cells differentiated to osteoblasts as well as control cells grown in normal 
media. 
 
Results showed that when MSCs from young, adult and OVX rats were differentiated 
to osteoblasts, a large variability in ALP expression was seen between days 3 and 21 
in all 3 groups of cells. In the young group, the percentage ALP change decreased 
from day 3 to day 7 and increased thereafter up to day 14, after which it dropped at 
day 21. However, this pattern was not observed in the adult control and OVX groups. 
A peak increase in ALP expression was seen in the OVX MSC groups on day 7, which 
later decreased at day 14. There was a significant difference in ALP change between 
young and OVX MSCs at day 14 (p = 0.003). However due to a large variability seen 
in data obtained from the adult MSC group, this significance was not observed at day 
14 when the young group was compared with the adult MSC group and also when 
the adult group was compared with the OVX MSC group. 
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Figure 3.5: Alizarin staining of calcium phosphate deposition following 
osteogenic differentiation of Young, adult control and OVX MSCs at day 7, 14 
and 21. The young MSCs had significantly more calcium phosphate deposition 
at day 7, 14 and 21 compared to MSCs from adult and OVX MSCs. 
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Figure 3.6: Graph showing the average Alizarin Red production when MSCs 
from young, adult control and OVX rats (n=3) differentiated to osteoblasts, at 
day 7, 14 and 21. (* and ** shows significant differences p<0.05). 
 
It is worth noting that two of the adult MSC cultures at day 14 showed very low 
expression whereas in one adult culture the ALP expression was very high. 
Interestingly, ALP expression in the young stem cell cultures was less variable over 
all the time periods investigated. There was a percentage increase in ALP expression 
in OVX MSCs at day 7 (37.5 ± 43.5%), and this was significantly more than young 
MSCs (p = 0.02). However, this surge in ALP was still not as high as that expressed 
by young MSCs at day 14 (123 ± 21.9%). 
The average ALP values for the young MSCs (9.52±6.97 to 3.20±1.74 U/ng) and adult 
MSCs (16.83±14.73 U/ng to 13.13±14.65 U/ng) decreased from day 3 to day 7 and 
increased at day 14 (7.34±4.3 U/ng and 18.15±20.91 U/ng) respectively. However, in 
the OVX MSC group, the average ALP readings increased at day 7 (1.64 ± 1.96 U/ng) 
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and then decreased at day 14 (1.50 ± 1.49 U/ng). At day 14, the young MSCs had 
significantly higher ALP readings compared to OVX MSCs (p = 0.04). However, 
although the young MSCs had a higher average ALP reading at day 14 compared to 
the adult MSCs, this difference was insignificant due to large variability in the readings 
(Figure 3.7).  
 
Figure 3.7: Percentage ALP/DNA change for young (a), adult (b) and OVX (c) 
MSCs differentiated to osteoblasts at day 3, 7, 14 and 21. Each line represents 
the results from a single culture.  
 
3.3.6 Adipogenic Differentiation  
At days 14 and 21, adipogenic differentiation was significantly greater in MSCs 
isolated from young animals compared to cells isolated from adult control and OVX 
animals (Figure 3.8). MSCs from young rats formed lipid droplets significantly faster 
from day 7 compared to the other two groups of cells. 
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Figure 3.8: Oil Red O staining following osteogenic differentiation of Young, 
adult control and OVX MSCs at day 7, 14 and 21. These images demonstrated 
that by day 7, the young MSCs had differentiated to adipocytes significantly 
more compared to MSCs from OVX and adult control rats. 
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Figure 3.9: Adipogenic differentiation of young, adult and OVX MSCs at day 7, 
14 and 21 measured using Oil Red O stain of fat droplets. MSCs from young 
rats had significantly higher lipid droplet accumulation compared to MSCs from 
adult control and OVX rats at days 7, 14 and 21. No differences in adipogenic 
differentiation between MSCs from OVX and adult control rats (* and ** shows 
significant differences p<0.05). 
 
Additionally, lipid droplet accumulation significantly accelerated from day 14 to day 
21 when young MSCs were differentiated while MSCs from adult and OVX rats 
showed no increase in lipid accumulation at day 7, 14 and 21. Fat droplet production 
was also assessed in the control group, which were seeded in normal media. On 
average all three groups of MSCs had minute amounts of fat droplet production in the 
control media (Figure 3.9, Table 3.3).  
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Table 3.3: Values of adipogenic differentiation (nm) of young, adult and OVX 
MSCs at day 7, 14 and 21 for cells differentiated to adipocytes as well as control 
cells with normal media. 
 
 
3.3.7 Flow Cytometry Analysis (CXCR4 Expression)   
Flow cytometry results demonstrated that rBMCs from adult (p <0.001) and OVX rats 
(p<0.001) expressed significantly lower levels of CXCR4 compared to rBMCs from 
young rats (Figure 3.10). rBMCs isolated from adult rats expressed a significantly 
greater amount of CXCR4 in comparison to cells obtained from OVX rats (p= 0.04). 
On average, 32.1±6.2% and 19.4±9.8% of the rBMCS from adult and OVX rats 
respectively expressed CXCR4, while 87.5±5.1% of the young rBMCs expressed 
CXCR4.  
3.3.8 Cell Migration 
Results demonstrated that significantly lower numbers of OVX MSCs migrated 
towards SDF-1 compared to the adult and young rat groups. The migration to SDF-1 
was 2-fold greater in young cells compared to adult rat cells (p = 0.023) and was four 
times higher when compared to cells isolated from OVX rats (p = 0.013) (Figure 3.11). 
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Figure 3.10: Flow cytometry showing CXCR4 surface expression in MSCs from 
young (A), adult control (B) and OVX rats (C). Young MSCs have the highest 
expression of CXCR4 (87%), followed by MSCs from adult control (32%) and 
MSCs from OVX rats (19%) had the lowest expression of CXCR4 (n = 3).  
 
Figure 3.11: Mean percentage migration of uninfected MSCs from OVX, adult 
control and young rats in a Transwell chamber towards SDF1. * and ** represent 
significance p<0.05. The images of young (A), adult (B) and OVX (c) MSCs 
migrated towards SDF-1 in a Boyden chamber and stained with Crystal Violet 
stain. Scale:  
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3.4 Discussion 
Impaired MSC recruitment from the stem cell niche, reduced differentiation to bone 
or decreased proliferative activity of mature stem cells are all possible causes of 
reduced bone formation (Yellowley, 2013a). The results obtained in this chapter have 
highlighted that during ageing and osteoporosis, the proliferative potential of the stem 
cells is maintained but their differentiation ability is compromised. Many studies have 
investigated differences in stem cell populations obtained from old and young animals 
however, the novelty in this study includes comparing stem cell function between 
young, normal adult and OVX rats. Results from this chapter have demonstrated that 
there are differences between MSCs isolated from young, adult and OVX rats. 
Although all cells positively expressed CD90 and CD29 and negatively expressed 
CD45 and CD34, they showed significant differences in their osteogenic and 
adipogenic differentiation potential.  Further I showed that expression of CXCR4 and 
the migration of cells towards SDF-1 was much greater in the young stem cell group 
when compared with older adult cells. Cells isolated from OVX rats showed a 
reduction in migration compared with adult cells. It is interesting to note that CXCR4 
expression of MSCs from OVX and adult rats was significantly lower than those 
obtained from young rats hence impairing their migration. CXCR4 expression was 
measured using flow cytometry and although it is quantitative, it measures the number 
of cells expressing CXCR4 rather than the amount expressed by each individual cell. 
Individual CXCR4 cell expression can be measured using ELISA or immunostaining 
assays and when combined with migration over a known period of time, the rate of 
migration of each of the cell types can be quantified and compared. 
The capability of cells to differentiate to bone and their use in cell based therapy is 
vital in many orthopaedic treatments such as osteoporosis and osteoarthritis, 
especially in the ageing population. There is contradictory data on the differentiation 
potential of MSCs from young and aged rats. In this chapter I hypothesized that MSCs 
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obtained from OVX rats would have a lower osteogenic potential and would more 
likely differentiate to adipocytes when compared to MSCs isolated from young rats 
however, this was not the case. MSCs from OVX rats had a lower osteogenic 
differentiation potential but they also had a lower adipogenic differentiation ability 
compared to MSCs obtained from young rats. Asumda and Chase did not look at the 
differentiation potential of MSCs from osteopenic rats, but they showed similar 
differences to this study in terms of osteogenic and adipogenic differentiation between 
MSCs from young and old rats. They demonstrated a reduced differentiation ability in 
cells from old rats compared to MSCs from young rats (Asumda and Chase, 2011). 
However Singh et al. (2016) found no observable difference in osteogenic and 
adipogenic differentiation between cells from young and old mice (Singh et al., 2016). 
Likewise, Beane et al (2014) showed no differences in Alkaline Phosphatase 
expression as well as Alizarin Red staining between bone marrow derived MSCs from 
young and old rabbits but they found that age affected the adipogenic differentiation 
of the same cells (Beane et al., 2014). Moerman reported changes in the expression 
of phenotype specific gene markers in bone marrow mesenchymal stem cells from 
older mice that encouraged differentiation to fat rather than bone in the bone marrow 
niche. Bone marrow from old mice had increased levels of PPAR-γ, which stimulated 
cells to turn to fat rather than bone and inhibited osteoblast function. Bone marrow 
obtained from young mice on the other hand, had increased levels of BMP-2 and 
TGF-β, which induced MSCs towards the osteoblastic lineage (Moerman et al., 
2004a).  My results demonstrated that differentiation is associated with the origin of 
the cells and that this is independent of the cytokine profile in their environment.     
In this study, no significant difference in proliferation was seen in the different types 
of MSCs investigated. This is in contrast to several studies that have shown that 
MSCs from older rats have a significantly lower proliferation rate compared to MSCs 
isolated from young rats (Asumda and Chase, 2011, Kretlow et al., 2008). Beane and 
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co-workers (2014) investigated MSCs from young and old rabbits from the bone 
marrow, muscle (MDSC) and fat (ADMSCs) and demonstrated a relative reduction in 
proliferation with age of MSCs from the bone marrow but not from the other two 
sources (Beane et al., 2014). Georgen (2014) found that MSCs from OVX rats had a 
lower proliferation rate than their control counterparts and therefore concluded that 
the low proliferation rate would correlate with reduced self-renewal capacity which 
might cause a gradual depletion of MSC sources in the bone marrow of OVX animals 
(Goergen et al., 2013). In addition, variability between same species of animals is 
another important factor to consider. Stem cells from every individual would be 
different and this variability could possibly have affected the significance of ALP 
expression between MSCs from young, adult control and OVX rats. To overcome this 
a large number of rats would have to be used within each group.  
This study showed that MSCs from OVX rats have a lower in vitro migration and 
CXCR4 expression compared to MSCs from young rats and the adult rats. SDF-1 is 
a chemokine receptor for CXCR4 and the SDF-1/CXCR4 biological axis plays an 
important role in the migration of stem cells and the wound repair of tissues and 
organs (Molyneaux et al., 2003, Toupadakis et al., 2012, Shao et al., 2011, Lien et 
al., 2009b, Wynn et al., 2004a). The impaired migration capacity of MSCs from 4-
month post-ovariectomy rats could be due to their low expression of CXCR4 and may 
explain the impaired bone formation seen in osteoporotic patients as cells from these 
patients have a reduced capacity to migrate to the site of bone loss. SDF1 is produced 
in the periosteum of injured bone and encourages endochondral bone repair by 
recruiting mesenchymal stem cells to the site of injury. Therefore mobilization of 
osteoblastic progenitors to the bone surface is an important step in osteoblast 
maturation and the formation of mineralised tissue (Kitaori et al., 2009).   
This study supports the notion that although stem cells remain active with age, their 
differentiation ability is affected, therefore impairing their regenerative and 
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differentiation capacity. The contradictory results reported in various studies could be 
due to patient variability, osteoporotic models used and source of stem cells. Further 
in vivo studies are necessary to clarify whether the in vivo bioactivity of MSCs 
obtained from young patients are efficacious in the regeneration of bone in 
osteoporotic patients.  The rat OVX model is an osteopenic model and does not fully 
represent human osteoporosis. This study could therefore be validated by 
investigating MSCs isolated from human osteoporotic, old non-osteoporotic and 
young patients. 
Using cells from younger hosts could be an option for cellular and genetic therapies 
for bone degenerative diseases. Another stem cell therapy factor to consider is 
whether use of an allogenic cell source from young patients would be compatible in 
osteoporotic patients? Although we have shown that stem cells from OVX rats are 
similar in their proliferation and expression of CD markers to their younger 
counterparts, their inability to migrate to the site of bone loss as well as their reduced 
capacity to differentiate reduces their ability to form bone.  
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4.1 Introduction  
The controlled delivery of growth factors and cells at sites of bone injury can enhance 
and accelerate functional bone formation. Current bone regeneration therapies 
include delivery of growth factors such as BMP-2, 4 and 7 to the site of repair and 
have many disadvantages such as short half-life and instability which results in the 
repeated administration of the growth factors. The focus is therefore moving towards 
gene therapy where cells are transfected in vitro with a virus carrying a gene which 
has perceived beneficial effects,  before being transplanted in vivo (Hao et al., 2009).  
Gene therapy offers an alternative means to achieve controlled delivery of specific 
proteins for bone regeneration through the transfer of nucleic acids to somatic cells 
for a continuous therapeutic expression of osteoinductive factors. This regulates cell 
activity at a specific site by the release of appropriate concentrations of functional 
growth factors. There are two main gene therapy strategies for bone repair; stem-cell 
based gene therapy and direct gene therapy. Stem-cell based gene therapy involves 
the delivery of genetically engineered cell populations that act as the carrier for 
therapeutic genes. On the other hand, direct gene therapy involves the direct delivery 
in vivo via viral or non-viral vectors. The efficiency of direct gene therapy for bone 
repair has been demonstrated with different vectors in various animal models (Vo et 
al., 2012). Viruses are effective vectors for delivering cDNA as they are designed to 
efficiently infect cells and transmit genetic material (Pensak and Lieberman, 2013).  
The advantages of using an adenoviral vector system for this type of gene therapy 
include; extremely high transduction efficiencies compared to liposome- mediated 
gene transfer methods and the ability to accommodate large (up to 7.5kb) cDNAs. 
The virus can also be grown to high titers, which can readily be prepared and used to 
efficiently infect a number of cell types.  Unlike retrovirus transfection, adenovirus has 
a low pathogenicity in humans and does not integrate into the host genome, which 
avoids potential problems associated with insertional mutagenesis. This is important 
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because the viral genome will not be replicated into the host cells and would 
eventually be lost by dilution, cell division and apoptosis (Luo et al., 2007, Franceschi 
et al., 2000). 
 The hypothesis of this study was that using an adenovirus vector system to transfect 
rBMSC with cDNA encoding for CXCR4 would result in a larger number of cells 
expressing CXCR4 and that transfected cells would express increased levels of 
CXCR4 compared to non-transfected cells. In addition, the nature of these cells in 
terms of CD marker expression, their proliferation rate and the ability of cells to 
differentiate down an osteoblastic lineage would not be affected by the incorporation 
of cDNA encoding for CXCR4.  
The overall aim of this chapter was to over-express CXCR4 in MSCs from young, 
adult and OVX rats by transfecting using an adenovirus carrying CXCR4 gene and to 
determine whether this affected phenotype, migration, proliferation and differentiation 
of these cells. 
Therefore, I investigated the following: 
• The establishment of the CXCR4 gene in MSCs using an adenoviral vector 
system. 
• The expression of CXCR4 expression in infected and uninfected MSCs from 
young, adult control and OVX rats. 
• The effect of CXCR4 expression on cell proliferation, differentiation, CD 
marker expression in MSCs from young rats. 
In subsequent chapters, the effect of cell migration on osteopenic bone generated 
following ovariectomy will be investigated.   
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4.2 Methods 
4.2.1 Cloning the CXCR4 gene into the pShuttle vector  
The human CXCR4 cDNA (pCMV-XL5-CXCR4 Origene) was digested by restriction 
endonucleases NotI and XhoI (ThermoFisher Scientific, UK) and then inserted into 
pShuttle-CMV (AdEasy XL Adenoviral vector system; Stratagene, United States) to 
form pShuttle-CMV-CXCR4. The human CXCR4 gene and the pShuttle-CMV vector 
were both cut by restriction endonuclease NotI and XhoI (ThermoFisher Scientific, 
UK) and were then repaired to form blunt ends. The cuts were confirmed by gel 
electrophoresis. Human CXCR4 cDNA was then cloned into the pShuttle-CMV vector 
using DNA ligase (ThermoFisher, Scientific, UK). The presence of the insert was 
confirmed by restriction digest as well as Sanger sequencing. The incorporated 
shuttle vector was then linearised with PmeI restriction endonuclease and 
transformed into BJ5183-AD-1 competent cells using electroporation (Figure 4.1). An 
empty plasmid was created using similar steps but the cDNA sequence was not 
inserted into the pShuttle-CMV vector.  
Following selection of the smallest colonies, the recombinant plasmid was collected 
using a miniprep kit (ThermoFisher Scientific, Loughborough, UK) and cut using the 
PacI restriction enzyme (ThermoFisher Scientific, UK) (Figure 4.2). The correctly 
identified copies were then expanded in bulk using the recombinant-deficient XL10-
Gold strain.  
4.2.2 Production of the viral particles  
Purified recombinant plasmid DNA, cut with PacI was used to transfect AD-293 cells. 
The viral particles were generated by alternate freezing and thawing of the infected 
AD293 cells and collecting the supernatant. An anti-hexon antibody stain (Stratagene, 
USA) was used to determine the plaque forming units/ml (pfu/ml) of the infected cells 
by counting the number of dark infected cells. 
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Figure 4.1: A schematic diagram showing the production stages of the 
recombinant adenovirus using the AdEasy XL adenoviral vector system. 
 
4.2.3 Sequencing method 
A polymerase chain reaction (PCR) was carried out on 3.5μl (500ng) of the purified 
plasmid DNA (pShuttle-CMV- CXCR4) using the forward and reverse primer, 
sequencing buffer (ABI 4336699) and BigDye v3.1 (ABI 4337455). PCR products 
were then purified using ethanol precipitation and centrifuged at 3000rpm for 30 
minutes. The products were dried and washed with 70% ethanol, spun down and 
resuspended in HiDi Formamide (ABI 4440753) and analysed in a Sanger sequencer. 
A negative control with no DNA was also sequenced to validate the results.    
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4.2.4 Analysis of CXCR4 Expression  
4.2.4.1 Analysis using Flow Cytometry  
In order to validate whether transfection had increased CXCR4 expression in MSCs 
from young, adult control and OVX rats, CXCR4 expression was analysed in 
uninfected and infected MSCs (n = 3).    
Young rBMCs from the third passage were infected with the CXCR4 adenovirus at a 
Multiple of Infection (MOI) of 800, trypsinised and centrifuged at 2000 rpm for 10 
minutes before being resuspended at 100,000 cells in phosphate buffered saline 
(PBS). Cell aliquots were incubated with primary CXCR4 antibody (Abcam, UK) for 
30 minutes at room temperature. The cells were washed in PBS and then incubated 
in secondary goat anti-rabbit antibody (Abcam, UK) for 30 minutes at room 
temperature. The negative control consisted of cells incubated in the secondary 
antibody only. 10,000 cells were then analysed using a flow cytometry machine 
(Cytoflex, Beckman Coulter, UK).   
 In order to measure the natural expression of CXCR4 on young, adult control and 
OVX cells, rBMCs from the third passage were trypsinised and centrifuged at 2000 
rpm for 5 minutes before being resuspended at 100,000 cells in phosphate buffered 
saline (PBS). The cells were fixed in 4% formaldehyde for 10 minutes at room 
temperature. After 10 minutes, the cells were washed in PBS to remove the 
formaldehyde. Cell aliquots were permeabilised in ice cold 90% methanol (Sigma 
Aldrich, UK) for 10 minutes, washed with blocking buffer (0.5% Bovine Serum 
Albumin in PBS) and incubated with primary CXCR4 antibody (Abcam, UK) for 1hour 
at room temperature. The cells were then washed with blocking buffer and then 
incubated in secondary goat anti-rabbit antibody (Abcam, UK) for 30 minutes at room 
temperature.  
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For the negative control, cells were treated in the same manner but only incubated in 
the secondary antibody for an hour. All cells were then resuspended in PBS and 
analysed using flow cytometry (Cytoflex, Beckman Coulter). The above procedure 
was repeated for young, adult control and OVX rBMCs from the third passage that 
were infected with the CXCR4 adenovirus at a MOI of 800. 
4.2.4.2 Immunocytochemistry 
CXCR4 expression on these cells was also analysed using immunocytochemistry. 
Briefly the CXCR4 infected cells were fixed with 4% formalin (Sigma Aldrich, UK), 
incubated in a blocking buffer (1% Bovine serum albumin (Sigma Aldrich, UK)) for an 
hour and then incubated with primary CXCR4 antibody (Abcam, UK) for 2 hours at 
room temperature. The cells were washed with PBS and then incubated in secondary 
goat anti-rabbit antibody (Abcam, UK) for 30 minutes at room temperature. DAPI was 
used to counter stain cell nuclei. The cells were imaged using a fluorescent 
microscope (Zeiss – Axiovision 4.5) (Cell Signalling Technology) .  
4.2.5 CD Marker expression of CXCR4 infected MSCs 
10,000 young MSCs from passage 3 infected with CXCR4 adenovirus at MOI of 800 
were analysed for CD29, CD90, CD45 and CD34, to investigate whether infection 
with an adenovirus affected their stem cell features (n = 3). As described in chapter 
2, the cells were labelled with Anti-mouse/Rat CD29-FITC (eBioscience, UK), anti-
mouse/Rat CD90-APC (eBioscience, UK), Anti-Rat CD45-APC (eBioscience, UK) 
and CD34-PE (Abcam, UK). CD expression was compared to the isotype control. The 
cells were fixed in 4% formalin for 15 minutes at room temperature, washed with 0.5% 
BSA-PBS, stained with the conjugated primary antibody for 1 hour at room 
temperature in the dark. After 1 hour the cells were washed with 0.5% BSA and 
analysed using a flow cytometer (Cytoflex, Beckman Coulter, UK) (Cell Signalling 
Technology).   
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4.2.6 Differences in proliferation between infected and uninfected cells. 
10000 CXCR4 infected and uninfected young MSCs (n=3) were seeded in a 6 well 
plate and metabolic activity was measured using an Alamar Blue assay (AbD Serotec, 
UK) for 4 hours.  Excitation at 560 nm and an emission at 590 nm were measured 
using a Tecan plate reader. The mean absorbance was determined from triplicate 
samples. The absorbance was then normalised to the DNA assays and a comparison 
was made between the infected and uninfected cells (methodology described in detail 
in chapter 3) (Czekanska, 2011).  
4.2.7 Differences in ALP production between infected and uninfected cells. 
Transfected and non-transfected young MSCs were harvested and differentiated to 
osteoblasts (n = 3). Their ALP activity was measured at 0, 7, 14 and 21 days. Briefly 
p-Nitrophenyl Phosphate (Sigma Aldrich, UK) was added to the cell lysate and the 
absorbance was measured at 405 nm. This was then normalised against DNA 
readings of each sample (Oreffo et al., 1998) (described in detail in chapter 3). 
4.2.8 Statistical analysis. 
Data was analysed using a student T-test using SPSS version 21 and results 
considered significant at the 0.05 level. The normality of the data was checked using 
a parametric test (Shapiro Wilkinson test).  
4.3 Results 
4.3.1 Production of the CXCR4 adenoviral vector system 
The CXCR4 gene was successfully cloned into the pShuttle-CMV vector and the 
presence of the CXCR4 insert was confirmed by Sanger sequencing (Figure 4.4) as 
well as HindIII and Sal1 restriction enzymes, which generated a band of 
approximately 1.8 kb, the size of the CXCR4 insert using gel electrophoresis. The 
pShuttle-CMV-CXCR4 plasmid was linearised with PmeI and recombined into the Ad-
plasmid in BJ5183 cells (e.coli strain). This insert was confirmed by a PacI restriction 
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cut which generated a band of 3 kb and 23 kb (Figure 4.3). The plasmid was then 
linearised and inserted into the AD293 cells (packaging cell line) and the sign of viral 
production was observed by a colour change in the medium from red to orangish 
yellow, compared to the negative control. Additionally, a further sign of viral infection 
was shown by some of the cells rounding up, detaching from the plate and floating in 
the media. Anti-hexon antibody staining generated dark brown cells which were 
counted to calculate the pfu/ml of the CXCR4 and empty plasmid virus (n=2) (Figure 
4.5, Figure 4.6). Immunocytochemistry further confirmed the presence of CXCR4 in 
the AD293 cells (n=3) (Figure 4.8). 
 
 
Figure 4.2: Screening of the potential adenovirus recombinants after 
recombination in AdEasier cells. The small colonies most likely contain the 
recombinant plasmid. The larger colonies are background clones. 
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Figure 4.3: Gel electrophoresis confirming the CXCR4 insert into the Pshuttle-
CMV vector, using SalI and HindIII restriction enzyme resulting into a band size 
of 1.8 kb (left). The recombination of the pShuttle-CMV-CXCR4 with the Ad 
plasmid was also confirmed with the 3 kb and 23 kb bands.  
 
 
Figure 4.4: The insert of the gene was further confirmed by an 
electropherogram from Sanger sequencing (left) and was also validated using 
the negative control, which was the empty insert (right). 
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Figure 4.5: Ad-293 cells, 10 days after transfection with linearised pShuttle-
CMV-CXCR4 plasmid (a), anti-hexon staining of the infected Ad293 cells (b) 
x20magnification, immunocytochemistry staining for CXCR4 expression of 
uninfected AD293 cells (c) and infected AD293 cells (d) (x100 magnification).     
 
         
Figure 4.6: CXCR4 infected MSCs has a much rounder and larger nucleated 
morphology (left), compared to their uninfected counterparts that have retained 
their spindle like morphology (x10 magnification).  
 
4.3.2 CXCR4 expression of infected and uninfected cells 
Surface expression of CXCR4 on these cells was analysed by flow cytometry and 
immunocytochemistry using an anti-CXCR4 antibody (n=3). The CXCR4 infected 
cells over-expressed CXCR4 evident by immunocytochemistry and flow cytometry in 
comparison to uninfected cells and empty infected cells. This was also evident when 
AD293 cells were infected with a CXCR4 adenovirus. The AD293 and MSCs infected 
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with the empty virus showed no expression of CXCR4 when compared to their 
infected counterparts (Figure 4.8).  
After transfection with the CXCR4 virus at MOI 800, 92±2.6%, 44.2±8.2% and 
40±16.1% of young, adult control and OVX MSCs respectively over-expressed 
CXCR4. CXCR4 expression in OVX MSCs was doubled while in young MSCs it only 
increased by 5% after CXCR4 transfection (Table 4.1, Figure 4.7).  This could be 
because the young MSCs already expressed high levels of CXCR4 and over-
expression did not affect further CXCR4 expression.  
 
Table 4.1: The percentage change in CXCR4 expression before and after CXCR4 
transfection in young, adult control and OVX MSCs. * & ** & *** represents 
significance p<0.05 (n=3).     
Type of cells CXCR4 expression 
before transfection 
(%) 
CXCR4 expression 
after transfection 
(%) 
Percentage 
increase (%) 
Young MSCs 87.5±5.1*, ** 92±2.6*** 5.1 
Adult MSCs 28.1±1.5* 44.2±8.2*** 57.2 
OVX MSCs 20.2±9.8** 40±16.1*** 97.9 
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Figure 4.7:  FACS analysis of CXCR4 infected cells and uninfected cells of 
young MSCs (a); adult control (b) and OVX MSCs (c). The secondary isotype is 
represented by red, CXCR4 expression in MSCs is represented by green and 
pink represents the CXCR4 over-expression in the infected MSCs.  
                   
 
Figure 4.8: Immunocytochemistry of CXCR4 expression in CXCR4 infected (a), 
empty infected AD293 cells (b) (x100 magnification), infected young rBMCs (c), 
and ‘empty plasmid’ infected rBMCs (d) (x40 magnification).   
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4.3.3 CD Marker expression of CXCR4 infected MSCs 
To investigate whether adenovirus infection of MSCs effected ‘stem’ phenotype of 
MSCs, the expression of CD29, CD90, CD34 and CD45 from the infected groups was 
compared to the uninfected young cells (n = 3). Overall the CD marker expression of 
the infected cells was not significantly different from uninfected cells. On average 
81.97±6.97% of the infected and uninfected cells expressed CD29, 94.67±7.6% of 
the cells expressed CD90, 2.47±3.24% of the cells expressed CD34 and 
26.9±18.24% of the cells expressed CD45 ( 
Figure 4.9).  
 
Figure 4.9: CD Marker expression of CXCR4 infected young MSCs from passage 
3. CD34 (A), CD90 (B), CD29 (C) and CD45 (D) expression shown using FACS 
analysis, with histograms in the middle showing the secondary isotype control 
and histograms on the far right showing the expression of the CD markers 
(n=3).  
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4.3.4 Differences in proliferation between infected and uninfected cells 
To measure cell proliferation, the Alamar blue assay normalised against the DNA 
content was measured for the CXCR4 infected cells and the uninfected cells (n=3). It 
was observed that the infected cells had higher cell proliferation in comparison to the 
uninfected cells at day 5 with a decrease at day 7 and thereafter increased again at 
day 14. In contrast, the uninfected cells had lower proliferation at day 5, which peaked 
at day 7 and then reduced at day 14 (Figure 4.10a). The differences in proliferation 
between the infected and uninfected cells were not significant at day 5 (p = 0.063), 
day 7 (p = 0.08) and day 14 (p = 0.25), showing that infecting rBMCs with CXCR4 
adenovirus did not affect their proliferation. 
 
Figure 4.10: Average Alamar blue readings normalised against DNA content for 
CXCR4 infected and uninfected cells (a) and ALP normalised against DNA 
content (b) for CXCR4 infected and uninfected cells when they were 
differentiated to osteoblasts and control cells which were grown in normal 
media (n=3). 
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4.3.5 Differences in ALP production between infected and uninfected cells 
To ensure that infecting rBMCs with CXCR4 did not affect osteogenic differentiation, 
the CXCR4 infected cells and the uninfected cells were differentiated into osteoblasts 
and their ALP expression was measured from day 0 to day 21 (n=3). The ALP 
readings were normalised against the DNA content. The uninfected cells had a peak 
increase in ALP at day 14. However, the infected cells showed higher ALP at day 1, 
which was observed to decrease by day 7 and rise by day 14. For both the infected 
and uninfected cells the ALP readings were observed to decrease at day 21(Figure 
4.10b). No significant difference in ALP expression of the infected and uninfected 
cells at day 0 (p = 0.21), day 7 (p = 0.55), day 14 (0.79) and day 21 (p = 0.25) was 
found, implying that CXCR4 infection did not affect ALP expression of rBMCs. 
4.4 Discussion 
The aim of this chapter was to establish a reliable system for modifying MSCs in order 
to make these cells over-express CXCR4 so as to increase their migration ability to 
sites of injury or to osteopenic bone. An adenovirus is an appealing transfection 
system for gene therapy because of its high transfection efficiency for a wide range 
of cell types and most importantly the virus does not integrate with the DNA of the cell 
(Luo et al., 2007). The cytopathic effect of AD293 cells during the adenovirus 
production procedure demonstrated the assembly of the virus particles in the cells. 
This was observed in stem cells during viral transduction. MSCs were seen to have 
an altered morphology; with a rounder and larger nucleus. The uninfected MSCs 
maintained a spindle like morphology (Figure 4.6).  
Adenovirus infects cells by the attachment of Cocksackie adenovirus receptor (CAR) 
on the cell surface. Following receptor-mediated endocytosis, adenovirus escapes 
from the endosomes to the cytoplasm and translocates into the nucleus where viral 
transcription and replication begin.  Completion of the virus life cycle is marked by cell 
death and the release of progeny viruses, which was clearly demonstrated when the 
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AD293 cells became rounder and detached from the surface of the flask (Luo et al., 
2007). The AD293 cells were used to amplify the adenovirus, by collecting viruses 
from small numbers of AD293 cells and infecting a larger number of AD293 in a bigger 
flask and thereby using virus isolated after passage 2. After confirming the 
adenovirus’ infection ability on AD293 cells using anti-hexon staining, we transfected 
MSCs and tested the expression of CXCR4 in both the infected (MOI 800) and 
uninfected MSCs using flow cytometry and in ‘empty plasmid’ infected MSCs using 
immunocytochemistry. MSCs from OVX and adult control rats demonstrated an 
average 20% increase in CXCR4 expression after CXCR4 infection in comparison to 
the uninfected cells. After transfection, CXCR4 expression was 40% greater in the 
OVX and adult control MSC groups. It was interesting to note that an increase in 
CXCR4 expression after transfection in young MSCs was not as prolific as that 
observed in OVX and adult control cells. This may be because young MSCs already 
have a high expression of CXCR4 and infecting them would only increase their 
CXCR4 expression per cell, which was captured by immunocytochemistry. 
Immunocytochemistry demonstrated high amounts of CXCR4 in the infected MSCs 
and AD293 cells in comparison to the cells infected with an empty plasmid. 
Although the infected MSCs had a rounder morphology compared to the uninfected 
cells, their CD marker expression was unchanged. The transfected cells retained their 
high expression of CD90 and CD29 and low expression of CD34 and CD45. There 
was also no significant difference in proliferation and ALP expression when infected 
and uninfected cells were compared. This proved that the viral vector system and 
CXCR4 over-expression did not affect cell physiology and function, especially the 
ability of the cells to differentiate to osteoblasts and the MSCs retained their stem cell 
characteristic post-transfection. This was an important characteristic to investigate 
because the CXCR4 transfected MSCs would be used to augment bone formation in 
OVX rats.  
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In this chapter, a reliable adenoviral gene modifying system has been established to 
transfect rat MSCs with CXCR4, with expression of CXCR4 effectively quantified 
using flow cytometry. The effect of CXCR4 on the migration of young, adult control 
and OVX MSCs will be tested in vitro in Transwell chambers.  The goal of this work 
is to use these transfected cells in vivo in osteopenic rats to test the effect of over-
expressing CXCR4 in stem cells potentially making their migration and homing ability 
more efficient.  This would retain transfected cells at sites producing SDF-1 that are 
likely to be associated with injury. Potentially this could lead to better bone repair and 
regeneration.  
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5.1 Introduction 
It has been suggested that MSCs from postmenopausal women have a slower growth 
rate and osteogenic differentiation ability compared to MSCs from premenopausal 
women, which causes lower bone density and reduced fracture healing capacity in 
osteoporotic humans (Rodriguez et al., 1999, Rodriguez et al., 2000). Wang et al. 
injected MSCs embedded within a calcium alginate gel, into the femora of OVX 
rabbits. After 2 months, an increase in bone apposition, trabecular thickness and bone 
stiffness was seen in femora from rabbits treated with MSCs, compared to the 
controls (Wang et al., 2006). Similar results were shown by Ocarino Nde et al. when 
GFP labelled MSCs were injected into the femoral bone marrow cavity in OVX rats. 
Most interestingly, the GFP labelled cells were shown to line the surface of the newly 
formed femoral bone (Ocarino Nde et al., 2010). This highlights the importance of 
stem cell movement for bone healing. 
Cellular movement and re-localization are crucial for many important physiologic 
properties such as embryonic development, neovascularisation and angiogenesis, 
immunologic responses, wound healing, and organ repair. Both local MSCs from the 
injured tissue and circulating MSCs can contribute to tissue and organ regeneration. 
Cytokines and chemokines play important roles in maintaining the mobilization, 
trafficking and homing of stem cells from the bone marrow to the site of injury (Dar et 
al., 2006, Ito, 2011, Liu et al., 2009). During tissue regeneration, it has been 
suggested that local MSCs derived from the injured tissue and circulating MSCs work 
together to heal damaged organs. Stem cells detect the tissue injury, migrate to the 
site of damage and undergo differentiation (Shyu et al., 2006, Ito, 2011) and this may 
explain the increase of stem cells found in damaged tissues such as impaired sites in 
the brain after hypoglossal nerve injury (Ji et al., 2004) and cerebral injury (Imitola et 
al., 2004) when compared to normal healthy tissues. As a result of injury, the surviving 
Chapter 5. Migration of Stem Cells is Enhanced CXCR4 
133 
 
cells may produce chemoattractants such as SDF-1. With its receptor CXCR4, SDF-
1 directs the migration of MSCs to the injury site (Imitola et al., 2004).  
Wynn et al.(Wynn et al., 2004a) showed that when a neutralizing anti-CXCR4 
antibody was used to block CXCR4 expression, it inhibited MSC migration to the bone 
marrow by approximately 46%. This study also demonstrated a dose dependent 
migration of MSCs towards SDF-1 in a transwell assay, when MSCs were seeded in 
the upper chamber of a Boyden chamber and SDF-1 was used as a chemoattractant. 
Blocking CXCR4 expression significantly reduced cell migration towards SDF-1 
(Wynn et al., 2004a). Lien and co-workers transfected murine MSCs with CXCR4 and 
Cbfa-1 and injected these modified cells into osteopenic mice. A complete recovery 
of bone stiffness and strength in these animals was seen after 4 weeks (Lien et al., 
2009b). A similar study by Cho et al. also showed that over-expression of MSCs with 
CXCR4 and RANK-Fc improved bone mineral density in ovariectomized mice, with 
CXCR4 acting as an important migratory factor and enhancing the therapeutic effects 
of RANK-Fc for bone loss (Cho et al., 2009b). However, information on differences in 
the ability of MSCs to migrate in osteopenic, adult and young rats are limited.   
The purpose of this part of my thesis was to investigate the scope of CXCR4 in 
improving the migration of MSCs from these three different groups of rats. In patients 
with osteoporosis, there is often an increased incidence of delayed union associated 
with fragility fractures. This may be associated with recruitment of stem cells to the 
fracture site and their differentiation to bone. Considering the significance of the SDF-
1/CXCR4 axis in homing and engraftment of bone marrow cells and the potential of 
MSCs in bone regeneration therapy, I investigated the novel concept of using over-
expression of CXCR4 in stem cells to affect and enhance the migratory capacities of 
MSCs from three rat populations: young, adult and osteopenic.  
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The first hypothesis of this chapter was that young MSCs transfected with CXCR4 
would migrate more towards SDF-1 compared to CXCR4 infected MSCs from OVX 
and adult rats.  
The second hypothesis was that uninfected MSCs differentiated to osteoblasts would 
not migrate towards SDF-1 in a Boyden Chamber, however CXCR4 infected MSCs 
differentiated to osteoblasts would migrate towards SDF-1 in a Boyden Chamber.  
5.2 Methods 
5.2.1 Migration of Infected and Uninfected Cells from Young, Adult and OVX 
Rats 
For this part of the study, the in vitro migration of MSCs was investigated in the 
following experimental groups: 
• Groups A – Uninfected Young MSCs 
• Group B – CXCR4 infected young MSCs 
• Group C – Uninfected adult MSCs 
• Group D – CXCR4 infected adult MSCs 
• Group E – Uninfected OVX MSCs 
• Group F – CXCR4 infected OVX MSCs 
• Group G – ‘Empty plasmid’ infected Young MSCs. 
A chemoinvasion assay was used to evaluate the ability of CXCR4 infected MSCs to 
migrate towards SDF-1 in comparison to uninfected MSCs. 10,000 cells (i) 
transfected with CXCR4, (ii) with an empty plasmid at MOI 800, and (iii) uninfected 
cells were introduced into the chamber. The lower compartment of the Boyden 
chamber was filled with 100ng/ml SDF-1 in DMEM, FCS and penicillin/streptomycin. 
The chambers were incubated at 37°C, 5% CO2 for 16 hours. After 16 hours, cells 
that migrated to the opposite side of the membrane were fixed in 10% formaldehyde 
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and stained with crystal violet. The migrated cells were counted by selecting six 
random fields at x20 magnification and calculating the percentage average number 
of cells. The normalised number of cells was calculated by dividing the infected cells 
by the uninfected cells of the same group. Each experiment was repeated three times 
with cells from three different rats. In the control group, both the top and bottom of the 
chamber were filled with normal media with no SDF-1 and the cells were loaded in 
the upper chamber as before. This was to create an environment with no SDF-1. The 
migrated cells were stained and counted after 16 hours. Data was analysed for both 
studies using SPSS and results considered significant at the 0.05 level.  
5.2.2 CXCR4 expression of Osteogenic differentiated rBMCs and CXCR4 
infected rBMCs differentiated to osteoblasts 
CXCR4 infected and uninfected young rBMCs from the third passage were treated 
with osteogenic media for 21 days. The cells were thereafter trypsinised and 
centrifuged at 2000 rpm for 5 minutes before being re-suspended at 100,000 cells in 
phosphate buffered saline (PBS). The cells were fixed in 4% formaldehyde for 10 
minutes at room temperature. The cells were then washed in PBS to remove the 
formaldehyde. Cell aliquots were permeabilised in ice cold 90% methanol for 10 
minutes, washed with blocking buffer (0.5% Bovine Serum Albumin in PBS) and 
incubated with primary CXCR4 antibody (Abcam) for 1hour at room temperature. The 
cells were then washed with blocking buffer and incubated in secondary goat anti-
rabbit antibody (Abcam) for 30 minutes at room temperature.  
For the negative control, cells were treated in the same manner but only incubated in 
the secondary antibody for an hour. All the cells were then resuspended in PBS and 
analysed using a flow cytometry machine (Cytoflex, Beckman Coulter). The above 
procedure was repeated for young rBMCs seeded in normal media for 21 days. 
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CXCR4 expression was therefore investigated in three groups of cells in this part of 
the study: 
• Group A – Young MSCs grown in normal media (Control). 
• Group B – Uninfected Young MSCs differentiated to osteoblasts. 
• Group C – CXCR4 infected young MSCs differentiated to osteoblasts. 
Young MSCs were only used for this part of the study because they had very high 
initial levels of CXCR4 and any observable differences in CXCR4 expression after 
osteogenic differentiation could easily be compared to controls. 
5.2.3 Migration of rBMCs and CXCR4 Infected rBMCs grown in Osteogenic 
Media 
A chemoinvasion assay was used to evaluate the ability of undifferentiated and 
osteogenic differentiated MSCs to migrate towards SDF-1. To confirm osteogenic 
differentiation of rBMCs, cells were stained with Alizarin red and their osteocalcin 
expression analysed after 21 days.  For the chemoinvasion assay 25000 osteogenic 
differentiated rBMCs and undifferentiated rBMCs were loaded in serum free medium 
in separate upper compartments of the Boyden chamber. The lower compartment of 
the Boyden chamber was filled with 100ng/ml SDF-1 in DMEM, FCS and 
penicillin/streptomycin. The chambers were incubated at 37°C, 5% CO2 for 16 hours. 
After 16 hours, the cells that migrated to the opposite side of the membrane were 
fixed in 10% formaldehyde and stained with crystal violet. The migrated cells were 
counted by selecting six random fields at x20 magnification and calculating the 
percentage average number of cells. Each experiment was repeated three times with 
cells from three different rats. For the control, both the top and bottom of the chamber 
were filled with normal media with no SDF-1 and the cells were loaded in the upper 
chamber as before. This was to create an environment with no SDF-1 (Figure 5.1). 
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Figure 5.1: A schematic diagram demonstrating a Boyden Chamber. The cells 
loaded in the upper chamber, would migrate to the bottom depending on 
whether the bottom chamber is filled with SDF-1 or normal media. The number 
of cells that migrated to the opposite side of the membrane would be counted 
using crystal violet stain.  
 
5.2.3 Statistical Analysis 
The normality was checked using Kolmogorov- Smirnov and Shapiro Wilkinson test 
and where the data was normal, comparison was made using independent student 
T-test. Where the data was non-parametric comparison was made using Mann-
Whitney U test with a Bonferroni correction. All data was analysed using SPSS 
version 24 (Chicago, USA).  
5.3 Results 
5.3.1 Migration of Infected and Uninfected Cells from Young, Adult and OVX 
rats 
The effect of SDF1 on the migration of CXCR4 infected cells, empty plasmid-infected 
cells and uninfected cells was investigated using the transwell migration assay. The 
data was normalised to the uninfected cells. Over-expression of CXCR4 significantly 
increased the migration of young rBMCs towards SDF-1 by 87±27% in comparison 
to uninfected cells (p = 0.006). Similarly, the effect of infecting the cells with an empty 
plasmid on their migration towards SDF-1 was measured. Although, significantly 
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fewer ‘empty plasmid’ infected cells migrated towards SDF-1 in comparison to the 
uninfected cells (p = 0.03), there was a significant decrease in the migration of ‘empty 
plasmid’ infected cells towards SDF-1 when compared with infected cells (p = 0.003), 
demonstrating that over-expression of CXCR4 increased cell migration towards this 
cytokine. Most importantly the effect of CXCR4 was significantly more profound in 
rBMCs from OVX rats. Five times more rBMCs from OVX rats migrated towards SDF-
1 after being over-expressed with CXCR4 compared to uninfected cells (p = 0.025) 
(Figure 5.3 & Figure 5.4).  
 
 Figure 5.2: Crystal violet staining of migrated Young MSCs on the opposite 
side of the Boyden Chamber; uninfected (A), CXCR4 infected (B) and ‘empty 
plasmid’ infected MSCs (C) towards SDF-1 and control uninfected (D), CXCR4 
infected (E) and ‘empty-plasmid’ infected (F) towards plain media. CXCR4 
transfection significantly improved migration of young MSCs compared to 
‘empty plasmid’ infected and uninfected MSCs (x20 magnification). 
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Figure 5.3: The mean percentage migration of infected cells normalised against 
uninfected cells. Cells were normalised by dividing infected with their 
uninfected counterparts. *, ** and *** represent significance p<0.05.  
 
Figure 5.4: The mean percentage migration of CXCR4 infected cells compared 
to uninfected cells. * and ** represents significance p<0.05 and *** represents 
significance p<0.001.  
Chapter 5. Migration of Stem Cells is Enhanced CXCR4 
140 
 
5.3.2 CXCR4 Expression of Infected and Uninfected rBMCS Differentiated to 
Osteoblasts 
To investigate whether osteogenic differentiation affects CXCR4 expression of 
differentiated rBMCs, the CXCR4 levels were measured using flow cytometry. 
Differentiation of young rBMCs to osteoblasts was confirmed by osteocalcin and 
alizarin red staining at day 21 (Figure 5.6). A control group of young rBMCs grown in 
normal media for 21 days was used to investigate whether culturing cells for 21 days 
affected CXCR4 expression. Overall, flow cytometry analysis demonstrated that the 
CXCR4 expression of young MSCs dropped significantly when differentiated to 
osteoblasts irrespective of the fact that these MSCs were transfected with the CXCR4 
virus (Table 5.1, Figure 5.5). Culturing young MSCs for 21 days in normal non-
osteogenic media (68.7±15.4%) did cause their CXCR4 expression to drop compared 
to culturing them for 7 days until confluency (84.4±8.2%), but this was not a significant 
drop.  
Table 5.1: Flow cytometry results demonstrating the percentage CXCR4 
expression of CXCR4 infected and uninfected MSCs differentiated to 
osteoblasts for 21 days. * and ** represent significance p<0.05. 
Type of cells Undifferentiated 
MSCs 
Uninfected 
osteoblasts 
CXCR4 infected 
osteoblasts 
Percentage 
CXCR4 
expression. 
68.7 ± 15.4 *    ** 6.3 ± 0.6 * 8.0 ± 5.2** 
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Figure 5.5: Spectra obtained following flow cytometry and analysis of CXCR4 
expression in young rBMCs cultured for 21 days in non-osteogenic media (a), 
uninfected MSCs differentiated to osteoblasts (b) and CXCR4 infected MSCs 
differentiated to osteoblasts (c). The red peak represents the secondary control 
while the green peak represents the cells labelled with the primary anti-CXCR4 
antibody. 
 
5.3.3 Migration of Osteogenic Differentiated rBMCs and CXCR4 Infected rBMCs 
Differentiated to Osteoblasts 
In order to determine whether osteogenic differentiation of rBMCs affected migration 
towards SDF-1 and whether transfection with CXCR4 increased their migratory 
capacity, I repeated the migration assay on stem cells grown in osteogenic medium. 
CXCR4 infected cells were also differentiated to osteoblasts and their migration 
measured using a Boyden chamber. It was observed that differentiating rBMCs to 
osteoblasts significantly reduced their migration towards SDF-1 (6.7 ± 2.3%) 
compared to undifferentiated rBMCs (23.2 ± 4%) (p = 0.0006). Results also showed 
that when CXCR4 infected rBMCs were differentiated to osteoblasts, their migration 
capability towards SDF-1 did not significantly improve (11.25 ± 8.6%), whereas 
transfection significantly improved the migration of undifferentiated rBMCs (47 ± 17%) 
(Figure 5.6).  
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Figure 5.6: The mean percentage migration of infected and uninfected rBMCs, 
osteogenic differentiated rBMCs and CXCR4 infected rBMCs differentiated to 
osteoblasts towards SDF1 in a Boyden chamber. * represent significance 
p<0.05. Positive Alizarin Red (a) and Osteocalcin staining (b) expressed at day 
21 of osteogenic differentiated rBMCs. 
 
5.4 Discussion  
This in vitro study has highlighted the pivotal role of the SDF-1/CXCR4 axis in the 
homing of stem cells and the potential significance this may have in improving bone 
formation in osteoporosis. Increased migration was seen in cells transfected with 
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CXCR4 when compared to uninfected cells. CXCR4 therefore plays a crucial role in 
stem cell migration as identified in these transwell in vitro assays. During aging, the 
composition, structure and function of bone deteriorates, resulting in osteoporosis 
(Raisz, 2005). It has also been demonstrated that MSCs from osteoporotic humans 
have impaired migration towards chemoattractants such as fetal calf serum (FCS), 
BMP-2 and BMP-7 in Boyden chambers as well as in micro-slide chemotaxis 
chambers (Haasters et al., 2014). SDF-1 has previously been shown to recruit more 
host stem cells to a fracture defect site and encourage osteogenic differentiation and 
production of bone (Ho et al., 2014a).  
When considering the effect of age on cells, the work in this chapter has also 
demonstrated that stem cells from OVX and adult rats express lower levels of CXCR4 
on their surface compared to stem cells from young rats, which might explain their 
impaired migration towards SDF-1. CXCR4, a receptor of SDF-1 is expressed in 
numerous tissues, including mature and immature hematopoietic and endothelial 
cells, EPCs, and smooth muscle cell (SMC) progenitors, which all have direct or 
indirect pro-angiogenic properties. SDF-1/CXCR4 pathway plays an important role in 
stimulating the trafficking and engraftment of hematopoietic stem cell and 
reconstitution of haematopoiesis (Ratajczak et al., 2006).  
SDF-1 is released from the stromal cells into the intravascular compartment and it is 
transported from the plasma to the bone marrow compartment (Dar et al., 2005), 
where it induces the activation of matrix metalloproteinase-9 (MMP-9) and the release 
of soluble kit-ligand (sKitL). Subsequently, sKitL induces the release of more SDF-1, 
enhancing mobilization of the CXCR4+ and c-Kit+ cells to the circulation (Heissig et 
al., 2002). SDF-1 also activates the nitric oxide (NO) pathway, causing the endothelial 
cells to release NO which causes an upregulation of MMP-9. NO induces 
vasodilatation of BM endothelium which induces the release of cells (Aicher et al., 
2003). In bone repair, SDF-1 is induced in the periosteum of injured bone and 
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promotes endochondral bone repair by recruiting mesenchymal stem cells to the site 
of injury (Urbich et al., 2005, Kollet et al., 2006).  
Liang and co-workers intravenously injected lethally irradiated young or old Ly-5.1 
mice with old or young Ly-5.2 bone marrow cells. 24 hours later, they analysed the 
marrow from the recipients for Ly-5.2+ stem cells that had homed there. It was found 
that the older cells migrated 2 to 3 times less to the bone marrow niche compared to 
the young cells (Liang et al., 2005). This was most likely to be due to defective CXCR4 
expression developing during aging, reducing the number of CXCR4-positive cells in 
the bone marrow and the circulation which would eventually cumulate towards 
reduced angiogenesis and vessel repair (Shao et al., 2011). In this study I improved 
the mobility of stem cells obtained from OVX rats towards SDF-1 by increasing their 
CXCR4 expression. It is believed that SDF-1 causes cell migration by binding with 
CXCR4.  Therefore, increased secretion of SDF-1 at the site of injury creates an 
environment that mediates the homing of circulating CXCR4-positive stem cells. The 
cells will subsequently differentiate into the surrounding tissue type and effect repair 
at the injury site (Stich et al., 2009). Poor homing ability of the stem cells to bone 
could result in a significant reduction in bone formation which ultimately contributes 
to osteoporosis (Antebi et al., 2014).  This poor migration may also lead to reduced 
fracture healing in these patients.   
Oestrogen deficiency is the main factor that causes postmenopausal osteoporosis. 
Oestrogen improves the osteoblastic differentiation of hBMSCs through ER-α (Hong 
et al., 2006) or through activating Wnt/β-catenin signalling (Bhukhai et al., 2012). A 
deficiency in oestrogen also increases the circulating levels of cytokines such as IL-
1, TNF-α and granulocyte macrophage colony stimulating factor (GM-CSF). 
Increased levels of these cytokines, due to a reduction in oestrogen, enhance bone 
resorption (Kular et al., 2012, Manolagas and Jilka, 1995). The Notch signalling 
pathway has been shown to induce osteogenic differentiation and inhibit adipogenic 
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differentiation of BMSCs (Ugarte et al., 2009). A study performed by Fan (Fan et al., 
2014) has shown that oestrogen up-regulated Notch signalling enhanced the 
proliferation and differentiation of hBMCs. This could further explain the difference in 
migration between the MSCs from the OVX and those from adult and younger rats, 
where the cells from OVX rats showed significantly reduced migration. However, the 
current study did not measure the effect of oestrogen on the migration of stem cells 
from young, OVX or from senile rats. 
The differentiation of MSCs to osteoblasts is a complex process that involves the 
interaction of numerous hormones, autocrine and paracrine processes and systemic 
growth factors (Mannello et al., 2006). We found that stem cell migration towards 
SDF-1 is reduced after osteogenic induction even though cells were over-expressed 
with CXCR4 prior to differentiation. The diminished migration of the differentiated 
MSCs may be a result of increased extra-cellular matrix deposition, and subsequently 
greater surface adherence. Matrix metalloproteinases (MMP) play a significant role in 
several differentiation events. MMPs are also involved in regulating osteoblast 
proliferation and apoptosis (Karsdal et al., 2002, Batouli et al., 2003). However, it has 
been shown that MMPs inactivate SDF-1 and this may have an implication on the 
migration of osteoblasts (Abbott et al., 2004). This could further imply that SDF-
1/CXCR4 axis is no longer required once the osteogenic differentiation pathway has 
been set into motion, (Liu et al., 2013). Additionally, the role of an osteoblast is to 
secrete osteoid in an orientated manner and the migration of cells may impair this 
localised production. Liu and co-workers found that when the cells were pre-treated 
with anti-SDF1 and anti-CXCR4 antibody for 6 hours, BMP-9-induced Runx2 and 
OSX expression, which are markers of osteogenesis, was reduced significantly, 
highlighting the importance of SDF1/CXCR4 in initiating osteogenesis (Liu et al., 
2013). However, although the CXCR4/SDF1 axis may be involved in the induction of 
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early stages of osteogenic differentiation, their levels were seen to diminish during 
osteogenesis (Kortesidis et al., 2005, Liu et al., 2013).  
The importance of CXCR4 in improving bone loss in osteopenic animals has been 
highlighted in previous studies. Lien’s study looked at the migration of MSCs 
transfected with CXCR4 and Cbfa-1 in osteopenic mice and Cho’s study similarly 
looked at the migration of stem cells transfected with CXCR4 and RANK-Fc in 
osteopenic mice (Lien et al., 2009b, Cho et al., 2009b). However, this study 
emphasizes the differences in CXCR4 expression between MSCs from 
ovariectomised rats, adult and young rats, as well as their differences in migration in 
vitro, which was improved after CXCR4 transfection. MSCs from OVX rats have poor 
migration ability and CXCR4 was observed to be the most effective in improving their 
migration compared to MSCs from young rats. Moreover, the migration of osteoblasts 
showed that CXCR4 over-expressing differentiated rat MSCs does not improve their 
migration.  
The in vitro work in this chapter showed that MSCs from osteopenic individuals 
have a poor migration capacity. This may be associated with the inability of 
osteoporotic patients to heal fractures. The reduced migration to SDF-1 producing 
cells may possibly indicate that there may be a reduced stem cell number at the 
fracture site compared to non-osteoporotic individuals. Nevertheless, the maintained 
migration response upon up-regulation of CXCR4 illustrates the therapeutic 
potential of CXCR4-expressing MSCs in the treatment of osteoporotic fractures. 
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6.1 Introduction 
The long term cure for osteoporosis would entail encouraging a positive bone balance 
with each remodeling cycle, resulting in a sustained increase in total bone mass and 
a skeleton that no longer fractures with minimal forces (Lelovas et al., 2008). The 
major complication of osteoporosis, fracture, is due to lower bone strength and 
therefore any treatment of osteoporosis must encourage improvement in bone 
strength. Bone strength is determined by bone geometry, cortical thickness and 
porosity, trabecular bone morphology, and intrinsic properties of bony tissue 
(Ammann and Rizzoli, 2003). 
Homing of bone marrow stromal cells (MSCs) to bone and bone marrow after 
transplantation is important for the correction of bone and cartilage disorders. For a 
MSC transplantation to generate a clinical benefit, MSCs must engraft at the site of 
bone injury or the bone marrow. Chemokines play significant roles in controlling 
cellular migration. SDF-1 and its ligand CXCR4 has been shown to be important in 
causing the migration of cells to the bone marrow. It has been shown that CXCR4 is 
important for MSC migration to the bone marrow (Wynn et al., 2004b, Yellowley, 
2013b). Transplantation of MSCs over-expressing RANK Fc(an antagonist of RANK 
L)  or CXCR4 (Lien et al., 2009a) as well as, CXCR4 and Cbfa1 (Cho et al., 2009a)  
have been shown to restore bone mass and strength in osteopenic mice. In both 
these studies, MSCs were intravenously introduced into the mice through the tail vein, 
and MSCs over-expressing CXCR4 promoted in vivo cell trafficking to bone in OVX 
mice. This therapeutic effect of CXCR4 transfected MSCs therefore protects against 
bone loss and increases bone formation. 
 In this chapter I compare bone formation using MSCs from young rats, MSCs from 
OVX rats transfected CXCR4 and un-transfected OVX MSCs in an osteopenic rat 
model. The comparison between the cell types is an important aspect of my thesis 
because it investigates the beneficial effects of autologous cells from osteoporotic 
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patients and whether CXCR4 modified cells would provide an advantage benefit in 
the treatment of osteoporosis.  
The aim of this chapter is to investigate the effect of stem cells transfected with 
CXCR4 on the migration and bone formation in osteoporosis. 
The hypothesis was that stem cells transfected with CXCR4 have increased migration 
to the bone marrow and they would enhance bone formation in osteoporosis.  
6.2 Methodology 
30 rats with bilateral ovariectomy were left for 16 weeks to become osteopenic. The 
rats were injected with 0.5ml Sodium Nitroprusside (25mg/ml), followed by cells 
suspended in 2ml sterile PBS or saline and finally 0.2ml of saline to clear any cells 
left in the syringe (Figure 6.2). 
The rats in this study were divided into two parts (Figure 6.1): 
a) Cell tracker group 
b) Experimental treatment group 
 
a) Cell tracker group: 6 rats were injected with DiI labelled cells. This group of 
rats was used to track the cells 7 days after injection. This was the ‘cell tracker 
group’ (Day 0 control rats). The rats were euthanised 7 days post-injection 
and the samples retrieved from these rats were also used to obtain baseline 
data. The rats were divided into 2 groups: 
• DiI labelled Young MSCs + Empty Plasmid (n=3) 
• DiI labelled Young MSCs + CXCR4 (n=3) 
 
b) Experimental treatment group: The rest of the 24 OVX rats were divided 
into 4 groups; Groups A, B and C were injected with cells and Group D 
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received saline injection. The rats in this group were euthanized after 11 
weeks.  
The treatment groups were divided as follows: 
• Group A – Young MSCs + CXCR4 (n=6) 
• Group B – OVX MSCs (n=6) 
• Group C – OVX MSCs + CXCR4 (n=6) 
• Group D – Saline (n=6) 
 
Figure 6.1: A schematic illustration showing the different groups of rats in the 
in vivo study. Cell tracker group (day 0 controls), were euthanised after 7 days, 
while the rest of the rats were euthanised after 11 weeks.  
 
From all the rats in both groups, the following samples were retrieved; the left and 
right femur and tibia, the left humerus and L4 and L5 vertebrae.  
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Figure 6.2: Tail vein injection of the rats. The rats were anaesthetised during 
the injection and were injected with Sodium Nitroprusside, followed by cells 
suspended in 2ml of saline, and finally a saline flush.  
 
6.2.1 Vertebral compression 
Each vertebra was carefully separated from the rest of the vertebral column by halving 
the discs and cutting the ligaments. The facet joints and spinous processes were 
preserved to maintain physiological motion of the vertebrae during compression. The 
vertebrae were compressed at a speed of 0.75mm/min until failure and the ultimate 
compressive strength was measured (Figure 6.3). The stiffness of the vertebrae was 
obtained by calculating the gradient of the force deformation graph (Figure 6.4). The 
mean compressive strength of each vertebrae was obtained from the graphs as 
explained in chapter 2.  
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Figure 6.3: A setup to measure the compression of the L4 and L5 vertebrae. L4 
and L5 vertebrae was compressed until failure to obtain a force/deformation 
curve using a Zwick machine.   
 
Figure 6.4: A typical Force against Deformation curve for L4 vertebrae.  
 
6.2.2 Three-point bending test of humerus, tibia and femur 
The humerus, femur and tibia were retrieved, and all the tissues and muscles around 
the bone were cleared. The length of the bones was measured, the loading pin was 
set up at the bone’s mid shaft and the bones were loaded at a speed of 0.5mm/min, 
until failure point when the bone fractured (Figure 6.5). The span between the two 
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lower supports was set 10 mm apart. A force against displacement graph was 
generated and it was used to calculate the stiffness and maximum loading force of 
the bones (Figure 6.5). The stiffness was calculated by working out the gradient of 
the force displacement curve.   
 
Figure 6.5: A set up to show the 3-point bending test being carried out on a rat 
femur. Femur, humerus and tibia were loaded until the bones fractured to 
obtain a force/deformation curve using a Zwick machine.   
 
Figure 6.6: A typical Force against Deformation curve for a 3-point bending 
test of a humerus. 
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6.2.3   Peripheral Quantitative Computed Tomography (pQCT) of the tibia and 
femur 
The skin and soft tissues around the right and left tibia were removed and the bones 
were examined in vitro using XCT 2000 pQCT (Stratec, Pforzheim, Germany). As a 
standard procedure the scout view was obtained to locate the desired scan position. 
A reference line was then placed through the adjacent joint region (articular face of 
the distal tibia or femur).  The total length of the bone was obtained prior to the 
measurements and the CT was positioned at the femoral head. The femoral head of 
each sample was scanned symmetrically and the interval between each slice was 
0.2mm (More detail provided in chapter 2).  
6.2.4 MicroCT of the metaphysis and epiphysis of the femur 
The femurs of rats were fixed in formalin. During the scanning process, the samples 
were wrapped in cling film, placed in a tube and placed on a sample holder. The x-
ray source was set at 70kV with a current of 120uA. To reduce beam hardening, a 
0.5mm aluminium filter was used during the scan. During the scan a rotation degree 
of 0.6°, a frame averaging of 2 and a voxel size of 6um was applied (Figure 6.7).  
The NRecon software (Bruker, Belgium) was used to reconstruct the scanned images 
with the following parameters: smoothing = 2, beam hardening factor correction = 
12% and ring artefact reduction = 41%.  
The trabecular bone was analysed using a CtAn software (Bruker, Belgium) at two 
regions of the femur; the proximal (metaphysis) and distal (epiphysis). The growth 
plate was selected as a reference point (Figure 6.8). To maximise the trabeculae and 
to ensure that the growth plate was not included in the analysis the following 
parameters were selected: 
• The metaphysis - a volume of 150 slices were selected, 200 slices above the 
growth plate  
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• The epiphysis - a volumetric region of 200 slices were analysed which was 
located 100 slices below the growth plate.  
 
The following was measured: 
• Bone Volume (BV) 
• Percentage Bone Volume (BV/TV) 
• Bone surface (BS) 
• Trabecular thickness (Tb.Th) 
• Trabecular number (Tb.N) 
• Trabecular separation (Tb.Sp) 
• Total Porosity 
 
 
Figure 6.7: A scan illustrating a scout view of the femoral condyle from the OVX 
rats using the SkySCan 1172 (Bruker). The femoral condyles were scanned at 
6µm pixel size. 
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Figure 6.8: The sagittal, coronal and transaxial display of a reconstructed image 
of the growth plate, whereby a reference point was selected for analysis of bone 
morphometry. 
 
6.2.5 Fate of systematically injected MSCs 
To investigate the homing ability of MSCs, cells were labelled with Vybrant DiI cell-
labelling solution (ThermoFisher Scientific, UK). 1x106 cells were plated in a T225 
flask. 100ul of the DiI solution suspended in 5ml media and the solution was then 
added to the cells and left for 30 minutes. The DiI labelled cells were then injected 
systemically through the tail vein as described above. 
The rats were euthanised 7 days (Day 0 controls) post-injection and their femurs and 
tibias retrieved.  
The specimens were fixed in 10% buffered Formaldehyde, and decalcified in 
ethylenediaminetetraacetic acid (EDTA). Decalcification was confirmed by 
radiography, after which the specimens were dehydrated in increasing alcohol 
concentrations, treated with chloroform for 2 days to de-fat the tissue and then 
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embedded in wax. Sections measuring 5µm thick were made using a sledge 
microtome (ThermoFisher Scientific, UK).  
Sections were de-waxed twice in xylene, placed in two changes of 100% alcohol and 
then hydrated in serial dilutions of alcohol. After hydration, samples were stained in 
haematoxylin, a nuclear stain, for 5-10 minutes. The excess stain was washed off by 
immersing the slides in water for 5 minutes. Samples were then differentiated in 0.5% 
HCL acid (made up in 70% alcohol) and washed using water. After removing the acid-
alcohol, samples were counterstained in 1% eosin for 3-4 minutes, washed in water 
and dehydrated by serial dilutions of alcohol. Finally, samples were cleaned by xylene 
and mounted under coverslips using Pertex Mounting Medium (CellPath plc, UK). 
Samples were observed under a light microscope (KS-300 Zeiss, UK). This was used 
to observe the DiI labelled that had migrated to the bone (See section 6.2.6 below). 
The H&E images observed under a light microscope allowed the location of the 
fluorescent cells to be identified in the bone.  
To observe the fluorescent cells, slices were imaged under a fluorescent microscope 
(Zeiss Apatome 2). The slides were stained with Hoechst 3342 (Thermofisher 
Scientific, UK) and mounted with FluoromountTM Aqueous Mounting Medium (Sigma 
Aldrich, UK) and viewed under an emission wavelength of 617nm.  
6.2.7 Statistical analysis 
The normality was checked using Kolmogorov- Smirnov and Shapiro Wilkinson test 
and where the data was normal, comparison was made using independent student 
T-test. Where the data was non-parametric comparison was made using Mann-
Whitney U test with a Bonferroni correction. All data was analysed using SPSS 
version 24 (Chicago, USA).  
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6.3 Results 
6.3.1 Vertebral compression   
The mean compressive strength of both the L4 and L5 vertebrae was higher for the 
group of rats injected with Young CXCR4 MSCs (179.9±41.5 N and 179.9±75.78 N), 
followed by the rats injected with OVX-CXCR4 MSCs (164.98±51.47 N and 
158.4±48.2 N) respectively. Overall the rats injected with OVX MSCs (141.93 ± 43.1 
N and 126.78±29.7 N) and saline (149.4 ± 40.95 N and 136.6 ± 43.63 N) had the 
weakest L4 and L5 vertebrae respectively (Figure 6.9). Although there was a visible 
trend whereby the rats injected with young MSCs transfected with CXCR4 had the 
strongest vertebrae and the groups injected with saline and OVX MSCs were the 
weakest, these differences were not significant. 
 
Figure 6.9: The mean compressive strength of L4 and L5 vertebrae. There was 
no significant difference between the treatment groups. Error bars represent ±1 
Standard deviation. 
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This similar trend was observed for the stiffness of the vertebrae. The stiffness of the 
L4 vertebrae was significantly higher (p = 0.008) for the group that received the 
Young-CXCR4 MSCs (251.5 ± 61.7 N/mm) in comparison to the rats that received a 
sham saline injection (99.2 ± 16.2 N/mm) (Figure 6.10). 
 
 
Figure 6.10: The stiffness of the L4 and L5 vertebrae calculated from the 
gradient of the compression graph (n=6). Error bars represent ±1 Standard 
deviation. * shows significance p < 0.05. 
6.3.2 Three-point bending test of the humerus, tibia and femur 
The stiffness of the humerus, tibia and femur were obtained by calculating the 
gradient of the force displacement graph. No significance difference was seen 
between the different groups for strength and stiffness of the bones. However, there 
was a trend, whereby the rats receiving the saline injections had the lowest stiffness 
compared to those that received OVX-CXCR4 MSCs and young-CXCR4 MSCs for 
the tibia and femur (Figure 6.11, Figure 6.12). 
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Figure 6.11: The mean strength for humerus, tibia and femur for rats that had 
either received saline, OVX MSCs, OVX-CXCR4 MSCs or young-CXCR4 MSCs 
(n=6). Error bars represent ±1 Standard deviation.  
 
Figure 6.12: The mean stiffness calculated from a force displacement graph for 
humerus, tibia and femur. The rats had either received saline, OVX MSCs, OVX 
CXCR4 MSCs or young CXCR4 MSCs (n=6). Error bars represent ±1 Standard 
deviation.  
Chapter 6. CXCR4 Enhances Bone Formation in Osteopenic Rats 
161 
 
6.3.3 PQCT of the tibia and femur 
pQCT data demonstrated that injecting young MSCs transfected with CXCR4 
significantly improved the BMD of the bone in the femoral condyles of the OVX rats, 
in comparison to injecting them with saline. This significant difference in BMD was 
seen for the trabecular bone (p=0.005), cortical/subcortical bone (p=0.02) and total 
BMD (p=0.02). OVX rats injected with young-CXCR4 MSCs transfected had a 
trabecular BMD of 716.4±105.7 mg/ccm, total BMD of 694±80.1mg/ccm and Cort/sub 
cort BMD of 715.2±45.4 mg/ccm, while OVX rats injected with saline had a BMD of 
535.5±61.6mg/ccm, 563.4±82.9 mg/ccm and 576.2±11 mg/ccm respectively (Figure 
6.12 & Figure 6.13). 
 
 
Figure 6.13: A typical scan result generated from PQCT of the femurs from rats 
injected with saline, OVX MSCs, OVX-CXCR4 and Young-CXCR4 MSCs. The 
blue regions represent the highest BMD and red represents the lowest BMD. 
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Figure 6.14: The mean BMD of the femur measured using PQCT. The BMD was 
measured for the femur and tibia and trabecular, cortical and total bone density 
was analysed for both bones. Significant increase in BMD was observed 
between rats injected with saline and young-CXCR4 MSCs. Error bars represent 
±1 Standard deviation. *, **, ** show significance of p<0.05. 
 
Although there was no significant difference between the groups that received young 
MSCs, OVX MSCs and OVX-CXCR4 MSCs, there was a general pattern, where the 
rats that received the OVX MSCs had the lowest femoral BMD, followed by the OVX-
CXCR4 in comparison to young MSCs group. This trend was also observed for the 
tibial BMD. However, there was no significant difference between any of the groups 
(Figure 6.15).  
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Figure 6.15: The mean BMD of the tibia measured using PQCT. The BMD was 
measured for the femur and tibia and trabecular, cortical and total bone density 
was analysed for both bones. Error bars represent ±1 Standard deviation. There 
was no significance between any of the data. 
 
6.2.4 MicroCT analysis of the femoral condyles 
Figure 6.16: Three dimensional images of the femoral heads to illustrate the 
trabeculae structure of the metaphysis and epiphysis. The rats injected with 
Young-CXCR4 cells had a denser meshwork of trabeculae compared to those 
injected with Saline, OVX cells and OVX-CXCR4 cells.  
 
MicroCT analysis of the femoral condyles was carried out on the metaphysis and 
epiphysis region. Overall the effect of stem cells injection on the bone volume was 
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subtle compared to saline injection but the groups injected with saline had the worst 
bone histomorphometric structure compared to the other groups (Figure 6.16). 
6.2.4.1 Histomorphometric Analysis of the metaphysis 
MicroCT examination of the metaphysis of the femur showed that injecting rats with 
saline caused a decrease in cancellous bone volume, percentage bone volume, 
trabecular thickness and increase in total porosity. Injection of Young-CXCR4 MSCs 
caused an increase in surface area and volume of the cancellous bone in the 
metaphysis, but this difference was insignificant compared to rats injected with saline 
and OVX MSCs. Even though there was no difference in trabecular number between 
groups receiving different types of injections, it was observed that the trabecular 
thickness was highest for the rats that received the cell injection while the rats injected 
with saline had the least developed trabecular thickness. Even though this difference 
was not significant, it implies that cell injections enhanced trabecular thickness in the 
metaphysis region of the femoral condyles. 
There was a general trend in the mean bone surface (BS) area. Although these 
differences were not significant, the rats treated with young-CXCR4 MSCs had the 
highest BS area (9.5x107 ± 5.3x107 µm2) compared to rats treated with OVX-CXCR4 
MSCs (7.6x107 ± 5.0x107 µm2), OVX MSCs (7.1x107 ± 1.7x107 µm2) and saline 
(7.3x107 ± 5.5x107 µm2). As expected the Time 0 controls had the highest bone 
surface area because they were euthanised 7-days post-injection while the other 
groups of rats were euthanised 5-weeks post-injection (Table 6.1). 
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Table 6.1: Bone histomorphometry of the metaphysis of the femurs obtained 
using microCT. The values presented are mean ± standard deviation. 
 
The rats injected with saline (p=0.03), OVX MSCs (p = 0.004) and OVX-CXCR4 ( p = 
0.02) MSCs had a significantly lower bone surface area compared to the rats injected 
with Young-CXCR4 MSCs (p = 0.07) (Figure 6.17). This demonstrates that with time, 
a further 11 weeks, the bone surface area of the cancellous bone in the femur 
reduced. The group injected with Young-CXCR4 MSCs had lower bone surface area 
compared to Time 0 controls but there was an increase in bone formation or retention 
of bone compared to the other injected groups.  
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Figure 6.17: Data showing the mean Bone Surface (µm2) of the femur obtained 
from rats treated with saline, OVX MSCs, OVX-CXCR4 MSCs and young CXCR4 
MSCs. Compared to time 0 controls, all groups of rats, except the ones that 
received young-CXCR4 MSCs, had significantly lower Bone Surface Area. The 
error bars represent standard error of the mean * shows significance p < 0.05. 
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Figure 6.18: Data showing the mean Bone Volume (µm3) of the femur obtained 
from rats treated with saline, OVX MSCs, OVX-CXCR4 MSCs and young CXCR4 
MSCs. The error bars represent standard error of the mean. * shows 
significance p < 0.05. 
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In all groups injected with stem cells bone volume (BV) was increased in comparison 
to saline injection. Although these differences were not significant, the rats treated 
with OVX-CXCR4 MSCs had the highest BV (1.7x 109 ± 1.4 x 109 µm2) compared to 
rats treated with Young-CXCR4 MSCs (1.5 x 109 ± 7.0 x 108 µm2), OVX MSCs (1.4 x 
109 ± 2.8 x 108 µm2) and saline (1.1 x 109 ± 8.5 x 108 µm2).  
6.2.4.2 Histomorphometric Analysis of the Epiphysis  
MicroCT examination of the epiphysis of the femoral head revealed a mild but 
statistically insignificant effect of injection of transfected and un-transfected MSCs. 
The increase in percentage bone volume, bone surface and trabecular number was 
evident in groups injected with Young-CXCR4 MSCs but this was insignificant 
compared to the other groups especially the saline group. The variability within the 
groups produced data which affected the significance (Table 6.2). 
Table 6.2: Bone histomorphometry of the epiphysis of the femurs obtained 
using MicroCT. The values presented are mean ± standard deviation. 
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Figure 6.19: Bone volume of the epiphysis of the femur measured using 
MicroCT, for the different groups of rats treated with saline, OVX MSCs, OVX-
CXCR4 MSCs and Young-CXCR4 MSCs. Compared to the Time 0 control rats, 
only the rats injected with saline had significant lower bone volume (BV), 
showing that cell injections that a positive effect on bone volume. The error 
bars represent standard error of the mean. * represents p<0.05.  
 
Although there was variability in the mean bone volume within each group of rats, the 
mean bone volume of the epiphysis was improved with various cell treatments. The 
rats injected with the saline had the lowest bone volume (3.1x109 ± 1.3 x109 µm3) 
compared to rats injected with OVX MSCs (3.46 x109 ± 5.7x x108 µm3), OVX-CXCR4 
MSCs (3.26x109 ± 1.6x109 µm3) and young-CXCR4 MSCs (3.49 x109 ± 9x108 µm3). 
The rats from Time 0 group had significantly higher bone volume compared to those 
injected with saline injections (p = 0.01). There were no significant differences 
between the Time 0 rat group and rats injected with any cell type, irrespective whether 
they were transfected or un-transfected or from young or OVX rats (Figure 6.19).  
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Figure 6.20: Bone surface area of the epiphysis of the femur measured using 
MicroCT, for the different groups of rats treated with saline, OVX MSCs, OVX-
CXCR4 MSCs and Young-CXCR4 MSCs. The error bars represent standard error 
of the mean. * represents p<0.05. 
 
The average epiphyseal bone surface was highest for the rats injected with Young-
CXCR4 MSCs (2.4x108 ± 1.9 x108 µm2) in comparison to all the other groups including 
Time 0 controls. However this difference was not significant and this could be due to 
large variability in the data (Figure 6.20).   
Chapter 6. CXCR4 Enhances Bone Formation in Osteopenic Rats 
171 
 
6.2.6 Fate of systemically injected MSCs 
 
Figure 6.21: DiI labelled cells (Red) located in the femur of rats systemically 
injected with Empty plasmid-Young MSCs (A & B) and CXCR4-Young MSCs (C 
& D). These images were taken from 5um wax histology slides with the nucleus 
stained for Hoechst (Blue). 7 days post-injection, the DiI labelled cells were 
located in the blood vessels in the bone. Images A and C are taken at x10 
magnification and Images B and D are taken at x20 magnification.  
 
Fluorescent imaging proved that the DiI labelled MSCs homed to the bone after 7 
days. In addition to blood cells, numerous DiI labelled nucleated cells were observed 
in the blood vessels in the cortical and trabecular bone of the femoral condyles. 
However, it would have been interesting to observe whether these cells engrafted 
and played a role in enhancing bone formation by keeping these labelled cells for a 
longer time in the rats. There did not seem to be any evident difference between 
Young MSCs transfected with an empty plasmid (Group D) or those transfected with 
CXCR4 (Group E) (Figure 6.21 & Figure 6.22). This could possibly be because 
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Young-MSCs already express high levels of CXCR4 as shown in chapter 3 and 
therefore have a high migration capacity. Additionally, no fluorescent cells were 
visible in slides from rats that were injected with unlabelled cells (Figure 6.23). 
 
Figure 6.22: DiI labelled cells located in the blood vessels of the femur (A).H & 
E staining of these cells of wax histology slides of the femur. The dark stained 
cells are nucleated cells which correspond to the DiI labelled cells (B & C).    
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Figure 6.23: Fluorescent images of histological slides of femur from rats 
injected with unlabelled cells. There were no visible DiI labelled cells in the 
blood vessels of these rats. 
 
6.4 Discussion 
Osteoporosis causes thinning of the trabeculae and an increase in cortical porosity, 
bone fragility and fracture risk (Chen et al., 2013). A fracture occurs when an 
externally applied load to the bone exceeds the strength of the bone. The strength of 
bone therefore relies not only on bone mass and cortical strength but also on the 
trabecular structure which determines the microarchitecture of bone. In osteoporosis 
the bone remodelling process is compromised due to the imbalance between 
osteoclasts and osteoblasts (De Souza et al., 2005, Chen et al., 2013, Laib et al., 
2001). The hypothesis of this study was that stem cells injected intravenously are able 
to contribute to bone formation by migration to the bone and differentiation into 
osteoblasts. I also hypothesis that bone formation would be further enhanced by 
transfecting stem cells with CXCR4   which would enhance their migration to bone.    
Fragility fractures commonly occur in the metaphysis. The trabeculae strengthen the 
thin cortex and transfer loads from the joint to the thicker cortical bone in the diaphysis  
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(Bala et al., 2015). It is therefore important for any osteoporotic treatments to have an 
effect on the metaphysis of the bones such as proximal femur, distal tibia, proximal 
humerus and distal radius. The deteriorating changes of bone in the OVX rats injected 
with saline was reflected by the thinning of the trabeculae, reduced bone surface area 
and bone volume in the proximal femur. These micro-structural changes are common 
problems in osteoporotic patients, causing fragility fractures (Chen et al., 2013, 
Kiernan et al., 2016). However, the results from this study reflect the enhancement of 
trabecular thickness in the metaphyseal region of the femoral condyles in OVX rats 
injected with cells. OVX rats that received saline injections had no improvement in 
trabecular thickness. Although these results were insignificant, they highlight the 
positive effect of cell injections on the trabeculae.  
 
The predominant issue with MSCs from OVX animals or osteoporotic patients is their 
poor capability to migrate, differentiate as well as be retained at the bone marrow site. 
The previous chapters in this study highlighted the poor CXCR4 expression as well 
as migration of MSCs from OVX rats. In this chapter, CXCR4 transfected MSCs were 
therefore intravenously injected into OVX rats, to see if their migration would be 
enhanced to the marrow, hence improving bone formation in these animals. The 
important aspect of osteoporotic treatments is not only to increase BMD but also to 
ensure this bone formation is retained and the bone microarchitecture is improved. In 
this chapter, I showed that injecting young MSCs transfected with CXCR4 significantly 
enhanced BMD (p=0.02) and L4 vertebral strength (p=0.008) compared to the group 
of rats that received a saline injection. It was also highlighted that injection of OVX 
and OVX-CXCR4 MSCs helped improve the BMD and trabeculae structure in the 
femoral condyles of the OVX rats compared to the groups that received saline 
injection.  
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The deteriorating bone structure of the OVX rat model was clearly observed as the 
Time 0 control rats had the most bone volume and density compared to the rest of 
the OVX rats which were treated for a further 10 weeks. However, the rats injected 
with cells had a higher bone surface area and volume compared to the rats injected 
with saline. There was an increased BMD in the animals injected with cells using 
pQCT which seemed to contradict the modest increase in bone volume observed by 
microCT. This is similar to results by Huang and co-workers, 2016 who injected 
allogeneic MSCs from 8 week old rats into OVX rats and looked at their bone 
formation. They concluded that although the systemic transfusion of allogeneic MSC 
is a safe procedure, administering cells only may not be the most effective procedure 
for preventing osteoporosis. They also observed an increase in BMD using PQCT but 
no difference in trabeculae structure using microCT (Huang et al., 2016). These 
differences could be because PQCT measures global bone formation while microCT 
is more specific as it measures slices specifically for analysing trabeculae structure.  
Regenerating the trabeculae may not be as simple as it seems. Cunningham et al, 
2005 investigated the recovery of the trabeculae in the right os-calcis in an ovine 
model. After removal of the trabeculae in the os-calcis animals were returned to their 
normal daily activities   however the trabeculae did not regenerate and the os-calcis 
remained hollow but with increased density in the cortical bone. This could be 
because the load was distributed to the upper and lower beams of the bone, hence 
the increase in density and thickness of the cortical bone (Li et al., 2003, Kim et al., 
2008, Cunningham et al., 2005). Once interconnectivity between trabeculae has been 
compromised it is difficult to reform cross-links because of the mechanisms of load 
transfer which is altered due to reduced number of bridging elements.   
Injecting MSCs, irrespective of the fact that they were from OVX or young rats or 
uninfected or infected protected against bone loss associated with ovariectomy in rats 
compared to rats injected with saline. These results are similar to those reported by 
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Lien and co-workers and Cho and co-workers, 2009 who injected CXCR4-infected 
cells in OVX rats and observed increased BMD in rats injected with cells compared 
to sham injections. However, both these studies used an additional recombinant 
protein that improves bone formation, to not only improve migration but to also 
enhance the ability of the MSCs to differentiate to bone (Lien et al., 2009, Cho et al., 
2009a).  
Lien injected CXCR4 and Cbfa-1 transfected MSCs and Cho injected CXCR4 and 
RANK-fc. Both studies showed even more improved bone formation when they were 
injected with cells co-transfected with the recombinant proteins. The CXCR4 
transfected MSCs were shown to migrate to the bone marrow, 7 days after injection 
and improved bone formation in OVX rats compared to the sham control rats. 
However, cells transfected with CXCR4 and the additional recombinant proteins, had 
the most improved bone formation, showing the therapeutic role of Cbfa-1 and RANK-
Fc. They showed that, in addition to improving migration of MSCs, an additional factor 
is necessary to boost the differentiation potential of MSCs (Cho et al., 2009b, Lien et 
al., 2009).  
Indeed, it is interesting to see whether these homed MSCs contribute to bone 
formation. Lien and co-workers labelled their cells with Qdot nanoparticles for short 
term tracking and fluorescently labelled them with Green Fluorescent Protein (GFP) 
for long term tracking of injected MSCs in mice. They observed homing and 
engraftment of labelled MSCs to the bone marrow which was enhanced by CXCR4 
(Lien et al., 2009). However, it is unknown whether these MSCs have a paracrine 
function or whether they actually contribute to the bone mass. 
Sheyn and co-workers, 2016 injected a combinational therapy of MSCs and PTH and 
showed that PTH aided with the migration of MSCs and also played an anabolic role 
in bone formation in vertebral defects in pigs (Sheyn et al., 2016). This highlights the 
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importance of improving migration of cells and also stimulating their ability to form 
bone. It is important for cells to home and engraft into the marrow cavity (Kim et al., 
2006) as well as help with the bone loss (Cho et al., 2009a, Kim et al., 2006). Studies 
by Lien and Cho showed significantly improved BMD after injection of MSCs, however 
these results were based on pQCT data and unlike this work did not look at changes 
in the trabeculae using MicroCT. Additionally, they induced osteopenia in younger 
mice (around 3-4 months old) compared to this study. In this study the rats were 
ovariectomised when they were around 6-9 months old and were injected when they 
were 10-13 months. The work in this chapter has utilised much older rats, therefore 
the rats were injected when their bone structure would have been more deteriorated 
due to age as well as osteopenia.  
Although significant differences were seen in this study, there were a number of 
trends noted that were not significant. The number of significant differences seen in 
this study may have been increased by increasing the number of animals in each 
group. A power calculation done in the main discussion (Chapter 7) demonstrates 
that n=10 would have helped the study to achieve a power of 80%. 
However, the novelty and significance of the work in this chapter is that it investigates 
the prospect of injecting autologous stem cells in osteoporotic patients. Injecting OVX-
MSCs may not be as beneficial as injecting Young-MSCs or Young-CXCR4 MSCs, 
but it still enhances bone formation although to a lesser extent. 
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At the moment treatments for osteoporosis focus on improving the catabolic bone 
remodeling that is, preventing bone resorption and most treatments do not encourage 
bone formation.  Mesenchymal stem cells have a regenerative capacity and may be 
able to enhance anabolic bone formation. Information in the literature and presented 
in my thesis suggests that mesenchymal stem cells in patients with osteoporosis are 
down regulated  and  do not form bone as well as  cells from normal individuals 
(Rodríguez et al., 1999). Cell recruitment, migration and homing are very important 
factors for neovascularisation, chondrogenesis, osteogenesis and therefore bone 
remodelling. MSCs are required to find their way from the periosteum, local bone 
marrow, the circulation and also the distant bone marrow to sites of injury, which is in 
part a function of the SDF1/CXCR4 pathway (Yellowley, 2013a).  
The aim of this thesis was to investigate whether mesenchymal stem cells (MSCs) 
over-expressing CXCR4 would improve bone formation in osteoporosis. The results 
of the experiments in previous chapters support the hypotheses that: 
1) Bone marrow MSCs from OVX rats have reduced migration and osteogenic 
differentiation capability and CXCR4 expression compared to MSCs from young and 
senile rats.  
2) Genetically modifying MSCs to over-express CXCR4 would improve the migration 
of MSCs towards SDF-1. 
3) MSCs genetically modified to over-express CXCR4, when injected intravenously 
in ovariectomised (OVX) rats would improve bone formation compared to those 
injected with saline.  
This study has established the migratory and differentiation abilities of MSCs from 
young, adult and OVX rats. I hypothesized that MSCs from OVX rats would have 
reduced proliferation and osteogenic differentiation ability, but increased adipogenic 
Chapter 7. Main Discussion 
180 
 
differentiation. However, the MSCs from the three groups of rats had no significant 
differences in proliferation and CD marker expression, showing that age and 
osteopenia do not affect the phenotypic properties of MSCs. However, MSCs from 
young rats were capable of greater adipogenic and osteogenic differentiation when 
compared to cells isolated from osteopenic rats. This is in agreement as well as in 
contrast to studies carried out by other groups (Goergen et al., 2013, Beane et al., 
2014, Asumda and Chase, 2011, Singh et al., 2016). However, if findings from this 
study are correct then using autologous MSCs in patients that are old and 
osteoporotic may have an implication on subsequent bone formation as these cells 
would not be effective.  
MSC migration from blood, periosteum and marrow to the site of fracture is 
particularly important in fragility fractures. These fractures are at greater risk of  
delayed healing due to the poor fixation of screws used to stabilise the fractures and 
the reduced ability of patients to form bone and unite the fracture (Giannoudis et al., 
2007). The CXCR4-SDF1 pathway plays a crucial role in the retention and 
engraftment of MSCs during fracture repair.  At any site of injury there is a release of 
SDF1, which attracts CXCR4 expressing MSCs (Wynn et al., 2004a).  In this thesis 
results from flow cytometry demonstrated significantly lower expression of CXCR4 on 
MSCs from OVX rats in comparison to young and senile MSCs impairing their ability 
to migrate in vitro in a Boyden Chamber. This new information indicates that the poor 
bone formation associated with osteoporosis may be associated with an impaired 
CXCR4 expression in these cells. This migration was seen to be improved when the 
cells were transfected with CXCR4.  
In the in vivo experiments the homing destination of the injected MSCs was 
investigated by tracking DiI labelled MSCs in a group of rats. Although the cells were 
detected in the blood vessels in the bone, this was a short-term study and the animals 
were euthanized after 7 days and it was not possible to determine if these cells 
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differentiated into osteoblasts and contributed directly to bone formation. This is a 
limitation and a longer-term study investigating the engraftment of CXCR4 transfected 
stem cells is warranted. It is possible that these cells either had a direct role in bone 
formation or that they may have been acting in a paracrine fashion.  Indeed, it has 
been shown that osteoblasts or MSCs differentiated to osteoblasts have high α2-
integrin expression which is important for cell adhesion as it helps to facilitate 
mechanotransduction and serves as a mechanosensor from the cells to the matrix 
(Shih et al., 2011).  
In vitro CXCR4 transfection was seen to have a more prominent effect in MSCs from 
OVX rats. MSCs from young rats have a high CXCR4 expression and therefore 
transfection with CXCR4 did not further increase migration. However, MSCs from 
older rats transfected with CXCR4 had higher migration than the non -transfected 
MSCs. Clinically this could be a significant finding as the poor migratory ability as well 
as differentiation ability of stem cells from osteoporotic patients could affect their bone 
formation. Transfecting MSCs with CXCR4 would not only improve the migration but 
also aid in the retention of MSCs at those sites.  Lien and co-workers injected MSCs 
transfected with CXCR4 and Cbfa1 into young and adult osteopenic mice and showed 
significant improvement in bone formation in comparison to groups injected with just 
CXCR4 transfected MSCs or saline. In their study osteopenia was induced by the use 
of corticosteroids.  They measured BMD using pQCT and bone mechanical strength 
using a four-point bending test. However unlike this study, they failed to measure the 
bone trabecular structure using histology or micro-CT (Lien et al., 2009b). Another 
study by Cho et al, 2009 injected MSCs transfected with CXCR4 as well as RANK-Fc 
into ovariectomised mice. They observed that CXCR4 improved in vivo trafficking and 
retention of MSCs, which then enhanced the therapeutic effect of RANK-Fc (Cho et 
al., 2009b). Although RANK-FC and Cbfa1 play an important therapeutic role in 
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improving bone, CXCR4 enhances the migration of cells, hence aiding the 
therapeutic role of these recombinant proteins. 
Aging causes an increase in circulating inflammatory factors. SDF1, a 
chemoattractant for CXCR4 may have an important role in the homing and migration 
of stem cells to the bone marrow niche. Higher SDF1 levels in the plasma may perturb 
circulating stem cells and reduced rehoming to the stem cell niche over time. Low 
BMD in both men and women has been correlated to high SDF1 levels in blood, 
therefore implying that SDF1 is linked to bone homeostasis. As levels of SDF1 in the 
plasma increase,   greater numbers  of bone marrow stem cells  are mobilized into 
the blood (Carbone et al., 2017). This means that SDF1 may mobilise stem cells away 
from the bone marrow niche into the blood stream in patients with osteoporosis 
thereby reducing bone formation. Using MSCs transfected with SDF1 the beneficial 
effect of SDF1 in fracture healing has been demonstrated (Ho et al., 2014b). My study 
has shown the relationship between ageing, osteoporosis and levels of CXCR4 on 
stem cells. However, the relationship between SDF1 and osteoporosis yet remains to 
be established.  
To test the therapeutic treatments for osteoporosis, many animal models are utilised 
such as sheep, rats and mice. The rat OVX model is a commonly used model for 
osteoporosis (Lelovas et al., 2008, Kalu, 1991). The rat is an appropriate animal 
model for the research of postmenopausal osteoporosis. After OVX, bone resorption 
exceeds bone formation initially, causing bone loss. Soon thereafter, bone 
remodelling reaches a steady state, where resorption and formation are balanced 
(Lelovas et al., 2008). It must be noted that in osteoporotic women, the first and most 
severe bone changes occur in the spongy bone of the vertebral body, whereas in 
aged and mature rats they predominantly involve the trabecular bone of the 
metaphyseal region of the long bones and, more specifically, of the distal femur and 
proximal tibia.  Changes in the thickness and porosity of cortical bone after OVX in 
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rats is also different to that seen in humans with osteoporosis. Nevertheless, the rat 
OVX model has been extensively used. In my study I used aged OVX rats but more 
precise replication of human osteoporosis is seen in senile OVX rats but this was not 
possible due to time constraints, cost and variability of the animals. A large number 
of studies on osteoporosis utilise mature rats which are 3 months old. The advantage 
of using an aged model is that it replicates the skeletal characteristics of women who 
are susceptible to postmenopausal osteoporosis. The skeletal properties in aged rats 
has stabilised and is therefore no longer subject to changes due to age (Bonucci and 
Ballanti, 2014). 
The effect of CXCR4 on the migration of MSCs was tested in vivo in OVX rats by the 
injection of MSCs intravenously. The femoral bone mineral density and bone structure 
of these rats was analysed 11 weeks after cell administration and compared to the 
control group injected with saline. Three groups of cells were administered into the 
rats; Young-CXCR4 MSCs, OVX MSCs, and OVX-CXCR4 MSCs. Rats injected with 
young-CXCR4 MSCs had significantly improved BMD measured by pQCT and L4 
vertebral strength compared to rats injected with saline. Rats that received young-
CXCR4 MSCs, had higher BMD compared those that received OVX-CXCR4 MSCs 
and this could be attributed to the better migration and differentiation capability of 
young MSCs. Similar to studies by Lien and Cho (Lien et al., 2009b, Cho et al., 
2009b), further work could also implement gene therapy  to improve bone formation, 
in addition to CXCR4. In this way the migratory as well as bone formation capability 
of the MSCs would be improved.  
The data from this work demonstrate that although use of isogenic MSCs in 
osteoporosis protects against bone loss, MSCs from the bone marrow have a 
declining function with age, proving to be challenging for autologous cell-based 
therapy. This problem could be tackled by using an allogeneic source of stem cells 
from young patients. However, using allogeneic stem cells may cause immunological 
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problems in the patient. Additionally, from a regulatory point of view using genetically 
modified CXCR4-MSCs would require ethical approval and stringent safety checks 
before being applied clinically. Although adenovirus vectors are currently being used 
for gene therapy to treat cancer, and as vaccines to express foreign antigens 
(Westphal et al., 2013, SM Wold and Toth, 2013), their role in bone formation still 
needs to be established in humans.  
It was observed that there was an increase in BMD with injection of young CXCR4-
MSCs, however there was no significant difference in the trabecular architecture 
using micro CT. The increase in BMD could be due to increase in thickness of cortical 
bone. Huang and co-workers,  demonstrated an increase in BMD but no changes in 
trabecular structure when OVX rats were injected with young allogeneic MSCs 
(Huang et al., 2016). Of course the increase in trabecular structure, that is, trabecular 
thickness, number, length and connectivity, is important and these changes will 
enhance the microstructural properties if the bone as well as BMD. However, 
regenerating the trabeculae   where they are no longer interconnected is difficult as 
shown by Cunningham et al, 2005, who measured the response of the bone after 
removal of the trabeculae from the oscalis of sheep. To compensate for the loss of 
trabeculae bone, the load was distributed via a thicker and denser cortex and a hollow 
structure was retained without the formation of trabecular cross struts. This is 
probably because there is no load distribution across non-connected trabeculae. 
Additionally, in the OVX model there is significant loss of the trabecular bone and the 
interconnectivity between the trabeculae is reduced, altering the loading of bone. 
Hence it is very difficult to form new trabeculae bridges (Cunningham et al., 2005, 
Kim et al., 2008).  This may be associated with the trend towards an increase in 
thickness of the trabeculae in the MSCs-CXCR4 groups rather than an increase in 
number of trabeculae or an increase in connectivity.   
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In this in vivo study was that there was no significant difference in BMD between rats 
injected with young-CXCR4 MSCs and OVX-CXCR4 MSCs as well as those injected 
with OVX MSCs and OVX-CXCR4 MSCs. A higher BMD was observed for the 
CXCR4 group as well the young MSCs group. A number of measurement showed a 
trend but remained insignificant. A consideration for any future studies would be, the 
use of younger ovariectomised rats (not ex-breeders), would be important. In my 
study 6-9-month old ex-breeder rats were ovariectomised, left for 4 months and 
injected with the cell treatment and then left for a further 11 weeks until the end of the 
study. The older the rats, the more difficult it is to recover the trabeculae (McCann et 
al., 2008b, Tanaka et al., 2003). Although the age of the rats used in this study is 
reflective of a clinical scenario, the variability of age and type of rats used makes it 
difficult to obtain any significant data. Additionally, due to large variabilities between 
the wistar ex-breeder rats, it would have been useful to use inbred strains. A higher 
number of rats in each group for the in vivo study would also have helped to improve 
the significance in the data. An equation below shows an example of the power 
calculation for the percentage bone volume with data from my study and highlights 
that a higher sample size (number of rats) is needed to achieve a power of 80% 
(equation 1).  In this case the number of individuals would have to be 10 in order to 
show a significant difference and in my study an N of 6 was routinely used.   
Fragility fracture is a common problem in osteoporotic patients in both women and 
men, with 6 million hip fractures projected globally by 2020, leading to high costs, 
mortality as well as morbidity (SELECKI and EISMAN, Giangregorio et al., 2006, 
Pisani et al., 2016). As stem cells can be used for increasing BMD in osteoporotic 
patients but also for their ability to regenerate bone in fractures then this study is 
important as MSCs over expressing CXCR4 may be expected to be better retained 
at the site of injury. 
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Equation 1: An example of a power calculation equation showing the sample 
size of the rat number for percentage bone volume to achieve a power of 80% 
and significance of 95%. 
 
An interesting future study would therefore be to investigate the effect of systemic 
administration of MSCs, in osteoporotic rats with femoral fractures. The fracture, 
stabilized with an external fixator would reflect the non-union problems associated in 
fragility fractures. This could then be compared to the administration of cytokines such 
as GCSF, VEGF and IGF1 that have been shown to cause mobilization of stem cells 
into the blood steam.  
In conclusion, the work in this thesis has highlighted that injecting cells, be it from an 
older donor source or from a young donor, protects against bone loss caused due to 
osteoporosis. MSCs from OVX and aged rats have poor differentiation and migration 
ability, which makes it difficult for these cells to differentiate to bone. However, 
transfecting MSCs with CXCR4 and injecting them into OVX animals improves 
migration of cells and improves BMD and vertebral strength in OVX rats. Further work 
still needs to be carried out to help improve the trabeculae organization and 
regeneration leading to greater structural competence in osteoporotic bone.  
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